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1. Summary 
 
Ceramide (e.g. (2S,3R,4E)-2-Octadecanoylamino-octadec-4-en-1,3-diol) is a structural component of 
membrane glycosphingolipids and sphingomyelin, and occurs in free form as well as bound to proteins in 
the human skin (Kolter and Sandhoff, 1999). Certain conformationally rigid analogs of this lipid, such as 5b 
and 24 (figure 1.1), showed an unexpected interference with the biosynthesis of complex glycosphingolipids 
such as that of ganglioside GM2 (GalNAcβ1,4-(NeuAcα2,3)Galβ1,4Glcβ1Cer; Figure 1.2).  
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Figure 1.1: Structures of ganglioside GM2 and selected synthetic ceramide analogs that have been 
prepared and investigated during this work. 
 
 
To get insight into the molecular mechanism of this apparent inhibition, a series of experiments have been 
carried out in this work: 
1) New structural analogs of the halogenated oxazinanone (5a) and oxazolidinone (5b) have been 
prepared, and analysed in cultured cells. 
1a) The preparative route that gave access to these compounds (Fig. 4.2) was used for the preparation of 
the brominated compounds 7.2a and 7.2b (Fig. 4.4). At least in cultured fibroblasts, the biosynthetic 
incorporation of 3-[14C]L-serine into cellular glycosphingolipids in the presence of 5b and 7.2b were similar. 
1b) To further address the role of the halogen atom, oxazinanones bearing a hydroxyl group instead of a 
halogen (18a,b) were prepared from phytosphingosine (Fig. 4.18). As has been shown before, these 
substances were not accessible on the route used otherwise (Fig. 4.2) due to a competing rearrangement 
reaction (Fig. 5.2). 18a and 18b showed entirely different lipid labelling patterns, when glycosphingolipid 
biosynthesis is analysed in cultured neurons. These data indicate a vital role of the halogen atom for the 
observed effects. 
1c) Other structural analogs of 5a and 5b were prepared and analyzed: Title compounds bearing an 
additional methyl group in the head group were prepared from L-threonine (23.2a,b; Fig. 4.20). 23.2a 
behaved similar to 5a when analysed in cultured fibroblasts, indicating that the substituent does not hinder 
the molecular interaction leading to the observed effects. 
2) An appropriate way to investigate metabolism of 5a or 5b, was well as to address the question, if these 
substances are covalently bound to certain cellular proteins, is the incorporation of a suitable radioisotope 
into these substances. In model experiments, conditions for two reactions (Fig. 4.11) were found, under 
which incorporation of a tritium atom into newly synthesized suitable precursor substances should be 
possible, at least in low yields. 
        2
3) Oxazinanone 12 (Fig. 4.13) with an azide group within the alkyl chain was prepared. This substance 
should allow the identification of potential metabolites via Staudinger ligation, together with the identification 
of putative protein targets after affinity purification. 
4) Initially, 5a and 5b, as well as potential glycosidated metabolites, have been investigated on their effect 
of ganglioside GM2 synthase, a membrane bound N-acetylgalactosaminyltransferase of the Golgi-
apparatus. Baculovirus-infected insect cells overexpressing this enzyme were used as enzyme-source to 
investigate 5b in a liposomal assay system, since alteration of membrane properties caused by the 
compound has to be excluded as reason for the observed effects. Due to the instability of the enzyme in the 
proteoliposome preparation, no conditions could be found to analyse this possibility. Also a micellar GalNAc 
transferase assay in the presence of lipid extracts derived from fibroblast cells incubated with 5b showed no 
inhibition (Chapter 4.3). 
5) Metabolites of 5b were searched for by thin layer chromatography (Chapter 4.4.1) and mass 
spectrometry. For this purpose, fragmentation pattern of 5a, 5b, and a glucosylated potential metabolite 
were recorded and used for parent ion- and neutral loss-scans in the lipid extract of cultured fibroblasts 
(Chapter 4.4.2). No metabolites could be found by this method. For glycolipid quantification and analysis of 
molecular species distribution in the lipid extract of cells by electrospray (ESI) and atmospheric pressure 
chemical ionisation (APCI) mass spectrometry, a ganglioside GM3 and a sulfatide derivative were prepared 
as glycolipid standards with appropriate alkyl chain lengths for further investigation (Chapter 4.10). 
6) It could be demonstrated by fluorescence microscopy, that the Golgi apparatus is fragmented in 
response to 5b in cultured human fibroblasts. Although it cannot be distinguished at the moment, if this is 
cause or effect of altered sphingolipid metabolism induced by 5b, this observation points to a protein target 
of 5a and 5b that is required for vesicular transport through the Golgi apparatus. 
7) To investigate the role of the benzene substituent in another conformationally rigid ceramid analogue, the 
benzazepinone 24 (Fig. 1), phenylacetylsphingosine was prepared as an open-chain analog (Chapter 4.8.1) 
and analyzed in cultured murine granule cells and human fibroblasts. Since the ganglioside patterns in the 
presence of both compounds are similar, glycosyltransferase inhibition by this substance is not caused by 
conformational restriction, but by the presence of the benzene moiety. Analysis of the substances in 
fibroblasts indicated a higher toxicity of the open chain compound, which is in agreement with the current 
view on cytotoxicity of cell-permeable ceramide analogs.  
8.) In chapter 4.9, a direct influence of 5b and 24 on protein kinase C as another potential mediator of the 
indirect effect on glycosphingolipid metabolism has been ruled out experimentally. 
 
Although the molecular target of 5a,b could not been identified, novel tools to address this question have 
been prepared in this work, several possibilities have been ruled out, and the integrity of the Golgi 
apparatus has been shown to be affected by these substances. 
 
        3
GA2
GlcCer
GM2 GD2
SAT I SAT II
GalNAcT
Cer
GlcT
GalT
GD1aGM1
HN O
O
HO
I
C13H27
HN O
O
HO
I
C13H27
HN O
O
HO
OH
C14H29
5a active
18a inactive
5c inactive
 
LacCer GM3 GD3
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2. Introduction 
2.1. Sphingolipids 
2.1.1. Structure, metabolism, and function 
 
Sphingolipids, including ceramide, sphingomyelin, and glycosphingolipids, are components of the outer 
leaflet of eukaryotic plasma membranes (Kolter and Sandhoff, 1999). Ceramide (Figure 2.1) consists of a 
long chain 2-amino-1,3-diol, which is N-acylated with a fatty acid. Most of the long chain bases contain an 
E-configured ∆4,5-double bond. Especially in the human epidermis, the sphingoid base can also be 
saturated, 4-hydroxylated, and/or modified in other ways (Holleran et al., 2006). In mammalian tissues, the 
most common sphingoid base is D-erythro-C18-sphingosine. In vertebrates, the N-acyl group normally 
consists of 16-24 carbon atoms, wereas much longer acyl chains up to 36 carbon atoms are present in 
ceramides of the human skin to form the epidermal water barrier (Coderch et al., 2003; Holleran et al., 
2006). 
 
The de novo biosynthesis of ceramide is catalyzed by membrane-bound enzymes that are localized on the 
cytosolic leaflet of the endoplasmic reticulum (ER) (Mandon et al., 1992). The first step is the condensation 
of the amino acid L-serine with Palmitoyl-CoA to 3-Ketosphinganine, catalyzed by the pyridoxal phosphate-
dependent enzyme serine palmitoyltransferase (Braun and Snell, 1968; Stoffel et al., 1968; Hanada, 2003). 
Subsequent steps are the reduction to D-erythro-sphinganine catalyzed by 3-Ketosphinganine reductase in 
the presence of NADPH, followed by acylation to dehydroceramide. The acylation is catalyzed by enzymes 
encoded by different genes (longevity assurance genes). They control by which fatty acids the spingoid 
bases are N-acylated to generate different dihydroceramide species (Pewzner-Jung et al., 2006). Insertion 
of the 4,5-trans-double bond of ceramide is introduced by a dihydroceramide desaturase (Rother et al., 
1992). From the ER, ceramide is transferred to the Golgi apparatus or the trans-Golgi network (TGN) with 
the aid of a transfer protein, CERT (Hanada, 2006). 
At the cytosolic leaflet of the Golgi apparatus, ceramide can be transformed to glucosylceramide (GlcCer), 
while galactosylceramide (GalCer) is formed on the lumenal site of the Golgi and the phospholipid 
sphingomyelin (SM) is formed in the TGN and the plasma membrane (Huitema et al., 2004). The 
glucosyltransferase and galactosyltransferase transfer a hexose residue from the nucleotide-activated 
sugar (UDP-Glc, UDP-Gal) to the 1-OH-group of ceramide. These glycolipids are precursors of a number of 
complex glycolipids (chapter 2.2.2). The lipid-binding protein FAPP2 (four-phosphate adaptor protein) is 
reported to be required for the non-vesicular transport of glucosylceramide to the distal Golgi compartments 
(D’Angelo et al., 2007), and plays are role for the biosynthesis of glycosphingolipids (Halter et al., 2007). 
Sphingomyelin is synthesized by the transfer of phosphorylcholine from phosphatidylcholine to ceramide 
liberating diacylglycerol through the action of the sphingomyelin synthase (review: Tafesse et al., 2006). 
Another metabolite of ceramide, ceramide-1-phosphate (C1P), is formed by phosphorylation catalyzed by 
the ceramide kinase (Bajjalieh and Batchelor, 2000).  
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The major pathway for the catabolism of ceramide is its deacylation by ceramidases to sphingosine, which 
in turn can be phosphorylated at the 1-position to sphingosine-1-phosphate (S1P). S1P can be cleaved by a 
pyridoxal phosphate dependent lyase to phosphoethanolamine and hexadec-2-enal, or it can be 
transformed to sphingosine by the action of phosphatases. Another sphingolipid is 
sphingosylphosphorylcholine (SPC, lysosphingomyelin), which can be formed by deacylation of 
sphingomyelin by a sphingomyelin deacylase. SPC occurs naturally in plasma and is a consituent of 
lipoproteins. Several studies indicated that SPC can act as a mitogen in several different cell types and in 
certain circumstances may also be a pro-inflammatory mediator (Review: Nixon et al., 2008), but there are 
no exact information of the mechanisms involved available. In addition, SPC is discussed to be potentially 
involved in neurotoxicity in Niemann-Pick type A (NP-A) disease (Chiulli et al., 2007). This lysosomal 
storage disease is characterized by the genetically determined absence of acidic sphingomyelinase activity 
and accumulation of sphingomyelin and also SPC in various tissues, including the brain.  
In the salvage pathway, ceramide can be generated by acylation of sphingosine by the ceramide synthase. 
In addition, sphingomyelin and glycosphingolipids can be degraded to ceramide through the action of 
sphingomyelinases (Goni and Alonso, 2002) and glycosidases, specially in the lysosomes.  
 
Sphingolipids are structural components of the plasma membrane of eukaryotic cells. In this context, it is 
suggested that GSLs and sphingomyelin together with cholesterol and GPI-anchored proteins form 
organized microdomains on the plasma membrane (Simons ans Ikonen, 1997). These so-called “rafts” are 
believed to take part in processes such as protein sorting, cell adhesion, signal transduction or cell 
resistance towards viral infection (Hanzal-Bayer and Hancock, 2007; van Meer and Sprong 2004, 
Sangiorgio et al, 2004). However, the raft-concept is an extrapolation of in vitro-results (Brown and London, 
2000), and most of the biological studies of the domain organization of membranes are carried out using 
detergents (e. g. Triton, CHAPS) to extract detergent resistance membranes (DRMs), or with the aid of 
antibodies. There is no evidence that the composition of DRMs correlates with that of native lipid rafts in cell 
membranes (Heerklotz et al., 2003). Until now, the existence of these rafts has not been demonstrated 
experimentally and is still controversially discussed (Munro, 2003; Shaw 2006). 
In addition to their structural roles, sphingolipids attracted attention as bioactive mediators in a variety of 
biological processes, including the regulation of apoptosis (Ruvolo, 2003), cellular transformation, 
differentiation and proliferation, as well as other cell signaling processes (Figure 2.2; Liu et al., 1999; 
Fernandis and Wenk, 2007; Hannun and Obeid, 2008). In response to diverse extracellular stimuli, 
including tumor necrosis factor α, platelet-activating factor, and stress factors such as heat and UV 
radiation, ceramide is formed by the hydrolysis of sphingomyelin by sphingomyelinases or by enhanced 
biosynthesis. In most cell types, ceramide and its deacylated form (sphingosine) are mediators of cell-cycle 
arrest, cell differentiation, and apoptosis. The saturated form (dihydroceramide) is apparently not 
proapoptotic, indicating a functional role of the C4-C5 double bond for the induction of apoptosis (Bielawska 
et al., 1993). It has been suggested that ceramide mediates this action through binding and regulation of 
intracellular effectors such as protein kinases PKCα and PKCζ (Mathias et al., 1991; Wang et al., 2005), 
serine/threonine protein phosphatase-1 and –2A (Chalfant et al., 2004), and the cysteine protease 
cathepsin D (Heinrich et al., 2000). In addition, alteration of membrane properties (Goni and Alonso, 2006) 
have to be considered. Also the formation of ceramide-pores in mitochondria have been proposed to occur 
in apoptosis (Siskind et al., 2006) Recent studies support the notion that changes within ceramide 
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metabolism are critically involved in human diseases, such as neurological disorders, Wilson`s disease, 
lung injury, cancer, allergies, and infections (Schenk et al., 2007). The deacylated form of ceramide, 
sphingosine, is generated by the action of ceramidases and mediates cell cycle-arrest and apoptosis 
(Suzuki et al., 2004). Unlike ceramide and sphingosine, S1P is a mediator of cell growth and survival in 
most cell types (Milstien et al., 2007). S1P acts as ligand of extracellular receptors of the EDG family, now 
termed S1P receptors (Spiegel and Milstien, 2003). Furthermore, S1P acts as an intracellular second 
messenger to control calcium mobilization, although its intracellular target is not known. In contrast to S1P, 
little is known about its corresponding saturated form, dihydrosphingosine-1-phosphate (dhS1P), which is 
formed from dihydrosphingosine by the action of sphingosine kinase. Ceramide-1-phosphate is generated 
by phosphorylation of ceramide catalyzed by ceramide kinase (Bajjalieh and Batchelor, 2000). C1P 
stimulates DNA synthesis and promotes cell division. Phytosphingosine (PHS) and phytoceramide (PHC) 
are abundant in fungi and plants, and are also found in eukaryotic cells. Compared to other sphingosine-
derivatives, they possess a hydroxyl-group at C-4 in the sphingoid long-chain base instead of a trans 
double bond. It has been reported that PHS inhibits cell growth in a specific manner differing from that of 
other sphingolipids (Chung et al., 2001). In summary, the interconnected network of sphingolipid 
metabolism regulates the formation of diverse sphingolipids that function as critical determinants of 
membrane structure, as well as a source of bioactive molecules involved in various signalling mechanisms 
and cell regulatory pathways (Sims et al., 2007).  
SphingosineCeramide    S1P
SphK
Apoptosis
Cell-cycle arrest
Cellular senescence
Differentiation
Apoptosis
Cell-cycle arrest
Cell survival
Cell motility
Cell proliferation
Inflammation
Sphingomyelin
UV radiation
Chemotherapy
Death receptors
Heat stress
UV radiation
Chemotherapy
Death receptors
Growth factors (IGF, PDGF)
Cytokine (TNFα, IL-1)
SMase CDase
Inducers
Targets Protein kinases S1P receptors
CAPPs (PP1, PP2A)
Protein kinase C
Cathepsin D
Global membrane properties
Biology
 
Figure 2.2: Potential participations of ceramide and its metabolites as putative coordinators in cell 
biological responses (modified from Hannun and Obeid, 2008). Abbreviations: CAPP = ceramide activated 
Ser-Thr phosphatase; CDase = ceramidase; IGF = insulin-like growth factor; IL-1 = interleukin-1; PDGF = 
platelet-derived growth factor; TNFα = tumor necrosis factor α; SMase = sphingomyelinase; S1P = 
sphingosine-1-phosphate; SphK = sphingosine kinase. 
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2.2. Glycosphingolipids  
2.2.1. Function  
 
Glycosphingolipids (GSLs) are components of eukaryotic cell membranes. They consist of ceramide and an 
oligosaccharide chain. The hydrophilic oligosaccharde moiety is exposed to the extracellular space, while 
their hydrophobic ceramide part is embedded in the outer leaflet of the plasma membrane (Kolter and 
Sandhoff, 1999; Sonnino et al., 2006). Variation in type, number, and linkage of carbohydrate residues, and 
additional modifications of the lipid moiety of glycosphingolipids, give rise to a large number of naturally 
occurring GSL structures. On cellular surfaces, GSLs form complex patterns, which are cell-type-specific 
and change during cell differentiation, or viral and oncogenic transformation. The function of these complex 
GSL patterns is not entirely clear, and only relatively few GSLs have been shown to control cellular 
functions (Review: Hakomori, 2005).  
 
GSL
GSL
 
Figure 2.3: Interactions between GSLs and proteins. A: Glycolipid-mediated 
cell-cell recognition; B: regulation of receptor activity 
 
 
They can interact with soluble or membrane-bound lectins outside the cell (Figure 2.3. A), and thus serve as 
binding sites for bacteria, viruses, and toxins (Heung et al., 2006; Hanada, 2005), and mediate cell 
adhesion processes (Schnaar, 2004). An example is the axon-myelin-interaction mediated by binding of 
complex gangliosides such as GD1a and GT1b to the myelin-associated glycoprotein (Pan et al., 2005). 
Furthermore, GSLs can regulate the function of proteins present in the same membrane (Fig. 2.2, B). This 
has been demonstrated for the downregulation of insulin receptor activity by ganglioside GM3 in genetically 
engineered mice, lacking GM3 synthase (Yamashita et al., 2003). These animals did not develop insulin-
resistance when fed on a high-fat diet, suggesting that ganglioside GM3 is a potential therapeutic target in 
type 2 diabetes (Zhao et al., 2007).  
There is also evidence that GSLs can influence the conformation of several proteins. Recent studies 
showed that various gangliosides have a high affinity to the pathological conformers of the Alzheimer 
amyloid peptide and the prion proteins (Ariga et al., 2001). Additionaly, Galactosylceramide and 
sphingomyelin were detected in highly purified preparations of prion rods, and the composition of these 
lipids correlates inversely with the infectiveness of the material (Klein et al., 1998). 
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2.2.2. Biosynthesis of glycosphingolipids 
 
 
The synthesis of gangliosides and other GSLs starts with the formation of glucosylceramide (GlcCer) at the 
cytosolic leaflet of the Golgi apparatus which undergoes a transversal membrane translocation to the lumen 
of the Golgi apparatus (De Rosa et al. 2003), where membrane-resident glycosyltransferases transfer 
nucleotide activated sugars and sialic acids to the carbohydrate chain (Uliana et al., 2006). In has been 
shown that the transfer of GlcCer for the synthesis of GSLs requires the action of the lipid-binding protein 
FAPP2 (D’Angelo et al., 2007). A new model suggests that GlcCer, which is formed at the cytosolic leaflet 
of the Golgi apparatus is transported back to the ER via FAPP2, translocates across the ER membrane and 
enters the vesicular membrane flow to the Golgi (Halter et al., 2007).  
The formation of complex ganglioside patterns on the cell surface is based on a combinatorial synthesis 
(see figure 2.3), which is now better understood through the analysis of animal models (Review: Kolter et 
al., 2002) and is coupled to the exocytotic vesicle flow through the Golgi apparatus to the plasma 
membrane. At least for GSLs of the ganglio series, it has been shown that in the early compartiments of the 
Golgi, glycosyltransferases control the generation of precursors (LacCer, gangliosides GM3, GD3, and 
GT3) of several series of gangliosides and are the branching point of ganglioside biosynthesis. Expression 
and activity of the glycosyltransferases influences the final pattern of glycolipids at the cell surface. The 
GM3 synthase (ST3Gal V; SAT I) and the GD3 synthase (ST8Sia I; SAT II) have a high specificity for the 
glycosyl acceptor, while the sialyltransferase IV (ST8Sia IV; SAT IV) and the sialyltransferase V (ST8Sia V, 
SAT V) use different substrates (Pohlentz et al., 1988). Pohlentz et al. and Iber et al. showed that the 
sequential glycosylation of the precursor GSLs to the complex 0, -a, -b, and –c ganglioside series is 
catalyzed by unspecific glycosyltransferases (Pohlentz et al., 1988; Iber et al., 1991). For example, the N-
acetyl-galactosaminyl-transferase catalyzes not only the reaction from GM3 to GM2, but also from GD3 and 
GT3 to GD2 and GT2, and in vitro and in SAT-1-deficient mice also from LacCer to GA2. The heterogeneity 
in the expression pattern of ganglioside synthase genes during mouse development shows that the 
transcriptional regulation of transferases and translocators is the most important level of control of glycolipid 
biosynthesis (Yamamoto et al., 1996). The activity of glycolipid glycosyltransferases can also be regulated 
by post-translational modifications like phosphorylation. Bieberich and co-workers reported that ganglioside 
compositional changes accompanying differentiation may be specifically induced by activation and inhibition 
of, respectively, GalNAc-T and Sial-T2 by protein kinase A- and protein kinase C-related phosphorylation 
systems of these cells (Bieberich et al., 1998). 
Specific transporters translocate the nucleotide sugars from the cytosol to the lumen of the Golgi-apparatus 
and can be rate-limiting e.g. in the supply of UDP-galactose into the Golgi lumen (Review: Csala et al., 
2007; Brändli et al. 1988; Perez and Hirschberg 1985). Experiments with mutant polarized epithelial cells 
deficient in the UDP-Gal-transporter showed that the levels of the sugar nucleotide play a regulatory role in 
determining the composition of galactose-containing glycosphingolipids (Toma et al., 1996). 
The activity of glycosyltransferases can also be affected by the pH value of their environment. Labeling 
studies in primary cultured murine cerebellar cells showed the influence of the pH value of the medium on 
the biosynthesis of glycolipids (Iber et al., 1990). After lowering the pH of the culture medium from 7.4 to 
6.2, the pattern of gangliosides changed in a reversible manner from the a- to the b-series. 
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Other studies indicate a regulation of glycosphingolipid biosynthesis by feedback control either by their 
respective reaction product or by an end product of the respective glycosphingolipid series (Yusuf et al., 
1987; Review: Kolter et al., 2002). Sphingosine, as degradation product of GSLs, downregulates the serine 
palmitoyltransferase which catalyses the first step of sphingolipid biosynthesis (Mandon et al., 1991). 
Furthermore, the formation of multi enzyme complexes from glycosyl- and sialyltransferases was 
demonstrated by coimmunoprecipitation (Bieberich et al., 2002; Giraudo et al, 2003), after it has been 
postulated by Roseman many years ago (Roseman, 1970). The enzyme complex of GalNAc-transferase 
and galactosyltransferase II may accept ganglioside GM3, and finally releases ganglioside GM1. This might 
explain why the brain contains large amounts of gangliosides GM1 and GD1a, but little amounts of 
ganglioside GM2 (Review: Kolter et al., 2002). 
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Figure 2.4: Ganglioside biosynthesis (Pohlentz, 1988; Kolter et al., 2002). Enzyme 
defects in knockout mice are indicated. A: ceramide glycosyltransferase -/-, B: 
galactosyltransferase -/-, C: sialyltransferase I -/-, D: sialyltransferase II -/-, E: GalNAc 
transferase -/-, ‘GM3-only’ mice have enzyme defects D+E. 
 
 
To date, only a few human diseases are known to be associated with sphingolipid biosynthesis. A 
deficiency of a biosynthetic enzyme associated with a human disease is reported for lactosylceramide 2,3 
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sialyltransferase (GM3-synthase). Deficiency of this enzyme causes an autosomal recessive infantile-onset 
symptomatic epilepsy syndrome (Simpson et al., 2004). Another human disease is caused by alteration of a 
biosynthetic enzyme in the biosynthesis of ceramide. In hereditary sensory neuropathy, type 1, there is an 
increased activity of serine palmitoyltransferase, which results in increased de novo ceramide synthesis and 
triggers apoptosis of neural cells (Dawkins et al., 2001).  
 
2.2.3. Catabolism and sphingolipid storage diseases 
 
The constitutive degradation of sphingolipids and GSLs occurs in the acidic subcellular compartments, the 
endosomes and lysosomes, at the surface of intra-endosomal and intra-lysosomal membrane structures 
(Fuerst and Sandhoff, 1992; Kolter and Sandhoff, 1999). During endocytosis, parts of the plasma 
membrane are internalized and transported via the endosome to the lysosomal compartment. The inner 
leaflet of the lysosomes is covered with a thick glycocalix made of sugar chains (mostly lactosamine 
structures) of LIMPs (lysosomal intergral membrane proteins) and LAMPs (lysosomal associated 
membrane proteins) (Eskelinen et al., 2003). This glycocalix protects the membrane from enzymatic attack, 
but is also involved in the targeting of soluble lysosomal enzymes (Griffiths, 2007). Along the endocytic 
pathway, the luminal pH value of these organelles steadily decreases from 6.0 to 4.0 to reach optimal 
conditions for the action of lysosomal enzymes. The carbohydrate residues of GSLs are sequentially 
cleaved off by the action of watersoluble exohydrolases. Membrane-bound glycosphingolipids with less than 
four carbohydrate residues require the additional presence of activator proteins and negatively charged 
lysosomal lipids such as BMP for degradation (Wilkening et al., 1998; Fürst and Sandhoff, 1992). 
Sphingolipid activator proteins (SAPs) solubilize membranes and mediate the interaction between the 
membrane-bound substrate and the enzyme.  
In humans, inherited defects of glycosphingolipid and sphingolipid catabolism give rise to lysosomal storage 
diseases, the sphingolipidoses. For almost all of the steps of the constitutive degradation of sphingolipids, 
an inherited disorder is known (Gieselmann, 1995; Futerman and van Meer, 2004; Kolter and Sandhoff, 
2006). These storage disorders are generally caused by genetic defects of enzymes or activator proteins 
acting in the degradation pathway (Figure 2.4). To these belong GM1- and GM2 gangliosidoses, Niemann-
Pick-disease, type a and b, Gaucher-, Farber-, and Krabbe disease, as well as metachromatic 
leucodystrophy. With the exception of Fabry disease, which exhibits an X- chromosomal mode of 
inheritance, the sphingolipidoses are inherited in an autosomal recessive mode. 
The GM2 gangliosidoses are caused by the deficiency of one of the polypeptide chains required for 
degradation of ganglioside GM2. β-Hexosaminidase α-chain deficiency is known as Tay-Sachs disease, β-
chain deficiency as Sandhoff disease, and deficiency of the GM2 activator protein as AB-variant of the 
GM2-gangliosidoses. The accumulation of nondegradable enzyme substrates damages cells and organs 
that synthesize the relevant lipid by only partially clarified mechanisms. Due to their cell-type specific 
expression, the dysfunction in the metabolism of gangliosides leads primarily to the degeneration of the 
CNS.  
The correlation between lipid storage and cellular dysfunction is not fully understood (Silence and Platt, 
2003). The accumulation of morphogenetically active compounds (Purpura and Suzuki, 1976) such as toxic 
lysoglycolipids (Neuenhofer et al., 1985; Suzuki, 1998) and cholesterol, which modulates the endocytotic 
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membrane flow (Puri et al., 1999) and induces Golgi vesiculation (Grimmer et al., 2005), are among the 
factors that are considered to be relevant for the pathogenesis.  
 
 
Figure 2.5: Pathways for lysosomal glycosphingolipid metabolism (Kolter and Sandhoff, 2005). Degradative 
enzymes and activator proteins and corresponding storage diseases are shown. 
 
The aim of most causal therapies of sphingolipidoses is the restauration of the defective degradation 
capacity within the lysosome. A causal therapy for sphingolipidoses exists only for the adult forms of 
Gaucher and Fabry disease. In these cases, the degradation capacity can be enhanced by intravenous 
application of the recombinant intact enzyme (enzyme replacement therapy; Barranger and O’Rourke, 
2001; Brady, 1997). A new concept is the so-called enzyme-enhancement therapy with the aid of “chemical 
chaperones” (Tropak and Mahuran, 2007; Fan and Ishii, 2007; Yu et al., 2007). This strategy aims to 
enhance the fraction of correctly folded, and thus active, enzyme by binding to an inhibitor. Radin (1996) 
suggested an additional strategy for the treatment of sphingolipidoses, the substrate reduction therapy. The 
treshold theory (Conzelmann and Sandhoff, 1983/84; Leinekugel et al., 1992) explains how the ratio of 
substrate influx into the lysosomes and degradation capacity determines the course of a sphingolipid 
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storage disease like the GM2-gangliosidoses or metachromatic leukodystrophy. The substrate reduction 
therapy consists in the reduction of substrate influx into the lysosomes. This can be achieved by inhibition of 
biosynthetic enzymes (Platt et al., 1997) or in genetic model animals (Liu et al., 1999). A necessary 
condition for this treatment is the existence of residual activity of the defective enzyme in the lysosome. Two 
classes of sphingolipid derivatives have been investigated as inhibitors of ceramide glucosyltransferase and 
used for substrate reduction therapy of sphingolipidoses: imino sugar derivatives such as N-
Butyldeoxynojirimycin and compounds like D-threo-(1R,2R)-1-phenyl-2-decanoyl-amino-3-morpholino-1-
propanol (Abe et al., 1992; Platt and Butters, 2000; Tifft and Proia, 2002). 
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Figure 2.6: Pharmacologic strategies for the treatment of glycosphingolipid storage diseases. 
Abbreviations: DNJ = N-Butyldeoxynojirimycin; PDMP = D-threo-(1R,2R)-1-phenyl-2-decanoyl-
amino-3-morpholino-1-propanol 
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2.3. Conformational restriction of ceramide 
 
Conformationally flexible compounds can adopt a variety of conformations, which may make it possible for 
them to bind to different proteins, sometimes via different conformations (Figure 2.7), basing on the “lock 
and key rationale” proposed by Emil Fischer many years ago (Fischer, 1894). Restriction of conformational 
flexibility is a commonly used technique in the design of biologically active compounds and is a widely used 
approach in drug development (Review: Harrold, 1996; Mann, 2003).  
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ligand destruction
 
Figure 2.7: Conformational equilibrium of a flexible ligand 
(Kolter, 2004) 
 
The conformational restriction strategy can lead to analogs with enhanced affinity (1), selectivity (2), and 
metabolic stability (3) compared to the parent compound (King, 1995).  
(1) The energy required to change a drug molecule from its most energetically preferred conformation in 
solution to its receptor-bound active conformation enzyme can be obtained experimentally. The contribution 
of the different types of interactions to the change of free enthalpy on ligand binding are loss of translational 
and rotational entropy, formation of hydrogen bonds, ionic interactions, lipophilic contact, and arrest of 
rotatable bonds (Review: Kolter, 2004). The conformational restriction of a molecule reduces entropy loss 
on receptor binding and contributes in this way to receptor affinity. Many examples of this concept are 
represented in Medical Chemistry, e. g. the development of enzyme inhibitors of HMG-CoA reductase for 
the treatment of hypercholesterolemia (Pfefferkorn et al., 2007) or inhibitors of tubulin polymerization for the 
treatment of cancer (Mateo et al., 2007). Other examples from the lipid field are phorbol esters and 
bryostatin, which can be regarded as conformationally rigid natural analogs of 1,2-diacylglycerol (DAG). 
DAG binds to and activates protein kinase C (PKC), and thus initiates biological processes such as signal 
transduction, cell regulation and, tumor promotion (Ron et al., 1999). The binding affinity of phorbol esters 
to PKC are 3-4 orders of magnitude higher than those of DAGs and they have been used as lead 
compounds in the development of analogs of more simple structures (Kang et al., 2004).  
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(2) Also binding selectivity toward receptor subtypes can be enhanced when alternative receptors recognize 
alternative conformations, which are not accessible for the restricted system. For example, the selective 
binding of histamine derivatives to the H3 receptor, which is one of four receptor subtypes for the 
neurotransmitter histamine (Watanabe et al., 2006). Antagonists of the H3 receptor are considered to be 
potential drugs for diseases such as Alzheimer’s disease, dementia, and epilepsy (Leurs, 1998). 
(3) Also Drug metabolizing enzymes can recognize distinct conformations of their substrates, which can 
differ from those bound by other receptors. Therefore, conformational restriction can also be used to 
enhance the biological half life of a ligand and improve its pharmacokinetic properties. In this context, DAG 
is metabolized immediately through phosphorylation or hydrolysis, while phorbol esters persistently activate 
PKC because there is no natural mechanism to terminate their action.  
 
With the exception of sterols, most membrane lipids including sphingolipids are conformationally flexible 
molecules. The question arises, whether the concept of conformational restriction can be extended to the 
field of sphingolipids (Review: Kolter, 2004). Ceramide and ceramide analogs exogenously applied to 
cultured cells can induce a variety of complex effects, including metabolic transformation and apoptotic 
responses, which complicates the analyses of their function. Ceramides with selectivity for one of the 
putative ceramide binding proteins or metabolizing enzymes are potential means to characterize the 
proteins involved and to influence their respective pathways. To date, only a few conformationally 
constrained sphingolipid analogs have been characterized (Figure 2.8).  
The sphingosine analog Penazetidine A, bearing an azetidine ring as structural component, was isolated 
from Penares sollase (Shier and Shier, 2000). Penazetidine A inhibits proteinkinase C (PKC) with an IC50 of 
1 µM and has been considered as an anticancer agent (Alvi et al., 1994). A synthetic pyrrolidine-derivative 
(Figure 2.8) can be regarded as a conformational restricted analog of 1-deoxy-5-hydroxysphinganine, which 
showed cytotoxic effects against HT-29 cells (human colon adenocarcinoma; Dougherty et al., 2006). 
Examples for conformationally restricted ceramide-derivatives are the synthetic Uracil- and Thiouracil-
derivatives that showed moderate effects in terms of toxicity and anti-tumor activity in vitro and in vivo 
(Maccia et al., 2001). Isoquinoline-derivatives were investigated as ligands of protein phosphatase 2A, a 
ceramide binding protein involved in the transmission of the ceramide-mediated signal into the cell (Leoni et 
al., 1998). Oxazolidinone-derivatives were shown to exhibit cytotoxity in human cancer cell lines (Ha et al., 
2006). The lactone-derivative can also be regarded as a conformationally rigid ceramide derivative. They 
have been reported as potent and selective inhibitors of neutral sphingomyelinase (Wascholowski and 
Giannis, 2006). 
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3. Aim and Concept of the present study 
 
 
Ceramide can be metabolized to a series of sphingolipids that play a role in a number of cellular events. 
The exogenous application of ceramide analogs to cells leads to a variety of effects (van Blitterswijk, 2003), 
including metabolic transformation and apoptotic responses, thus complicating the analysis of sphingolipid 
function. The initial aim of the present study was to reduce the multitude of ceramide-mediated effects using 
synthetic ceramide analogs. The restriction of biologically active, conformationally flexible ligands is a 
widely used approach in drug development, especially in the area of peptide mimetics (Giannis A. et al., 
1993). Extrapolation of this concept, from peptides to lipids we designed and synthesized ceramide 
derivatives and investigated their effect on the biosynthesis of complex GSLs. Following questions arised 
from the observation, that ceramide analogs such as 5a and 5b (Figure 4.2) can interfere with the 
biosynthesis of complex GSLs in cultured cells: 
 
1) Which molecular mechanism underlies the modulation of GSL biosynthesis in cultured cells 
incubated with halogenated ceramide derivatives? 
 Exogenous addition of 5a and 5b to cultured cells led to the accumulation of ganglioside GM2-
synthase-substrates. However, no inhibition of the recombinant enzyme could be detected in vitro. It 
was therefore necessary to clarify the exact mechanism of action.  
 
2) What is the function of the iodine atom in the ceramide derivatives? 
 The ceramide derivatives 5a and 5b bear an iodine atom, which distinguishes them from most other 
ceramide derivatives that have been applied to cultured cells. To investigate, if the presence of a 
halogen atom is required for the biological activity, ceramide derivatives like 18a and 18b (Figure 4.18) 
had to be synthesized for structure-activity analysis.  
 
3)   How are ceramide derivatives 5a and 5b metabolized after added to cultured cells?  
To investigate if a metabolite of the exogenously added compounds mediates the effect on GSL 
biosynthesis, the lipids of cultured fibroblasts incubated with the active compounds had to be analyzed 
for putative metabolic products derived from the exogenously added substances.  
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4. Results 
4.1. Strategy for the synthesis of ceramide analogs 
 
Ceramide analogs are potential inhibitors of pharmacologically relevant enzymes or ligands of putative 
ceramide binding proteins. In addition, they might be metabolically incorporated into glycosphingolipids and 
sphingomyelin and alter membrane function. Several preparative approaches to sphingolipids have been 
reported, which can be modified for the synthesis of sphingolipid analogs. Ceramides are long chain 2-
amino-1,3-diols, which are N-acylated with a fatty acid. The long chain base has an E-configured ∆4,5-
double bond, but can also be saturated, 4-hydroxylated, and/or modified in other ways (Futerman and 
Hannun, 2004). In mammalian tissues, the most common sphingoid base is D-erythro-C18-sphingosine, and 
the typical N-acyl group has chain lengths of 16-24 carbon atoms, although much longer acyl chains are 
present in ceramides of the skin (Holleran et al., 2006). For the synthesis of the ceramide analogs prepared 
in this work, the amino acid L-serine, and in the case of ceramide analogs with an additional methyl group in 
the 1-position, also L-threonine, has been chosen as starting material.  
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Figure 4.1: Transformation of protected α–amino aldehydes (2a,b) derived from L-serine and L-threonine 
with organometallic (R1 = H, CH3) or Wittig reagents. 
 
These amino acids carry the functional groups at C1 and C2 of the sphingoid backbone including the 
configuration of naturally occurring sphingosine at C2. They allow elongation at C3 (Fig. 4.1) by alkylation or 
olefination, and, in the first case, the establishment of a defined configuration at C3 (Review: Kulkarni et al., 
1999). The alkyl chain was introduced by reaction of Garner’s aldehyde 2a or the corresponding aldehyde 
derived from L-threonine (2b). These intermediates were derived from the natural amino acids in 4 steps. 
The resulting compounds 3a-c were further modified as described in chapters 4.2.1, 4.2.3, 4.4.2, 4.4.3, 
4.7.1,and 4.8.1. 
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4.2. Substituted cyclic carbamates as ceramide analogs 
4.2.1. Synthesis 
 
The conformationally restricted ceramide analogs 5a and 5b (Fig 4.2) have been prepared in a sequence of 
3 reaction steps according to (Sawatzki, 2003a). These structures are of great interest, because previous 
studies in cultured cells showed that oxazinanone 5a and oxazolidinone 5b, but not oxazinanone 5c (Figure 
1.2), led to a reduction of ganglioside biosynthesis on the stage of GM2-synthase (Sawatzki, 2003a).  
The synthesis started with the preparation of Weinreb-amide 1a from L-serine. This was reduced to 
Garner’s serine aldehyde (2a) by treatment with LiAlH4 according to a modified procedure (Campbell et al. 
1998) of the original route (Garner, 1984). The amino aldehyde was elongated by a Wittig reaction, which 
leads to a mixture of (Z)- and (E)-isomers (Z:E = 8:1) of 3a in 73 % combined yield. The two products were 
isolated by column chromatography with silica gel using the solvent system cyclohexane/ethyl acetate (9:1 
by vol.) to afford pure Z-alkene (43 % of total product) and a mixture of both compounds that could be 
further resolved by repeated chromatography. The treatment of (Z)-allylic carbamate 3a with N-
iodosuccinimide (NIS) in dichloromethane according to (Casado-Bellver et al., 2002) leads to the formation 
of the bicyclic products 4a and 4b in 52 % combined yield with the oxazolidinone-derivative 4b as major 
product. The two products were purified by column chromatography with silica gel using the solvent system 
cyclohexane/ethyl acetate (9:1 by vol.), but the separation of 4a and 4b was quite difficult, which explains 
the low isolated yields.  
The relative configuration of the products was determined from the coupling constants of the ring-protons in 
the 1H-NMR-spectra. The coupling constants in the spectrum of compound 4a (J4,5 = 4.5 Hz, J5,6 = 11.3 Hz) 
agree with the expected values and with those of related compounds (Jorda-Gregori et al., 2000). 
Deprotection of the bicyclic compounds 4a and 4b by acidic treatment lead to the compounds 5a and 5b. 
The ring size of the cyclic carbamates was also confirmed by IR absorption of the C=O stretch vibration. 
The strain in cyclic carbamates rises from the 6-membered system to the 5-membered system and causes 
a shift of the C=O stretch absorption to higher frequencies in the infrared spectra. The absorption for 
oxazinanone 5a at 1634 cm-1 and the absorption for the oxazolidinone 5b at 1698 cm-1 are in agreement 
with those of related compounds (Kemp et al., 1996). Treatment of the (E)-isomer of 3a with NIS and 
deprotection leads to the formation of the oxazinanone 5c (Figure 1.2; Sawatzki, 2003a). This reaction was 
not followed, since previous studies showed that the oxazinanone 5c has no influence on sphingolipid 
metabolism as described above (Sawatzki, 2003a). 
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Figure 4.2: Synthesis of compounds 5a and 5b (modified from Sawatzki, 2003a). Abbreviations: EDC.HCl = 
N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide Hydrochloride; DMP = 2,2,-Dimethoxypropane; NIS = N-
iodosuccinimide 
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4.2.2. Analysis of oxazolidinone 5b in primary cultured neurons 
 
Previous studies in cultured cells showed that oxazinanone 5a and oxazolidinone 5b, but not oxazinanone 
5c, led to a reduction of ganglioside biosynthesis on the stage of GM2-synthase (Sawatzki, 2003a). This 
has been demonstrated by metabolic labeling experiments in cultured murine granule cells using the 
radioactive precursor D-[14C]galactose, and in the case of 5a and 5c additionally using L-[3-14C]serine. 
Labelling with L-[3-14C]serine is a measure for de novo biosynthesis, while labelling with D-[14C]galactose 
additionally reflects the contribution of the salvage pathway, which accounts for the majority of 
biosynthetically formed glycosphingolipids in neurons. 
In previous experiments (Sawatzki, 2003a), the influence of 5b on incorporation of L-[3-14C]serine into 
sphingomyelin could not be unambiguously quantified. To proof, if the previous data are reproducible, and 
to analyze the influence of the ceramide-derivative 5b on the biosynthesis of sphingomyelin the target 
compound 5b was investigated again in primary cultured neurons on their effect on sphingolipid 
metabolism. Figure 4.3 illustrates the effect of oxazolidinone 5b on glycosphingolipid biosynthesis. Granule 
cells were prepared from the cerebellum of 6 days old mice. In this case, the cells display time-stable 
glycolipid-patterns. They were incubated with 50 µM 5b in the culture medium for 24 h. L-[3-14C]serine was 
added to the culture medium and its incorporation into newly synthesized sphingolipids was analyzed after 
labelling for 24h. Cells were harvested, lipids were extracted, sphingolipids and GSLs were separated into 
acidic and neutral fractions. After the glycerolipids were removed by mild alkaline hydrolysis the lipid 
extracts were desalted, separated by thin layer chromatography (TLC) and visualized by phosphoimaging. 
In the presence of 5b the incorporation of radioactivity into sphingolipids is 85 % reduced (0.19 µCi/mg 
protein) compared to control (0.22 µCi/mg protein). Cells incubated in the presence of 50 µM 5b and L-[3-
14C]serine (Fig 4.4) accumulate large quantities of radioactively labelled ganglioside GM3 (up to 500% of 
control) and GD3 (to 630% of control). The decrease of glucosylceramide (112% of control) and 
lactosylceramide (125% of control) is not as drastic. The levels of higher gangliosides like GD1a and GT1b 
are reduced compared to the control. Taken together, these data indicate an inhibition of GM2-formation. 
The glycosphingolipid pattern obtained by L-[3-14C]serine labeling in the presence of 50 µM compound 5b 
shown in figure 4.3 is similar to those obtained previously (Sawatzki, 2003a). In addition, the separation into 
neutral and acidic sphingolipids allowed closer examination of SM-levels, which were not significantly 
altered. This indicates that 5b is not recognized by SM-synthase. Also the steady state concentration of 
GlcCer are not significally altered, which might be a result of accumulation of GlcCer as a lipid species 
proximal to the metabolic block, and inhibition of GlcCer formation, which might be expected for a ceramide 
analog. 
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4.2.3. Analysis of the oxazolidinone-derivatives (5b, 6 and 7.2b) in cultured fibroblasts 
 
Because of the low availability of cell material and time consuming preparations of primary granule cells, 
compounds were also tested in cultured human fibroblasts. The use of these cells has the advantage of the 
easy preparation of the cells and their availability from patients or animal models of various different 
diseases. Therefore, the target compounds were investigated in L-[3-14C]serine labeling experiments in 
cultured  human fibroblasts. To address the role of the iodine atom in oxazolidinone 5b for the alteration of 
lipid pattern in cultured cells, oxazolidinones 6 and 7.2b (see figure 4.5 (A)) were testet. Oxazolidinone 6 
was synthesized and provided by Sawatzki (2003a). The Bromine derivative 7.2b was prepared in a 
manner similar to the synthesis of the iodine derivative with NBS (N-Bromosuccinimide) instead of NIS (Fig. 
4.4). The bicyclic products 7.1a and 7.1b were obtained in 68 % combined yield, but the separation of both 
products by column chromatography with silica gel using the solvent system cyclohexane/ethyl acetate (5:1 
by vol.) was difficult. The oxazolidinone-derivative 7.1b was isolated in 21 % yield, while the oxazinanone-
derivative 7.1b was obtained only in a mixture with 7.1a. Deprotection of 7.2b by acidic treatment afforded 
the oxazolidinone 7.2b in 63% yield. The oxazinanone 7.2a was obtained by deprotection of the mixture of 
7.1a and 7.1b. Purification by column chromatography on silica gel using the solvent system 
chloroform/methanol = 10:1 yielded 7.2a in 5% over two steps.   
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Fig. 4.4: Synthesis of Bromocarbamates 7.2a and 7.2b 
 
Cultured fibroblasts were incubated with 25 µM 5b, 6 and 7.2b in the culture medium for 24 h. L-[3-
14C]serine was added to the culture medium and its incorporation into newly synthesized sphingolipids was 
analyzed after labelling for 24h. Lipid extracts were prepared as described above, separated by thin layer 
chromatography (TLC), and visualized by phosphoimaging (Figure 4.5 (A)).  
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Figure 4.5: Effect of oxazolidinones 5b, 6 and 7.2b on the incorporation of 3-[14C]serine into neutral 
sphingolipids of human fibroblasts. Cells were treated with 25 µM target compounds in the culture 
medium for 24h. Then, cells were fed with L-3-[14C]serine in the presence of the tested compound for 24h. 
Lipids were extracted, separated into acidic and neutral fractions, and glycerolipids were removed by 
alkaline treatment. A: Sphingolipids were separated by thin layer chromatography by threefold 
development (as decribed in the material and method section; chapter 6.3.2) Radioactive bands were 
visualized by phosphoimaging. (X = the nature of this band is not known). B: Data are normalized to the 
total radioactivity found in each lane and radioactivity of each TLC spot of untreated cells was set equal 
100%. Data for neutral lipids are given as mean values of two different experiments. 
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The experiments with fibroblasts were complicated by the fact that they contain additional neutral 
glycolipids, GbOse3 and GbOse4, compared to murine granule cells. No solvent system suitable for the 
separation of all neutral sphingolipids from fibroblasts by TLC was described in the literature. The standard 
solvent system chloroform/methanol/water (60:35:8 by vol.) does not provide sufficient separation of 
sphingomyelin and GbOse4. In addition, in order to analyse cholesterol and ceramide, a separate analysis 
(using the solvent system chloroform/methanol/glacial acetic acid 190:9:1 by vol.) is required. The lipid 
analysis of fibroblasts by TLC required the development of a new solvent system. Therefore, a threefold 
development was used with progressively increasing migration distances (chapter 7.3.8, Farwanah et al., in 
preparation). For the separation of neutral lipids, the tlc plate was developed two times using the solvent 
system chloroform/methanol/glacial acetic acid (70:30:8 by vol.), and the solvent front was allowed to 
migrate to about two-thirds of the planned migration distance. This separates the polar sphingolipids (SM, 
GbOse3, GbOse4, LacCer and GlcCer), while the less polar lipids (ceramide, cholesterol) are migrating with 
the solvent front without being separated. In the third stage, ceramide and cholesterol are separated over 
the total migration distance by using the solvent chloroform. The polar lipids do not migrate on the plate in 
this mobile phase and remain in their original position. 
In the presence of 25 µM of the oxazolidinone-derivatives 5b, 6 and 7.2b in the medium of cultured 
fibroblasts, the incorporation of L-[3-14C]serine into sphingolipids was increased. Compared to untreated 
control cells (2.33 µCi/mg protein), the incorporation of L-[3-14C]serine into sphingolipids increased in the 
presence of 5b by 178 % (4.15 µCi/mg protein), in the presence of 6 by 106 % (2.47 µCi/mg protein), and in 
presence of 7.2b by 141 % (3.2 µCi/mg protein). This is in contrast to the results obtained from the 
experiments in cultured neurons (chapter 4.2.2, figure 4.3). We observed, that in the presence of the 
halogenated oxazolidinones 5b and 7.2b, the incorporation of radioactivity into ceramide drastically 
increased, whereas the incorporation of radioactivity into sphingomyelin was slightly reduced. It has been 
shown in human keratinocytes, that the expression rates of several enzymes involved in ceramide 
metabolism, including serine palmitoyl transferase, increase in the presence of ceramide-derivatives 
(Brodesser and Kolter, in preparation). In addition, the authors showed, that the transcription of the gene 
encoding acid sphingomyelinase, that cleaves sphingomyelin into ceramide and phosphocholine, is also 
increased. In order to clarify, if the accumulation of ceramide and the decreased level of sphingomyelin 
brought about by 5b, are a consequence of an inhibition of the ceramide metabolizing enzyme 
sphingomyelin synthase, or are a consequence of an increased expression or of acid sphingomyelinase, we 
have to make further experiments, including the quantification of mRNA levels and activity assays of 
ceramide metabolizing enzymes. In terms of the influence on GSL biosynthesis the iodine substituted 
oxazolidinone 5b has the effect on the L-[3-14C]serine incorporation. In the presence of 25 µM 5b in culture 
medium, levels of neutral GSLs (GlcCer, LacCer, GbOse3 and GbOse4) were elevated up to 200 % 
compared to control cells. In addition, in the presence of 5b we observed an increased L-[3-14C]serine 
incorporation into all gangliosides. However, we did not observe a specific accumulation of ganglioside 
GM3. The ganglioside content, pattern, and, in particular, the molar ratio of GM3 and GD3 of cultured 
fibroblasts have been shown to be very variable (Sciannamblo et al., 2003; Colombo et al., 2000). The 
influence of ceramide derivative 5b on ganglioside biosynthesis was analyzed in only one experiment yet. 
Therefore, the results should not be used for any conclusions, and have the to be confirmed by further 
experiments.  
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4.3. Determination of GalNAc-transferase (GM2-synthase) activity in the presence 
of oxazolidinone 5b in vitro 
 
 
The glycolipid pattern generated by exogenous addition of compounds 5a and 5b to cultured murine 
neurons are qualitatively identical to those obtained from cells derived from the GM2-synthase ko-mice 
(Yamashita et al., 2003). 
To determine whether oxazolidinone 5b inhibits GalNAc-transferase directly, 5b was tested in vitro with 
murine recombinant GM2-synthase in a micellar assay. GalNAc-T was isolated as membrane fraction from 
Baculovirus-transfected insect cells overexpressing murine GalNAc-transferase, as described in the 
Material and Methods section. The assay was conducted under conditions described by Wendeler et al., 
2003, with some modifications. Samples of the enzyme were incubated with 200 µM 5b in the assay buffer, 
radiolabeled UDP-[3H]GalNAc, and different concentrations of ganglioside GM3 under micellar conditions 
for 30 min at 37°C. Glycolipids were separated by reversed phase chromatography (Kyrklund, 1987), the 
flow-through containing watersoluble UDP-[3H]GalNAc was discarded, and radiolabeled ganglioside GM2 
was eluted and measured by scintillation counting. The ratio of transferred [3H]GalNAc on the acceptor 
ganglioside GM3 was determined by quantification of radioactivity incorporated into the lipid substrate. 
For the determination of enzyme activity, the assay was conducted in the absence of 5b (Figure 4.6). In the 
presence of 200 µM 5b, incorporation of [3H]GalNAc is increased compared to control. This indicates a low 
activation of the enzyme, or a higher availability of the substrate in the presence of the oxazolidinone 5b. In 
conclusion, no inhibition of the enzyme by 5b could be obtained in vitro under micellar conditions. Also a 
micellar GalNAc transferase assay in the presence of lipid extracts derived from fibroblast cells incubated 
with 5b showed no inhibition. 
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Figure 4.6: Effect of compound 5b on activity of recombinant 
GM2-synthase in a micellar assay. The incorporation of 
[3H]GalNAc into lipids is shown in dependence of GM3 
concentration. Test series have been carried out in the presence 
and absence of 5b.  
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Micelles composed of detergents such as N-Octyl-beta-D-glucopyranoside represent a quite simplified but 
unphysiological model of biological membranes. Nevertherless, the preparation of micelles is rapid and 
straightforward and they are widely used in activity assays of membrane-bound enzymes. Compared to 
micelles, unilamellar liposome modelsystems resemble biological membranes more closely. To test the 
influence of the oxazolidinone 5b on GalNAc-transferase activity under more physiological conditions, we 
planned to test the ceramide-derivative in a detergent-free liposomal assay according to Wendeler (2004). 
Up to now, our attemps were not successful. The composition of the liposomes (45 mol% PC, 20 mol% 
cholesterol, 15 mol% GM3, 10 mol% PE, 10 mol% PG) was based on the described content of lipids in 
Golgi membranes (van Meer, 1998). Through sonication, the exchange or fusion of the GalNAc-transferase 
preparation with GM3-containing liposomes was stimulated and the samples were then incubated for 30 
min at 37°C. The specific activity of the GM2-synthase determined in the liposomal assay system was only 
3% compared to the activity determined in a micellar testsystem. For further experiments, we have to 
optimize the fusion of GM3-containing liposomes and enzyme-containing membranes.  
 
 
4.4. Analysis of potential metabolites derived from carbamates 5a and 5b 
 
Since the effect of substances like 5b on GSL biosynthesis is an indirect one, we investigated if a 
metabolite of 5b might be the inhibitor of the GalNAc-transferase. Synthetic ceramide derivatives 
exogenously added to cultured cells can be metabolized to various compounds. In contrast to most other 
drugs, ceramide analogs added to cells can undergo anabolic reactions similar to those of the parent 
compound. They can be metabolized like endogenous ceramide by the enzymes that catalyze the formation 
of glucosylceramide, sphingomyelin, or ceramide-1-phosphate. Several strategies were followed to monitor 
metabolism of the synthetic ceramide derivatives. In one approach, it was attempted to incorporate a 
radioisotope into the substance. This could be followed by the analysis of lipid extracts from cells incubated 
with the labeled compound by thin layer chromatography and quantification by phosphoimaging. Attemps to 
introduce a radiolabel into 5a and 5b by different strategies were not successful (chapter 4.4.2). 
Metabolite identification requires high recovery and a sensitive detection method. In cellular lipid extracts, 
gangliosides coexist as minor components with phospholipids and other lipid species, which can hinder 
metabolism studies. In most cell types, the content of glycolipids is in the range of only a few mol% of total 
lipids. In the case of fibroblasts, the glycosphingolipids constitute about 3% of the total lipid (Dawson et al., 
1972).  
Although the effect of oxazolidinone 5b on GSL biosynthesis in cultured neurons is different than that in 
cultured fibroblasts, metabolism studies of the oxazinones 5a and 5b (chapter 4.3) and other experiments 
(chapter 4.5) were conducted in cultured fibroblasts.       
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4.4.1. Analysis of metabolites of oxazinanone 5a by thin layer chromatography (TLC) 
 
As mentioned above, the effect of oxazolidinone 5b on GSL biosynthesis in cultured neurons is different 
than that in cultured fibroblasts. It can be expected that the cell type specifity of this effect derived from a 
different metabolism of the ceramide derivatives in cultured fibroblasts and neurons. Because of the higher  
amounts required for lipid analysis, we startet with the analysis in fibroblasts. Therefore, the lipids of 
cultured fibroblasts incubated with the ceramide derivatives 5a and 5b were analyzed by thin layer 
chromatography for putative metabolic products derived from the exogenously added substance. Cells were 
incubated with 25 µM compound 5a in the culture medium for 10 days. Lipids were extracted, separated 
into acidic and neutral lipids and desalted. Analyzed lipids were normalized on protein content, separated 
by thin layer chromatography, and were visualized by staining with Kägi-Miescher (Material and Methods 
section; figure 4.7). 
Before tlc-separation, glycerolipids are usually removed by mild alkaline treatment of the lipid extract. 
Because of the lability of iodine-containing metabolites, the samples could not be treated with an alkaline 
solution in this case. The high amounts of phospholipids and endogenous lipids prevented the detection of 
lipid bands derived from 5a. In figure 4.10, the tlc of the neutral lipid extract from untreated cells (lane 2) 
and incubated cells (lane 3) is shown. Lane 1 shows standard bands corresponding to 5a, and the 
chemically synthesized neoglucosylceramide and neolactosylceramide derivatives derived from 5a (Wirtz, 
2004). As expected, the neoglycolipids derived from 5a have a lower retention factor than the native 
glycolipids with the same head group derived from ceramide. 
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Figure 4.7: Analysis of metabolites: cultured fibroblasts were incubated with 25 µM 
compound 5a in culture medium for 10 d, harvested and extracted. Neutral lipid 
fractions were separated by tlc using the solvent system: CHCl3/MeOH/0.22% 
aqueous CaCl2 60:35:8 by vol. The lipids were visualized by staining with Kägi-
Miescher (see Material and Method section). The assignment of lipid class 
structures to the separated bands is based on comparison of their Rf values with 
those of commercially available standards.  
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In the lipid extract of the incubated cells, only one weak new band could be visualized by staining with Kägi-
Miescher. The characteristic blue staining indicates the formation of a sphingomyelin-derivative. Attemps to 
extract this band to proof the assigment by a more sensitive method like mass spectrometry were not 
successful, because the extract contained large amounts of impurities derived from the chromatography 
material and the solvent. To avoid this kind of contaminations, we made several analyses of the crude lipid 
extracts derived from cells incubated with the ceramide derivatives 5a and 5b by mass spectrometry 
(chapter 4.4.2).  
 
4.4.2. Analysis of metabolites of oxazolidinone 5b by mass spectrometry 
 
In the study of the lipid metabolome (Lipidomics), electrospray ionization mass spectrometry (ESI-MS) has 
become increasingly popular. Methods for lipid analysis of crude cell extracts (“shotgun” analysis) have 
been published for the analysis of phospholipids, sphingolipids, and cerebrosides (Watson, 2006; Houjou et 
al., 2004; Han and Cheng, 2005). On the other hand, in the lipid extracts of cells treated with exogenously 
added lipid analogs, possible metabolites coexist as minor components with phospholipids and other 
endogenous lipid species, which can hinder metabolism studies. As mentioned above, the separation of 
sphingolipids from glycerolipids by mild alkaline treatment was not possible in the case of metabolism 
studies of the carbamate 5b due to the base-lability of the iodine-group. The mass spectrometric profile (full 
scan method) of lipids derived from lipid extracts of fibroblasts contains a large number of ions in the mass 
range of m/z 700-900 (data not shown). These signals originate predominatly from phospholipids. Signals of 
other lipids like ceramide, glycolipids, and metabolites of the exogenously added ceramide analogs can be 
overlaid or can be suppressed.  
In mass spectrometry, different scan techniques are known that allow the specific detection of molecular 
ions from complex mixtures. The collision-induced dissociation (CID) of compounds through collision with 
neutral gas molecules like argon generate characteristic daughter ions (Ekroos 2003). In a precursor ion 
scan (PIS), those parent masses are identified that yield the specific daughter ion with chosen m/z. In a 
neutral loss experiment, only those masses are detected, which originate from the cleavage of a defined 
neutral molecule.  
To profile metabolites containing 5a or 5b, characteristic fragment ions of oxazinanone 5a and 
oxazolidinone 5b had to be found. Therefore, purified 5a and 5b were analyzed by ESI-MS/MS in positive 
ion mode as shown in figure 4.8 (A). Fragmentation of oxazolidinone 5b generates a fragmentation pattern 
similar to 5a.  
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Figure 4.8: ESI-MS/MS-spectra (positive ion scan) of 5a, 5b and Glc-5a, scan range: 50-650, cycle time: 
1.1s, CID: 20-22 eV.  
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In figure 4.9, possible pathways for the formation of characteristic fragments are given. For each molecular 
ion, only one of several possible structures is given. The elimination of one water molecule from the parent 
ion [M+H]+ can result in the formation of a terminal double bond in the fragment ion at m/z 422.13 (see a1). 
A neutral loss of carbon dioxide, hydrogen iodide and ammonia can yield an allene product ion at m/z 
235.24 (see a4). The cleavage of the C3-C4 bond in the resulting ion a4 yields an aliphatic ion a5 at m/z 
197.15, which is the most prominent fragment in the spectrum. Alternatively, HI can be eliminated from the 
parent ion to form a fragment at m/z 312.13 (see b1). Then, loss of CO2, NH3, and H2O leads to the 
formation of product ion allene c4 at m/z 233.20. On the other hand, the product ion c4 can be formed by 
the neutral loss of one CO2 molecule from the parent ion, followed by loss of NH3, H2O, and HI. In addition, 
the glycosylated oxazinanone (Glc-5a), as representative metabolite was analyzed by ESI-MS/MS (Figure 
4.8, C). Fragmentation of Glc-5a leads to neutral loss of glucose and to the formation of 5a as product ion 
m/z 440.17. In addition, we detected several fragments with masses that are similar to fragments derived 
from 5a. For example, fragments at m/z 396, 379, and 361 appear in the spectra of the MS/MS-spectrum of 
Glc-5a as well as in the spectrum of 5a. This allowed us to analyse the crude lipid extracts by parent ion 
scans for these specific fragments.  
For the profiling of metabolites of lipid 5a and 5b, cultured human fibroblasts were incubated with 5a or with 
5b respectively for 48h, harvested, and lipids were extracted with chloroform/methanol/water (1:2:0.8 by 
vol.). Then the dried lipid extract was redissolved in chloroform/methanol/water (1:2:0.8 by vol.) and upon 
changing the solvent system to chloroform/methanol/water (2:2:1.8 by vol.), two phases separated following 
the method of Bligh and Dyer (1959). The upper aqueous layer containing gangliosides and sphingosine 
was removed for further purification by reverse-phase chromatography. The chloroform (organic) phase 
contained glycerolipids, glycolipids, ceramide, sphingomyelin, and cholesterol. Both extracts were dried 
under a stream of nitrogen, redissolved in chloroform/methanol (1:2 (v/v)), and analyzed by ESI-MS/MS 
experiments. The spectra for precursor ion scan of iodine (m/z 126) contained signals that originate from 
ion adducts of 5b (m/z 438.6 for [M-H]-, m/z 498.6 for [M+CH3COO]-, and m/z 474.3 for [M+Cl]-), but no 
other signals corresponding to iodine-containing metabolites could be detected. In addition, the neutral loss 
analysis of carbon dioxide (m/z 44) gave no indication for the presence of metabolites of 5b.  
In addition, we calculated the theoretical mass of metabolites like SM-5b, Glc-5b, LacCer-5b, and GM3-5b, 
and their adducts and searched for them in the lipid extracts by scan techniques that are used in the 
identification of sphingomyelins (parent ion scan m/z 184) and glycosphingolipids (neutral loss scan 162). 
Also the parent ion scans for the fragments m/z 440.2, 396.2 and 379.2 gave no indication for the presence 
of such metabolites. 
In summary, we could not find any metabolites of 5a and 5b by different approaches, including the 
described mass-spectrometical techniques. From this, we may conclude that the synthetic ceramide 
derivatives are metabolically stable under the chosen conditions and that therefore their indirect effect on 
ganglioside biosynthesis is not mediated by a metabolite. However, we cannot exclude the possibility that 
putative metabolites are present in concentrations lower that the detection limit of the applied methods.   
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Fig.4.9: Suggested pathways for the formation of characteristic fragment ions by means of collision induced 
dissociation (CID) of synthetic ceramide analog 5b. 
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4.4.3. Attemps for the radiolabeling of 5a and 5b 
 
Detection of a metabolite of 5a and 5b by tlc turned out to be unsuccessful, due to the limited separation of 
endogenous lipids and of metabolites derived from the exogenously added substance by this method 
(chapter 4.4.1). In addition, the detection of metabolites of compound 5a and 5b by thin-layer 
chromatography was prevented by the low sensitivity of the method. Radiolabeling of 5a or 5b should 
facilitate the detection of their metabolites. In addition, radiolabeling should also be a suitable method for 
the detection of putative interacting proteins that might undergo covalent attachment to the substance by 
substitution of the iodine, in the case of a sufficiently high specific radioactivity. Therefore, various attempts 
were undertaken to prepare one of the active compounds 5a and 5b in radiolabeled form. The incorporation 
of a radioisotope requires a suitable method that uses one of the commercially available sources of 3H or 
14C. These isotopes were selected, although their low specific radioactivity might not be high enough for the 
detection of low-abundant proteins. Two strategies to introduce the radioisotope in the last synthetic step 
were followed. Figure 4.10 shows the strategy and the results of preliminary experiments. Here, the alcohol 
function of the iodolactones should be oxidized to the aldehyde, and subsequently reduced to the alcohol by 
reaction with tritium-labeled sodium borohydride.  
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Figure 4.10: Synthetic strategy for the preparation of radiolabeled lipid 5a 
 
Attemps to oxidize the alcohol function in the oxazolidinone 5b by Swern oxidation (Kobayashi and 
Kobayashi, 2000) did not result in the desired compound. Insolubility of the alcohol in dichloromethane at 
low temperatures prevents Pfitzner-Moffatt conditions (Pfitzner and Moffatt, 1963). Also the reaction with 
pyridinium chlorochromate (PCC) in dichloromethane did not lead to the formation of the target compound. 
However, oxidation of oxazinanone 5a with PCC yielded aldehyde 8 in 87% yield. However, preliminary 
experiments to reduce the aldehyde 8 with sodiumborohydride did not result in the formation of alcohol 5a. 
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It also has to be considered that, tritiated sodiumborohydride can only be handled in solutions of high pH 
values. TLC control showed the formation of many by-products, which were not characterized. The α-amino 
aldehydes are known for their chemical instability and configurational lability (Jurczak and Golebrowsky, 
1989; Reetz, 1991). We had to conclude, that due to the reactivity of the intermediate (8) and the lability of 
the iodine-group towards reducing reagents and basic conditions, this strategy is not suitable for the 
introduction of a radiolabel. 
 
In a second strategy, we tried to introduce the radioisotope by hydrogenation of an unsaturated alkyl chain 
(Figure 4.11). Therefore, the iodolactones with unsaturated alkyl chains had to be synthesized. The 
synthesis followed the scheme for the synthesis of lipid 5a-c (chapter 4.2.1).  
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Figure 4.11: Strategy and results of preliminary experiments for the preparation of precursors of 
radiolabeled form of lipid 5a and 5b. 
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The phosphonium salt required for the elongation by a Wittig reaction was synthesized starting from 3-
alkyne-1-ol in a yield of 87% over 3 steps. Wittig reaction of Garner’s aldehyde with the ylide derived from 
the phosphonium salt afforded the Z-alkene 9 in a lower ratio than that expected for nonstabilized ylides. 
For the synthesis of the active compound, the Z-configured alkene is required. After iodolactonization with 
NIS, all three isomers could be separated by column chromatography, and deprotected to the carbamates 
10.2a-b in good yield. 
 
The iodolactone 10.2c with the configuration of the biologically inactive compound 5c was preliminary used 
to control the conditions for mild and effective hydrogenation of the triple bond. First, the solvent system, 
reaction time, and temperature were varied. Reaction conditions for catalytic hydrogenation with Pd-C as 
catalyst in ethanol at room temperature yielded small amounts alkene 11 in a mixture with alkyne 10.2c. 
Longer reaction time resulted in the loss of the iodine. We had to conclude that the introduction of a 
radiolabel by this strategy is difficult under the investigated conditions. To avoid the loss of the iodine-group, 
we tried to hydrogenate the triple bond by ionic hydrogenation (Kursanov et al., 1974). Treatment of alkyne 
10.2c with triethylsilane and trifluoracetic acid in dichloromethane for 16h resulted in the formation of the E-
alkene 11. The structure was confirmed by the coupling constant of 3JHH = 18.0 Hz in the 1H-NMR spectrum. 
The alkene 11 could not be fully separated from the alkyne 10.2c by column chromatography with silica gel 
using the solvent system chloroform/methanol (10:1 by vol.). The ratio of alkene and alkyne was 9:1. Both 
methods described above, offer the possibility to obtain at least small amounts of radiolabelled substance. 
 
For the second method, we have to prepare the reagents ((Et3Si3H or CF3COO3H) in tritiated form, and 
have to carry out the hydrogenation reaction of 10.2b with these radiolabeled reagents. [3H]Trifluoroacetic 
acid can be obtained by hydrolysis of trifluoroacetic acid anhydride with [3H]water (Dugger and Schwarz, 
1967), and [3H]triethylsilane (Et3Si3H) can be prepared by reduction of triethylsilylchloride with LiB3H4 
(Guillerm et al., 1977).  
 
4.4.4. ω-Azido-group as chemical reporter for the determination of metabolites 
 
As a new and non-radioactive alternative for the detection of metabolites, we attempted the introduction of 
an azido-group as chemical reporter. Alkyl azides are functional groups of sufficiently high chemical 
reactivity to be easily and selectively modified. The alkyl azides have several features that make them well 
suited for the tagging of biological molecules. An azido-group incorporated into the hydrocarbon chain of a 
ceramide analog provides a minimal structural change due to its small size and nonpolar nature. Moreover, 
it is not present in any known naturally occuring molecule and relatively inert within the cellular milieu. 
Azide- modified molecules can be selectively tagged to a fluorescent group or to a biotin residue by 
chemoselective ligation reactions developed by the Bertozzi-group: Staudinger ligation, Cu(I)-catalyzed 
azide-alkyne cycloaddition, or the strain-promoted [3+2] cycloaddition (Agard et al. 2006). The chemical 
properties of azides should make them suitable as tool to analyze metabolites of synthetic ceramide 
derivatives. This approach should consist of three steps (figure 4.12). First, the synthetic ceramide analog 
(12) is applied to cells, were it is metabolized. Second, after cell harvesting and lipid extraction, the azido- 
group containing metabolites in the lipid extract are selectively conjugated with a fluoresceine phosphine 
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capture reagent (13) by means of the Staudinger conjugation reaction (Saxon and Bertozzi, 2000), in which 
the nucleophilic aza-ylide can be captured by Staudinger reaction and intramolecular cyclization. Finally, the 
conjugated lipids can be separated by TLC and detected by fluorescence. 
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Scheme 4.12. Strategy for the detection of metabolites in cells with ω-azido-ceramides (modified from Wirtz 
and Kolter, 2007) based on Staudinger ligation (Saxon and Bertozzi, 2000). Cells are incubated with azido-
containing ceramide derivatives, followed by bioorthogonal labeling with a phosphine-fluorescein reagent 
via a modified Staudinger ligation. Resulting labelled ceramide derivatives should be separated by tlc and 
visualized with UV (R1 = metabolites of ω-azido-ceramide, R2 = fluorescein). 
 
 
For this approach, oxazinanone 12, bearing an ω-azido-group in the alkyl chain was prepared (Figure 4.13). 
The synthesis started with the Wittig reaction of 2a with the methyltriphenylphosphonium ylide generated 
from methyltriphenylphosphonium bromide with potassium bis(trimethylsilyl)amide (Campbell et al., 1998). 
The vinyl-derivative 14 was obtained in 92% yield. The terminal azido-group was introduced by two different 
strategies. In method A, first the alkyl chain was elongated via cross metathesis with undec-10-en-1-ol to 
give 15, then the alcohol function was converted to the methanesulfonate and substituted with an azide by 
reaction with sodium azide in acetone. The desired product 16 was obtained from 15 in 23 % yield over 2 
steps. Within the second strategy (B), the ω-azidoalkene was generated from undec-10-en-1-ol and the 
following cross metathesis with head group equivalent 14 generated 16 in 54 % yield. The iodocyclization 
was performed as described for 4b (chapter 4.2.1) and led to 17 in 35 % yield. The oxazinanone 12 could 
be obtained in 71 % yield by acidic treatment of 17. It has been reported that the Wittig reaction of the α-
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amino aldehydes 2a under the conditions used in this work, should provide the alkene 14 without loss of 
optical purity (McKillop et al., 1994). Since the enantiomeric purity of this 14 cannot be taken for granted, we 
still have to determine the optical purity. This can be done by cleavage of the isopropylidene group and 
converting the alcohol function into the Mosher ester, followed by NMR analysis. In the following steps, we 
have to synthesize the capture reagent (13) according to Saxon et al. (2007) and we have to test this 
approach in lipid extracts of fibroblasts. 
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Figure 4.13: Synthesis of ω-azido-oxazinanone 12 (Abbreviations: KHMDS = Potassium 
hexamethyldisilamide; MsCl = Methanesulfonyl chloride; NIS = N-iodosuccinimide; Grubbs cat. 2nd 
generation = C46H65Cl2N2PRu. 
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4.5. Influence of oxazolidinone 5b on intracellular membrane flow  
 
The major intracellular transport pathway coupled to the biosynthesis of membrane lipids, glycoproteins, 
and secreted proteins is exocytotic vesicle flow from the Endoplasmic Reticulum (ER) via the Golgi 
apparatus to the plasma membrane. Effects of different drugs that interfere with this intracellular membrane 
flow on GSL biosynthesis have been studied before (van Echten and Sandhoff, 1989). Brefeldin A (BFA), a 
fungal metabolite, disrupts the integrity of the Golgi apparatus by preventing the binding of small GTP-
binding proteins, ADP-ribosylation factors (ARFs), and the coatomer coat proteins to Golgi membranes 
(Renault et al., 2003). Monensin, a cationic ionophore, interferes with vesicular processing between cis-and 
trans-cisternae of the Golgi apparatus (Tartakoff, 1983).  
Previous studies (van Echten et al., 1990, van Echten and Sandhoff, 1989) have shown that treatment of 
cultured cerebellar granule cells with BFA or monensin result in a block of glycolipid biosynthesis on the 
stage of GlcCer, LacCer, gangliosides GM3, and GD3. These obtained pattern are qualitatively similar to 
the lipid patterns that are obtained in the presence of the cyclic carbamates 5a and 5b. In addition, it has 
been reported that some cell-permeable ceramide derivatives accumulate in the Golgi apparatus (Lipsky 
and Pagano, 1985), lead to an inhibition of protein transport on the level of the trans-Golgi (Rosenwald and 
Pagano, 1993), and lead to the fragmentation of the Golgi apparatus (Hu et al., 2005; Nakamura et al., 
2002; Fukunaga et al., 2000).  
To proof, if the synthetic ceramide derivatives 5a and 5b disrupt the integrity of the Golgi apparatus like 
BFA or C6-ceramide and produce the altered lipid pattern by this mechanism, cultured cells were incubated 
with oxazolidinone 5b and analyzed by fluorescence microscopy. Although the oxazolidinone 5b showed no 
drastic alterations of GSL-pattern in fibroblasts as in neurons, we started with the analysis in cultured 
fibroblasts. The Golgi apparatus was stained with NBD-C6-ceramide (see figure 4.15), according to (Pütz 
and Schwarzmann, 1995). 
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Figure 4.15. Structure of NBD-C6-ceramide (N-[7-(4-Nitrobenz-2-
oxa-1,3-diazole)]-6-aminohexanoyl sphingosine) 
 
After addition to the culture medium of fibroblasts, NBD-C6-ceramide can diffuse through the cytosol to the 
ER and the Golgi apparatus due to its short apolar acyl chain. In the Golgi apparatus, the fluorescent 
analog is metabolized to the sphingomyelin and glucosylceramide analogs, which cannot diffuse across 
membranes and are to some extent trapped at the site of their synthesis. C6-NBD-ceramide is therefore a 
useful tool for labeling of the Golgi apparatus and to investigate morphological changes of the Golgi by 
fluorescence microscopy (Lipsky and Pagano, 1985). 
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The effect of 5b on the Golgi membranes is shown in Figure 4.16. Cells treated with derivative 5b 
underwent extensive Golgi vesiculation (Figure 4.16b), and reproduced the morphological phenotype of 
cells incubated with Brefeldin A (Figure 4.16c). We cannot conclude that the vesiculation of the Golgi-
apparatus is responsible for or a consequence of the observed reduction of the biosynthesis of higher 
gangliosides in neuronal cells. Further experiments are required to clarify the mechanism of action that 
leads to the observed effects in cell culture.  
 
a b c  
Figure 4.16: Effect of carbamate 5b and Brefeldin A on the morphology of the Golgi apparatus in 
cultured cells. Human skin fibroblasts (a) were incubated with 25 µM of 5b (b) for 24h and 1 µg/ml 
Brefeldin A (c) for 2h, stained with C6-NBD-ceramide-BSA complex, and examined in the 
fluorescence microscope (scale bar: 20 µm). 
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4.6. Requirement of the iodine atom in 5a for the mechanism of action 
 
To address the role of the iodine atom in oxazinanone 5a at position C-5 for the alteration of lipid pattern in 
cultured cells, derivatives 18a and 18b were synthesized, in which the iodine is substituted by a hydroxyl- 
group. These compounds are conformationally restricted ceramide analogs with a higher structural similarity 
to the parent compound (ceramide) than 5a. 
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4.6.1. Synthesis 
 
We decided to prepare the oxazinanones starting from phytosphingosine with selective protection of the 
1,3-diol and intramolecular ring formation as key steps. Commercially available D-ribo-Phytosphingosine 
(figure 4.18) with a purity of 80% was the starting material in the syntheses of both oxazinanones. The 
synthesis started with the protection of the amino function of phytosphingosine by treatment with di-tert-
butyl dicarbonate in 75% yield. The 1,3-diol in the N-Boc protected phytosphingosine (19) was protected by 
silylation with di-tert-butylsilyl ditrifluoromethanesulfonate (Hoberg, 1997), resulting in the silyl-derivative 20 
in 62% yield. The 4-OH-group of compound 20 was then sulfonated by treatment with methanesulfonyl 
chloride in pyridine to give the methanesulfonate 21. Key step in the synthesis of the desired compound is 
the intramolecular ring close reaction (Kemp et al., 1996). The use of tetrahydrofurane as solvent and reflux 
reaction conditions resulted in the formation of compound 22a in 75% isolated yield. Desilylation with 
tetrabutylammonium fluoride afforded 18a in nearly quantitative yield (Corey and Hopkins, 1982). 
Treatment of the silyl-derivative 21 with lithiumdiisopropylamide and intramolecular attack of the resulting 
oxyanion on the carbonyl group afforded 22b in 82% yield. The silyl group was cleaved by treatment with a 
solution of tert-butylammoniumfluoride in THF at 0°C to afford the desired oxazinanone 18b in 26% yield.  
The absorption of the C=O stretch vibration in the infrared spectrum at 1654 cm-1 of 18a and 1682 cm-1 of 
18b agree with those of related compounds in literature (Kemp et al., 1996). The trans,trans-relationship of 
the protons in compound 18b is reflected by the values of the coupling constant (J4,5 = J5,6 = 9.2 Hz). On the 
other hand, the smaller coupling constant of the protons in trans,cis-relationship (3J5,6 = 2.4 Hz) reflects the 
configuration of stereoisomer 18a. 
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 Figure 4.18: Synthesis of oxazinanone 18a and 18b starting from phytosphingosine 
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4.6.2. Effect of oxazinanones on glycolipid biosynthesis  
 
 
To determine the influence of the iodine atom in compound 5a on glycosphingolipid biosynthesis, the 
oxazinanones 5a, 18a and 18b were tested in cultured murine cerebellar granule cells. Cells were pre-
incubated with 50 µM target compounds in the culture medium for 24 h. L-[3-14C]serine was added to the 
culture medium, and its incorporation into newly synthesized sphingolipids was analyzed after labelling for 
24 h. Lipids were extracted, separated into acidic and neutral fractions, and glycerolipids were removed by 
mild alkaline hydrolysis. Desalted lipid extracts were separated by thin layer chromatography (TLC) and 
visualized by phosphoimaging. 
Figure 4.19 shows the L-[3-14C]serine incorporation into acidic glycolipids of control cells and of cells 
incubated with the heterocycles. In the presence of all tested compounds, the incorporation of L-[3-
14C]serine into SM was reduced. In the presence of 5a, the formation of glucosylceramide (112% of control) 
and lactosylceramide (300% of control) is increased. Cells incubated with the iodine derivatives (5a,b), 
gangliosides GM3 and GD3 are clearly labelled compared to control cell (5 times higher), while the 
formation of higher gangliosides like GD1a, GT1b and GQ1b is reduced. Differences in the labeling profile 
between 5a and 5b might be due to inhibition of GalNAc-transferase by both compounds, which formation 
of GM3 and GD3 appears also to be reduced in the presence of 5a. The influence of the hydroxy-derivative 
(18a) on serine-incorporation into these gangliosides is negligible. In the presence of oxazinanone 18a an 
additional band (X2) with a smaller retention factor that SM is found in the neutral lipid fraction. The nature 
of this band could not identified yet.  
Together with the results from L-[3-14C]serine labeling in cultured fibroblasts (chapter 4.2.3, Figure 4.5), 
these data indicate that the presence of a halogen atom (iodine, bromine) plays an important role for the 
biological effect on GSL biosynthesis. 
        43
 
neutral lipids acidic lipids
A
C      5a      18a     5b
50 µM  50 µM  50 µM
GlcCer
LacCer
?
SM
X
GT1b
GD3
GD1a
C        5a     18a      5b
50 µM  50 µM  50 µM
X
GM3
GM1
GQ1b
 
B 
L-3-[14C]serine incorporation
0
100
200
300
400
500
600
700
GlcCer LacCer SM GM3 GD3 GD1a GT1b GQ1b
%
 o
f c
on
tr
ol
 
5a 18a 5b
 
Figure 4.19: Effect of oxazinanones on ganglioside biosynthesis in primary cerebellar neurons. 
Cells were pre-incubated with 50 µM 5a, 5b and 18a in culture medium for 24 h and pulse-labeled with L-
[3-14C]serine. After 24h, cells were harvested and subjected to lipid analysis. A: Total lipids were separated 
by tlc using the solvent system chloroform/methanol/0.22 % aqueous CaCl2 60:35:8 by volume (C = 
control). B: Radioactivity found in the TLC spots of untreated cells were set equal 100 %. The results of 2 
experiments are given. Radioactivity was analyzed by phosphoimager analysis. Data are expressed as 
percentages of control values that were obtained by labelling cells with L-[3-14C]serine in the presence of 
methanol. All data are given as mean values of two different experiments. 
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4.7.  Synthesis and investigation of structurally modified cyclic carbamates 
4.7.1. Synthesis of an 1’C-Methyl oxazinanone 
 
A principle problem in the analysis of ceramide derivatives exogenously added to cells is their metabolic 
interconversion with other signaling molecules. The substitution of a proton by a methyl group in the head 
group of ceramide analogs can have consequences for the molecular recognition and the metabolic 
procession of the substance. Binding to specific proteins can be enhanced due to additional hydrophobic 
interactions, or binding can be reduced because of sterical hinderence in the binding pocket of the protein. 
Exogenously added ceramide derivatives can be modified to various metabolites in cultured cells. 
Modification of the 1-C should hinder the way by which the substances are metabolized, so that enhanced 
metabolic stability could be achieved.  
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Figure 4.20: Synthesis of compounds 23a,b starting from L-threonine. Abbreviations: 
EDC.HCl = N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride; DMP = 2,2-
dimethoxypropane;  NIS = N-iodosuccinimide 
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The synthetic route for the formation of target compounds 23.2a and 23.2b, which follows the preparation of 
the other iodolactones (5a,b), is shown in figure 4.20. 
Weinreb amide 1b was prepared from L-threonine in a yield of 55 % over 3 steps. The protected allylamine 
3b was prepared from the aldehyde derived from 1b followed by a Wittig reaction in 97 % yield and 
selectivity of E:Z = 1:7. The bicyclic products from the cyclization reaction could be isolated by column 
chromatography in 36 % (for 23.1a) and 57% (for 23.1b). The desired products 23.2a and 23.2b were 
obtained by acidic treatment with hydrochloric acid in THF.  
 
 
4.7.2. Effect of 1’C-Methyl oxazinanone 23.2a on sphingolipid biosynthesis 
 
The properties of oxazinanone 23.2a were investigated in cultured human fibroblasts. Cells were 
preincubated with 23.2a for 24 h in concentrations of 5, 10, and 25 µM in the culture medium.                     
L-[3-14C]serine was added to the culture medium, and its incorporation into newly synthesized sphingolipids 
was analyzed after labelling for 24 h. Lipids were extracted, and glycerolipids were removed by mild alkaline 
hydrolysis. The desalted lipid extracts were separated by thin layer chromatography (TLC) and visualized 
by phosphoimaging (Figure 4.21 A). In the presence of the oxazinanone-derivatives 5a and 23.2a in the 
culture medium, the incorporation of L-[3-14C]serine into sphingolipids was increased. This is in agreement 
with the results obtained from labeling experiments in fibroblasts in the presence of oxazolidinone-
derivatives 5b and 6 (chapter 4.2.3, Figure 4.5). The substitution of the proton by a methyl group leads to a 
more potent compound in regard to L-[3-14C]serine incorporation into lactosylceramide. At concentration of 
25 µM, the effect of 23.2a is two-fold higher than that of 5a. There is no explanation described in literature, 
why the biosynthesis of sphingolipids is increased in the presence of synthetic ceramide-derivatives. In 
following studies, we have to investigate the 1’C-Methyl derivatives 23.2a and 23.2b in cultured neuronal 
cells.  
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Figure 4.21: Effect of oxazinanones 23.2a and 5a on the incorporation of L-[3-14C]serine into 
sphingolipids of human fibroblasts. Cells were treated with target compounds 23.2a (10, 25 and 50 
µM) and 5a (25 µM) in the culture medium for 24h. Then, cells were fed with L-[3-14C]serine in the 
presence of the tested compounds for 24h. Lipids were extracted, and glycerolipids were removed by 
alkaline treatment.  
A: Sphingolipids were separated by thin layer chromatography using the solvent system: 
CHCl3/MeOH/0.22% aqueous CaCl2 60:35:8 by vol. Radioactive bands were visualized by 
phosphoimaging. B: Radioactivity found in the TLC spots of untreated cells were set equal 100 %. 
Radioactivity was analyzed by phosphoimager analysis. Data are expressed as percentages of control 
values that were obtained by labelling cells with L-[3-14C]serine in the presence of methanol.  
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4.8. Analysis of a Benzazepinone as a conformationally restricted ceramide analog 
 
The Benzazepinone has been 24 (Figure 4.22) has been prepared in further studies (Sawatzki, 2003a) as a 
conformationally restricted ceramide analog. Previous labeling experiments with D-[14C]galactose in the 
presence of 24 in primary neurons indicated an inhibition of sialyltransferase II at concentrations of 10 µM, 
and at higher concentrations (25 µM) inhibition of GalNAc-transferase.  
To decide, if the conformational restriction or the presence of the bulky aromatic group within the 
benzazepinone is responsible for the observed effects in cell culture, the open chain analog 25 was 
prepared as described in chapter 4.8.1. It was tested in cultured neuronal cells on its influence of 
glycosphingolipid biosynthesis. 
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Figure 4.22: Benzazepinones 24 and N-Phenylacetylceramide 25  
 
 
4.8.1. Synthesis of N-Phenylacetylceramide (25) 
 
To determine whether the conformation of the ceramide head group fixed in 24 or the aromatic ring inhibits 
the biosynthesis of glycosphingolipids, compound 25 was synthesized as open chain analog of 24. The 
synthetic route is summarized in figure 4.23. 
The sphingosine part of the molecule was prepared starting with alkynylation of Garner’s protected 
aldehyde 1a with a lithium alkyde to give a mixture of the diastereomers in a ratio of erythro:threo = 7:1 in 
55% combined yield. The erythro-isomer 3c was isolated by column chromatography with silica gel using 
the solvent system petroleum ether/ethylacetate (7:1 by vol.) in 24 % yield and was reduced with RedAl® to 
the alkene 26. Although the transformation of the intermediate 3c to 26 has been described to be efficient 
(65% yield by Herold, 1988; 71% by Sawatzki, 2003a). However, in our hands the transformation was less 
efficient, and the separation of the alkene 26 from the alkyne 3c by column chromatography with silica gel, 
using the solvent system cyclohexane/ethyl acetate (5:1, by volume), yielded 8% of pure alkene 26. After 
the protecting groups were cleaved off by acidic treatment, the amino group was acylated with phenylacetyl 
chloride in methanol. Although, the reaction procedure was not optimized, the target compound, N-
Phenylacetylceramide, could be isolated in 11% over two steps.  
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Figure 4.23: Synthetic route to compound 25 (RedAl® = Sodium bis(methoxyethoxy) aluminium hydride) 
 
 
4.8.2. Investigation of ceramide derivatives 24 and 25 in cultured granule cells 
 
The influence of the synthetic ceramide analogs 24 and 25 on GSL-biosynthesis was examined in cultured 
primary murine granule cells. Figure 4.24 shows the glycolipids of primary granule cells after labeling with D-
[14C]galactose in the presence of 25 µM synthetic ceramide analogs in the culture medium. Data are 
quantified in figure 4.24 B. In the presence of 25, the incorporation of D-[14C]galactose is increased in 
glucosylceramide (by 30% compared to control) and lactosylceramide (by 70% compared to control), as 
well as in gangliosides GM3 (by 60%), GM2 (by 40%) and GM1 (by 20%). At the same time, a reduction of 
labeling in gangliosides GD3 and GT1b is observed. These data indicate an inhibition of SAT-II and confirm 
with data obtained previously with the compound 24 by Sawatzki (2003a). A weaker effect on glycolipid 
biosynthesis is observed in the presence of the cyclic benzazepinone 24. The patterns obtained in the 
presence of both synthetic ceramide analogs are comparable. This indicates that the hydrophobic phenyl 
ring plays a key role for the observed effects and appears to be more important than the conformational 
rrestriction. The nature of the lipid bands indicated as X1 and X2 could not be elucidated. X1 shows the 
same retention factor like sphingomyelin. Labeling of this lipid may result from degradation of galactose and 
the subsequent biosynthetic incorporation of radiolabeled fatty acids into sphingomyelin. 
The influence of the synthetic ceramide derivative 25 has also been tested in cultured human fibroblasts. 25 
µM N-Phenylacetylceramide (25) in the culture medium showed cytotoxic effects after incubation of the cells 
for 24 h. This might be due to the higher membrane content and apoptotic protection of neurons. It can be 
expected, that compound 25 behaves like a short-chain ceramide (C2- and C6-ceramide). It has been 
described, that exogenous addition of short-chain ceramides to cultured cells leads to apoptotic responses, 
while the saturated form dihydroceramide has no effect (Bielawska et al., 1993). It can be expected that 
hydrogenation of the double bond in 25 should lead to a less toxic compound that should be more 
compareable compound to 24.   
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Figure 4.24: Effect of benzazepinone 24 and N-Phenylacetylceramide 25 on the 
incorporation of D-[14C]galactose into glycolipids of cerebellar cells. Cells were treated 
for 24h with 25 µM test compounds. Then cells were fed with D-[14C]galactose in presence of 
the test compounds for 24h. Lipids were extracted, separated into acidic and neutral fractions, 
and glycerolipids were removed by alkaline treatment. A: Lipids were separated by thin layer 
chromatography using the solvent system: CHCl3/MeOH/0.22% aqueous CaCl2 60:35:8 by 
vol. The lipids were visualized by autoradiography. (X1 and X2 = identity of this bands was not 
analyzed). B: Radioactivity found in TLC spots of untreated cells was set equal 100%. All data 
are given as means ± range of two experiments.  
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4.9. Investigation of the influence of 5b and 24 on PKC activity 
 
Ceramide is known to bind to and to regulate the activity of specific isoforms of Proteinkinase C (Huwiler et 
al., 1998, Wang et al., 2005, Bourbon et al., 2000). Proteinkinase C (PKC) represents a family of 12 
serine/threonine kinase isoforms that differ in structure, substrate specificity, expression, and localization. 
PKC is involved in the regulation of several cellular functions such as cell growth and proliferation, gene 
transcription, and protein synthesis. Many of PKC target substrates are components of signal transduction 
pathways and include proteins that regulate ion channels, structural and regulatory proteins of the 
cytoskeleton, and many other proteins. The activity of two glycolipid glycosyltransferases, GalNAc-T and 
Sia-T2, are regulated by protein kinase A- and protein kinase C-related phosphorylation systems (Bieberich 
et al., 1998). Bieberich and co-workers examined the effect of exogenous applied protein phosphatase 
inhibitors (okadaic acid and orthovanadate) and protein kinase activators (phorbol ester and forskolin) on 
GalNAc-transferase activity. By metabolic labeling studies in NG108-15 (mouse/rat, neuroblastoma-glioma 
hybrid cells), they could show that stimulation of intracellular phosphorylation leads to an enhancement of 
the relative amount of a-series gangliosides derived from ganglioside GM3. It can be expected that 
exogenously added ceramide derivatives might lead to modulation of cellular kinase systems and in this 
way influence glycosyltransferase activities.  
To analyse if the synthetic ceramide analogs 5b and 24 have a regulatory effect on protein kinase activity, 
in vitro-experiments were performed with PKC isolated from rat brain. The enzyme used in this assay was 
obtained from Promega and consists primarily of PKC-α, β and γ isoforms with lesser amounts of δ and ξ 
isoforms. The micellar assay is based on a rhodamine-labeled fluorescent peptide that is phosphorylated by 
PKC according to a literature protocol (Isbell et al., 1995). In agarose gel electrophoresis (0.8% agarose in 
50 mM Tris-HCl, pH 8.0), the phosphorylated peptide migrates toward the anode, while the non-
phosphorylated peptide migrates toward the cathode. PKC activity was quantified by analysis of the relative 
fluorescence intensity of the spots in the photograph of the gel estimated under UV-light (λ = 365 nm) and 
additionally by excision of the fluorescent bands and measuring their relative fluorescence. To minimize 
diffusion of the bands, the photograph and the spectrofluorimetric analysis were performed as rapidly as 
possible after electrophoresis. Figure 4.25 (A) is a photograph of an agarose gel with samples from different 
experiments. Two bands were separated by electrophoresis. Substrate alone (lane 1) migrated to the 
cathode, while addition of PKC (lane 2) resulted in the migration of phosphorylated substrate towards the 
anode. Lanes 3 to 5 represent assays, which were made in the presence of 200 nM PMA (phorbol-12-
myristate-13-acetate, lane 5), 50 µM ceramide derivative 5b (lane 3), and 50 µM ceramide derivative 24 
(lane 4) in the assay buffer. Phorbol esters like PMA are described as specific activators of PKC (Ryves et 
al., 1991). The increase of PKC activity in the presence of 200 nM PMA in the assay buffer (140 % of 
control) is in agreement with reported data (Isbell et al., 1995). In the presence of ceramide derivative 5b, a 
minimal inhibitory effect on PKC activity (95 % of control) was observed, while in the presence of 24 no 
significant change of PKC activity could be observed. From these results we conclude that PKC is not 
activated by the synthetic ceramide derivative, but we cannot exclude that the protein kinase A- and protein 
kinase C-related phosphorylation systems in the cell are indirectly activated. 
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Figure 4.25. Influence of PMA (phorbol-12-myristate-13-acetate) and ceramide derivatives (5b and 24) 
on PKC activity. (A) Photograph of an agarosegel. Bands were visualized under UV-light (λ = 365 nm) and 
photographed.  Well 1 and 2 represent control samples containing no PKC (1, negative control) and 
containing 0.25 µg PKC (2, positive control). Wells 3-5 represent samples containing 0.25 µg PKC and 5b 
(50 µM, well 3), 24 (50 µM, well 4), and PMA (200 nM, well 5) in the assay buffer. (B) Relative intensity of 
the product bands that moved towards the anode were determined using X-software. (C) Fluorescent bands 
were excised, solubilized, and fluorescence measured by spectrofluorometry (as described in the material 
and methods section, chapter 6.5.15). Measured intensity of positive control (lane 2) was set equal 100 %. 
The results of 2 independent experiments are given. 
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4.10. Synthesis of internal standards for glycolipid quantification by mass 
spectrometry 
 
4.10.1. Synthesis of C6-GM3 (30)  
 
The metabolic labeling experiments (chapter 4.2.2, 4.2.3, 4.6.2, and 4.8.3) gave no information on 
changes of the total content of cellular sphingolipids in response to exogenously added ceramide analogs. 
For pharmacological applications, it is important to know how differences in sphingolipid biosynthesis 
translate into alterations in the total content of certain GSL species. Mass spectrometric quantification 
gives more detailed information about the quantitative ceramide composition of individual GSL species, 
which could vary between different samples. To quantify the amount of ganglioside GM3, a standard 
substance of closely related structure is required that is not occurring in the investigated cell type. As an 
internal ganglioside standard for the quantification of GM3/GM2 levels in lipid extracts, we chose 
ganglioside GM3 with a capronic acid in the ceramide moiety (30). It was synthesized following the 
reaction scheme outlined in figure 4.28. In this work, only the last step was carried out. 
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Fig. 4.28: Synthesis of a ganglioside GM3 derivative 30 as standard substance for the determination of 
GM3-levels in cultured cells by mass spectrometry. Peracetylated C6-GM3 (29) was prepared and kindly 
provided by Karl Clasen (1994). 
 
 
The synthesis started with the condensation of azidosphingosine (Zimmermann et al., 1988) with the 
peracetylated 1-O-trichloroacetimidate of 3’-Sialyllactose methyl ester (27). The azide function was reduced 
with hydrogen sulfide in pyridine (Zimmermann and Schmidt, 1988), and the resulting amine was acylated 
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with capronic acid and EDCl to give 29, which was kindly prepared by K. Clasen. Cleavage of the O-Acetyl 
groups with sodium methanolate and purification by reverse-phase chromatography yielded the ganglioside 
derivate 30 in 84% yield.  
The synthetic ganglioside C6-GM3 (30) was analyzed by Nano-ESI-MS/MS to determine its suitability as 
internal standard for mass spectrometric analysis of ganglioside levels in lipid extracts. The product ion 
spectra of ganglioside C6-GM3 (30) is shown in figure 4.29. Cleavage of the glycosidic bonds of the [M-H]- 
ion of 30 produce fragments corresponding to C6-lactosylceramide (m/z 720), C6-glucosylceramide (m/z 
558), and C6-ceramide (m/z 396). The most abundant fragment in the spectra is the ion of m/z 290, which 
corresponds to N-acetyl dehydroneuraminic acid. This fragmentation pattern is in agreement with those 
described for natural gangliosides (Whitfield et al., 2000).  
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Figure 4.29: ESI-MS/MS spectrum of the [M-H]- ion of gangliosideC6-GM3 (30). 
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4.10.2. Synthesis of C17-sulfatide (34)  
 
During this work, a C17-sulfatide derivative was synthesized for the determination of sulfatide levels in 
biological samples. Sulfatide (galactosylceramide-3-sulfate) is a glycolipid found in high concentrations in 
the myelin sheats in the white matter of the brain as well as Schwann cells of the peripheral nervous system 
and in the kidney. In lower concentrations, it is also found in serum, granulocytes, and red blood cells. 
Sulfatide is implicated in diverse biological processes including the regulation of insulin secretion (Buschard 
et al., 2005), neuronal development, modulation of blood coagulation, and tumor cell metastasis (Ishizuka, 
1997). Alterations in sulfatide metabolism are present in Alzheimer’s disease and are associated with 
metachromatic leukodystrophy (von Figura et al., 2001).  
 
The C17-sulfatide derivative was already synthesized by Kim et al., 2004 as described in figure 4.30. The 
synthesis started with the deacylation of natural bovine brain sulfatide with sodium hydroxide in ethanol to 
form the lysosulfatide in 14% yield. C17-Sulfatide (34) was obtained by a base-mediated reacylation of the 
lyso-sulfatide (32) using the N-hydroxysuccinimide ester 33 and was isolated by column chromatography in 
17% yield. The intermediate 33 was prepared from reaction of C17-fatty acid with N-hydroxysuccinimide in 
the presence of EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide) following the method by Lapidot et 
al., 1967.  
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Figure 4.30: Synthesis of a sulfatide derivative 34 as standard substance for the determination of 
sulfatide-levels in cultured cells by mass spectrometry. 
 
The synthetic C17-sulfatide was analyzed by ESI-MS/MS in negative ion mode (Figure 4.31). The [M-H]--ion 
forms two characteristic fragment ions. The cleavage of the glycosidic bond forms a fragment of m/z 240 
(C2-H2O), and cleavage of the sulphate group forms a fragment ion of m/z 96 (C1). The fragmentation 
pattern is in agreement with previous data published for natural forms of sulfatide (Whitfield et al., 2000).  
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Figure 4.31: ESI-MS/MS spectra of the [M-H]- ion of C17-cerebroside sulfate (34). 
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5. Discussion 
5.1. General  
 
Sphingolipids comprise an important group of structurally diverse biomolecules. They are structural 
components of the plasma membrane of eukaryotic cells and are thought to play a role in the regulation of 
various cell functions. In order to gain further insights into the biological and biophysical functions of 
sphingolipids, genetically engineered mice have been generated that have defined defects in certain steps 
of sphingolipid metabolism. In addition, also efforts have been made to design synthetic ceramide analogs 
as chemical tools to alter intracellular sphingolipid levels (Brodesser et al., 2003; Degaldo et al., 2007). 
Several ceramide analogs have been investigated as potential enzyme inhibitors or as ligands of putative 
ceramide binding proteins that are of pharmacological relevance (Wendeler et al., 2005). Ceramide and 
ceramide analogs exogenously applied to cultured cells can induce a variety of complex effects, including 
metabolic transformation and apoptotic responses, that complicate the analyses of their function. 
Ceramides with selectivity for one of the putative ceramide binding proteins are potential means to 
characterize the proteins involved, and to influence their respective pathways. In addition, for 
pharmacological application of ceramide derivatives it is important to reduce side-effects. A substantial aim 
of this work was to analyze the effect of conformationally restricted ceramide analogs on cellular lipid 
metabolism. Several heterocyclic ceramide derivatives were designed, synthesized, and tested in cultured 
neurons, which express complex gangliosides. The major effect of these ceramide derivatives was their 
unexpected interference with the biosynthesis of complex glycosphingolipids. These data could not have 
been arisen from in vitro-experiments with ceramide-metabolizing enzymes, since their potent and 
unexpected effects are indirect and require a cellular environment. As it will be discussed below, some of 
the observed effects were specific for nerve cells, and did not occur, at least to the same extent, in the 
much more easily cultured fibroblasts. The investigated substances are of particular importance, since there 
are still no inhibitors available for enzymes that catalyze the formation of complex gangliosides. The 
availability of such substances would permit the evaluation of new types of substrate reduction therapy of 
sphingolipidoses (chapter 5.2.2) and might serve as pharmacological equivalents to glycosyltransferase 
knockout mice. 
   
 
5.2. Halogen-containing oxazinanones as conformationally restricted ceramide  
derivatives 
 
5.2.1. Synthesis  
 
The conformationally restricted ceramide analogs 5a and 5b (chapter 4.2.1, figure 4.2) represent scaffolds 
that present the 1-OH-group, the amide group, and one of the alkyl chains of ceramide in a defined 
conformation. However, the 3-OH-group of ceramide has been replaced by an iodine atom, which turned 
out to be crucial for their effect on GSL metabolism in cultured cells. They have been prepared in a 
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sequence of 3 reaction steps starting from Garner’s aldehyde. Key steps in the synthesis were the Wittig 
reaction and an iodocyclization reaction. The synthetic route permits the preparation of structurally related 
compounds like the alkyne-derivatives 10.2a and 10.2b (chapter 4.4.3, figure 4.11), the 1-methyl-derivatives 
23a and 23b (chapter 4.7.1, figure 4.20), the azido-derivative 12 (chapter 4.4.3, figure 4.13), and the bromo-
derivatives 7.2a and 7.2b (chapter 4.2.3, figure 4.4) for structure-activity analysis. The bromine derivative 
7.2b was prepared in a manner similar to the synthesis of the iodine derivative, but using NBS (N-
Bromosuccinimide) instead of NIS (N-Iodosuccinimide). We observed that treatment of the N-Boc-protected 
allylic carbamates (3a, 3b, 9 and 21) with NIS resulted predominantly in the formation of the corresponding 
oxazolidinone-derivatives (4b, 10.1b, 22b, 7.1b) by a 5-exo cyclization. Generally, the regioselectivity of the 
iodocyclization can be influenced by the substitution pattern of the alkene, the choice of the N-carbamate 
(Boc or Cbz), and the choice of the electrophile (NIS or I2). The isolated yield of the bicyclic products was 
limited due to the difficulties in the separation of the isomers by column chromatography with silica gel. Only 
isolated yield of pore substances were given. The relative stabilities of the isopropylidene groups towards 
hydrolysis changed with the structure of the ring system. The oxazolidinone-derivatives were cleaved under 
acidic conditions at room temperature, while the oxazinanone-derivatives were unaffected by treatment 
under the same reaction conditions. In this case, the reaction mixture had to be heated to 80°C. Longer 
reaction times and increasing reaction temperature were accompanied by an increase in the amount of 
side-products, e. g. by the elimination of hydrogen iodide and the formation of compound 35 (Figure 5.1), 
which was reflected in the lower isolated yield of the desired deprotected products (Figure 5.1). The 
oxazolidinone-derivatives could be isolated in 37% - 97% yield, the oxazinanone-derivatives only in 13% - 
26% yield.  
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Figure 5.1 
 
To evaluate the role of the iodine-group in compound 5a for the observed effects, the hydroxylated 
compounds 18a and 18b (chapter 4.6) were synthesized for structure-activity analysis. In previous 
experiments, the hydroxylated oxazinanone should have been prepared by substitution of the iodine in 4a 
by an oxygen-nucleophile (Sawatzki, 2003a; Figure 5.2). However, treatment of 4a with silver acetate in 
acetic acid resulted in the formation of compound 36 by an anionotropic 1,2-rearrangement-like reaction 
(Hüsken, 2005). Therefore, we elaborated an alternative strategy and synthesized the oxazinanones 
starting from commercially available phytosphingosine (chapter 4.6.1, figure 4.18), with selective protection 
of the 1,3-diol and intramolecular ring formation as key steps. By this strategy, we obtained the 
oxazinanone 18a in 26 % yield over 5 steps, and the oxazinanone 18b in 10 % yield over 4 steps. 
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Figure 5.2 
 
5.2.2. Investigation of ceramide derivatives in cultured cells 
 
Prior studies described oxazinanone 5a and oxazolidinone 5b as cell-permeable apparent inhibitors of the 
GalNAc-transferase (Sawatzki, 2003a). This was demonstrated by labeling experiments with                      
D-[14C]galactose and L-[3-14C]serine in cultured murine granule cells, which are rich in complex 
gangliosides. Labelling with L-[3-14C]serine is a measure of de novo biosynthesis of glycosphingolipids, 
while labelling with D-[14C]galactose additionally reflects the contribution of the salvage pathway, which 
accounts for the majority of biosynthetically formed glycosphingolipids in neurons. The glycosphingolipid 
pattern obtained in this work by L-[3-14C]serine labeling in the presence of 50 µM compound 5a and 5b were 
similar to that obtained previously (Sawatzki, 2003a). Cells incubated with iodocarbamates 5a and 5b (50 
µM in culture medium) and L-[3-14C]serine accumulated radioactively labeled LacCer, ganglioside GM3, and 
GD3, compared to controls. On the other hand, cellular levels of complex gangliosides such as GM1, GD1a, 
and GT1b were decreased. The separation into neutral and acidic sphingolipids allowed a closer 
examination of SM-levels, which were not significantly altered. Due to the low availability of cell material, the 
need to sacrifice animals, and the time consuming preparation of primary granule cells, compounds were 
additionally tested in cultured human fibroblasts. These cells are easy to prepare and are available in larger 
quantities. Furthermore, cells from patients with different diseases, like the GM2-gangliosidoses are 
available. A disadvantage of this cell type was that it expresses only low amounts of ganglio series-GSLs. In 
addition, we could show that the results obtained from exogenous addition of the ceramide-derivatives 5a 
and 5b to fibroblasts (chapter 4.2.3 and 4.7.2) differ from the results obtained with murine granule cells 
(chapter 4.2.2 and 4.6.2). The specificity of this effect for nerve cells can result from several factors, 
especially from differences in protein expression between both cell types. The major one is that the ganglio-
series of GSLs is much more expressed in neurons. Another one is, that the concentration of ceramide-
derivative in both cell types is different due to a different metabolism of the ceramide-derivative. It can also 
be expected that experimental factors contribute to the different results. It might be possible that even the 
different supplements of the culture medium, e. g. horse serum for nerve cells and calf serum for fibroblasts, 
that differ in their composition, can influence the results.  
In fibroblasts, we also analyzed the effect of ceramide derivative 5b on incorporation of L-[3-14C]serine into 
ceramide. In the presence of 25 µM 5b in culture medium, the ceramide level increases two-fold higher 
compared to control cells, whereas the incorporation of radioactivity into sphingomyelin was slightly 
reduced. This can be explained by competition of the substrate analog for the substrate binding side. Mass 
spectrometry indicated that 5b is no substrate of the enzyme. It has been shown in human keratinocytes, 
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that the expression rates of several enzymes involved in ceramide metabolism, including serine palmitoyl 
transferase, increase in the presence of ceramide-derivatives (Brodesser and Kolter, in preparation). In 
addition, the authors showed, that the transcription of the gene encoding acid sphingomyelinase, that 
cleaves sphingomyelin into ceramide and phosphocholine, is also increased in keratinocyte cells that do not 
form sphingolipids with 4,5-double bond. Therefore, it cannot be excluded that enhanced sphingomyelin 
degradation in the presence of 5b accounts for the observed effects. In order to clarify, if the accumulation 
of ceramide and the decreased level of sphingomyelin brought about by 5b, are a consequence of an 
inhibition of the ceramide metabolizing enzyme sphingomyelin synthase, or are a consequence of an 
increased expression of acid sphingomyelinase, we have to make further experiments, including the 
quantification of mRNA levels and activity assays of ceramide metabolizing enzymes.  
As the compounds 5a, 5b and 7b turned out to be effective inhibitors of ganglioside GM2-formation in 
neurons, the question arises, if these compounds are suitable for the substrate reduction therapy of Tay-
Sachs and Sandhoff disease. The advantage of these substances would be that glucosylceramide and 
lactosylceramide are still biosynthesized, while only the biosynthesis of the storage compounds is inhibited. 
The limitations of GalNAc-transferase inhibition as a therapeutical approach for GM2-gangliosidoses have 
been demonstrated by the genetic model of substrate reduction (Liu et al., 1999) in mice, were the 
accumulation of enzyme substrates of non-lipid nature were determined. For a pharmacological application, 
it is important to understand how differences in sphingolipid biosynthesis translate into alterations of the 
total content of certain GSL species. The metabolic labeling experiments give no information on changes of 
the total content of cellular sphingolipids in response to exogenously added ceramide analogs. The 
quantification of ganglioside levels in lipid extracts from fibroblasts by thin layer chromatography and 
densitometric analysis showed no significant change of the total content of gangliosides after 48h (data not 
shown). To quantify the amount and molecular species distribution on of gangliosides GM3 and GM2 by 
mass spectrometry, we synthesized a standard substance with a closely related structure that does not 
occur in the investigated cell type. We chose ganglioside C6-GM3 as internal ganglioside standard for the 
quantification of GM3/GM2 levels in lipid extracts. In this work, the last step of a partial synthesis was 
carried out; the key step was the condensation of azidosphingosine with the peracetylated 1-O-
trichloroacetimidate of 3’-Sialyllactose, which has been isolated from colostrum (Clasen, 2004). After 
reduction of the azido-group, the amine was acylated with capronic acid. The lysoform of gangliosides can 
also be prepared in a multistep sequence by deacylation of native gangliosides through alkaline treatment 
(Neuenhofer et al., 1985). However, this method has a drawback: alkaline treatment releases N-acyl 
residues in both, ceramide and sialic acid in the carbohydrate moiety. Thus, the amine residues in the 
carbohydrate moiety need to be selectively reacetylated. A second possibility consists in the use of a 
sphingolipid ceramide deacylase (SCDase, Kurita et al., 2000). The synthesized C6-GM3, prepared during 
this work will be used as an internal standard for the determination of GM3/GM2 levels in lipid extracts from 
nerve cells.  
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5.2.3. Investigation of oxazolidinone 5b in vitro 
 
To determine, to which extent oxazolidinone 5b inhibits GalNAc-T directly, the substance was tested in vitro 
with murine recombinant GM2 synthase. The enzyme has been expressed as a glycoprotein in insect cells, 
using the baculovirus expression system according to Wendeler et al. (2003). Surprisingly, no inhibition 
occurred up to a concentration of 200 µM 5b in the assay buffer (chapter 4.3). The micellar assay system 
contained N-Octyl-beta-D-glucopyranoside. Micelles composed of detergents represent a simplified, but 
unphysiological model of biological membranes. However, reconstitution of transmembrane enzymes in 
liposomes is usually accompanied by a loss of activity, which prevented such inhibition studies, also in our 
hands. In addition, the preparation of micelles is rapid and straightforward and they are widely used in 
enzyme activity assays. Attempts to test the ceramide-derivative in a detergent free liposomal assay 
according to Wendeler (2004) did not work, because the specific activity of the GM2-synthase, determined 
in the liposomal assay system was only 3 % compared to the activity determined in micellar test systems. 
Further experiments are required to optimize the fusion of GM3-containing liposomes and enzyme-
containing membranes. From the results of the micellar assay, we concluded that the inhibitory effect in cell 
culture is not through direct interaction with the enzyme, but appears to be mediated by a more complex 
mechanism.  
GalNAc-T is a type II membrane protein that can be cleaved by a cathepsin D-like protease to form a 
soluble species that is released from the Golgi membrane (Jaskiewicz et al., 1996). The cleaved 
catalytically active soluble domain shows a lower activity towards their membrane-bound substrate (2-
dimensional enzyme kinetics; Scheel et al., 1982), which results in an accumulation of its substrates like  
LacCer, GM3 and GD3. Studies in murine liver cells have shown that during acute-phase response 
(secretion of acute-phase reactants from the cells in reponse to inflammation), sialyltransferases are 
cleaved from the Golgi membrane by the action of a cathepsin D-like protease (McCaffrey and Jamieson, 
1993; Richardson and Jamieson, 1995). Cathepsin D is lysosomal aspartatic pretease that is synthesized in 
the ER as an 51-kDa inactive pre-proenzyme (Gieselmann et al., 1983). After transport through the Golgi 
into the lysosomes, it is processed via a 44-kDa intermediate to the active 31-kDa species. It has been 
described that in the presence of Golgi disturbing agents, the transport of Cathepsin D from the Golgi to 
lysosomes is inhibited and that Cathepsin D accumulates in the Golgi vesicles (Scheel et al., 1990). In 
addition, experiments with the Golgi disturbing agent Brefeldin A in CHO cells overexpressing myc-tagged 
GalNAc-transferase show higher amounts of a soluble form of GalNAc-T in the medium compared to control 
cells (Young et al., 1999). We have to consider that the accumulation of GalNAc-transferase substrates in 
the presence of 5b in nerve cells might result from the cleavage of the enzyme by Cathepsin D. Recent 
studies have shown that ceramide binds to Cathepsin D and stimulates the formation of the active 31-kDa 
form (Heinrich et al., 2000). The activity of Cathepsin D within the cell can be reduced by the addition of 
agents such as desipramine, methylamine, and chloroquine to the culture medium (Lammers and 
Jamieson, 1989; Heinrich et al., 2000). These compounds are well known as lysosomotropic agents that 
raise the pH of endosomal and lysosomal compartments, and affect the processing and activity of proteins 
such as Cathepsin D (Braulke et al., 1987). Other lysosomal proteins like acid sphingomyelinase (Hurwitz et 
al., 1994; Kölzer et al., 2004) and acid ceramidase (Elojeimy et al., 2006) are released from internal 
membranes by desipramine and are subsequently degraded. Pretreatment of cells with desipramine, should 
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prevent the effect of compound 5b, if ganglioside accumulation is due to the mechanism as described 
above. Activity assays with Cathepsin D in the presence of the ceramide derivatives 5a and 5b should 
answer the question, if the derivatives can enhance the activity of Cathepsin D directly, or if the effect is 
indirect through the increased ceramide levels in the cell caused by 5b.  
 
 
5.2.4. Analysis for putative metabolites of 5b 
 
 
It has been demonstrated in cultured cells that some exogenously added ceramide derivatives can be 
metabolized to various compounds. In contrast to most drugs, they undergo anabolic reactions similar to 
those of the parent compound. For example, short chain ceramide derivatives (C6-ceramide) applied to 
cultured cells are transformed to long chain ceramides (Ogretmen et al., 2002). In addition, they can be 
transformed like endogenous ceramides by enzymes that catalyze the formation of glucosylceramide or 
sphingomyelin (Pütz and Schwarzmann, 1995; Brodesser, 2007). It is possible that the observed effects of 
5a and 5b result from a metabolite of these ceramide-derivatives. We followed several strategies to monitor 
the metabolism of the bioactive synthetic ceramide derivatives 5a and 5b. One problem in the identification 
of metabolites in crude lipid extracts was the high concentration of endogenous sphingolipids and 
glycerolipids compared to the low concentration of putative metabolites. A sample preparation to remove 
glycerolipids by alkaline treatment was not possible, due to the base-lability of the iodine-group. The 
analysis of the neutral lipid fraction derived from fibroblasts incubated with 5a by thin layer chromatography 
(chapter 4.3.1) using the solvent system chloroform/methanol/water (60:35:8, by volume) revealed a spot 
that does not occur in the lipid extract from control cells. The spot has the same retention factor as 
lysophosphatidylcholine and disappears in lipid extract that underwent alkaline treatment. 
Lysophosphatidylcholine is a neutral phosphoglycerolipid that is formed from phosphatidylcholine by the 
action of phospholipase A1 or A2. Attemps to extract this spot from tlc and to proof the assignment by mass 
spectrometry were not successful up to now. In order to overcome the disadvantage of the tlc-procedure, 
we analyzed the neutral lipid extract by using normal phase LC (Liquid Chromatography) interfaced with 
APCI (Atmospheric Pressure Chemical Ionization) according to Farwanah et al. (in preparation, data not 
shown). However, phosphoglycerolipids, including lysophosphatidylcholine, are not accessible to APCI-MS 
methods (H. Farwanah, personal communication). Therefore, we plan to optimize procedures for the 
analysis of lipid extracts using LC/ESI-MS.   
The analysis of the lipid extracts derived from fibroblasts incubated with 5a by tlc and mass spectrometry 
(chapter 4.4.4) revealed no metabolites, but we cannot exclude that the sensitivity of the choosen methods 
was not high enough. Therefore, strategies were established to introduce a radiolabel in 5b (chapter 4.4.3). 
Two strategies were followed to introduce the radioisotope in the last synthetic step: In the first strategy, the 
aminoaldehyde 8 (Figure 4.10) should be reduced by reaction with tritium-labeled sodium borohydride. 
Various attempts to prepare one of the active compounds on this strategy failed. The most severe problems 
of this strategy were the reactivity of the intermediate 8 and the reduction of the aldehyde under mild 
reaction conditions without loss of the iodine atom by elimination or hydrogenolysis.  
In a second strategy, the introduction of the radiolabel was attempted by hydrogenation of a derivative of 5b 
with an unsaturated alkyl chain (Figure 4.11). In preliminary experiments we were able to transform the 
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alkyne into the alkene by ionic hydrogenation, but further experiments are necessary to optimize the 
reaction conditions. In the following steps, it would be necessary to prepare the tritiated reagents ((Et3Si3H 
or CF3COO3H) and to carry out the hydrogenation reaction of 10.2b with this them. [3H]trifluoroacetic acid 
can be obtained by hydrolysis of trifluoracetic anhydride with [3H]-water (Dugger and Schwarz, 1967), and  
[3H]triethylsilane (Et3Si3H) can be prepared by reduction of triethylsilylchloride with LiB3H4 (Guillerm et al., 
1977).  
A strategy that was not followed to introduce the radiolabel before the introduction of the iodine-atom, is 
shown in figure 5.3. The radiolabel might be introduced using the Wittig reaction of Garner’s aldehyde with 
a radiolabeled ylide. The corresponding phosphonium salt can be derived from commercially available [1-
14C]tetradecanol in a one pot reaction, as decribed by Lee and Kim (2000), or by the transformation of the 
alcohol into an alkyl halide (bromide or iodide), followed by reaction with triphenylphosphane (Beaulieu et 
al., 1990). The corresponding N-Boc allylamine can be transformed to the iodo-oxazolidinones by treatment 
with NIS in CH2Cl2. One drawback of this pathway is the very low substance amounts, with which the 
reactions in the presence of radiolabel have to be carried out. The yield is usually drastically reduced due to 
the presence of small traces of water, and multistep syntheses are usually not suitable with radioactive 
intermediates. Although all isomers (5a, 5b and 5c) might be obtained in radiolabeled form by this 
approach, the disadvantages make it not attractive.  
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Figure 5.3: An alternative strategy to introduce a radiolabel in bioactive synthetic ceramide analog 5b 
 
As an alternative, non-radioactive strategy, we prepared substances with an azido-group in the ω-position 
of the alkyl chain in oxazinanone 12 (Figure 4.10) instead of a radioactive isotope (3H, 14C) as chemical 
reporter. This strategy has been successfully applied in the field of proteomics (Review: Wirtz and Kolter, 
2007) and functional glycomics (Toshinori et al., 2007, Saxon et al., 2002). When the ω-ceramide derivative 
12 is exogenously added to cells and metabolized, the putative metabolical products are bearing the azido- 
group. In the cell lysate, such compounds can be usually selectively conjugated with a biotinylated 
phosphine capture reagent (Figure 4.10, compound 13) by means of the Staudinger conjugation reaction 
(Saxon and Bertozzi, 2000).  
 
 
5.2.5. Relevance of iodine of 5b for its activity towards inhibition of GSL bioynthesis 
 
 
It can be expected that the iodine atom present in 5a and 5b, plays a role for the observed effects. L-[3-
14C]serine labeling experiments in granule cells (chapter 4.6.2) and fibroblasts (chapter 4.2.3) indicate that 
the presence of a halogen atom (iodine or bromine) is required for the mechanism of action. Iodine 
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represents a good leaving group in nucleophilic substitution reactions. It is well known that alkyl halides 
behave as electrophils in a cellular environment and are trapped e.g. by the action of 
Glutathiontransferases (Guengerich, 2005). It is therefore not unlikely that the covalent modification of an 
unknown target molecule by the halogenated ceramide derivatives 5a and 5b might account for the 
observed effect.  
To analyze putative interacting proteins that might undergo covalent attachment to the ceramide derivatives 
5a and 5b by substitution of the iodine, we want to analyze the cell lysate of fibroblasts and neurons that 
were incubated in the presence of ω-azido oxazinanone 12. Proteins that are covalently bound to 12 can be 
selectively conjugated to a biotinylated Staudinger reagent (Saxon and Bertozzi, 2000), separated by SDS-
PAGE and visualized with strepatvidin horse-dish peroxidase. This strategy was successfully in the 
identification of fatty-acylated proteins (Hang et al., 2007) and farnesylated proteins (Kho et al., 2004). In 
addition, taken advantage of the strong interaction between biotin and streptavidin, putative proteins can be 
concentrated from the cell lysate by the use of streptavidin-conjugated materials (e.g. beads). Alternatively, 
proteins covalently bound to 12 can also be isolated by the reduction of the azido-group to the amine, and 
the conjugation to N-hydroxysuccinimide activated material (e. g. AffiGel® 10, Biorad). 
  
 
5.2.6. Effect of oxazolidinone 5b on Golgi morphology 
 
 
The major intracellular transport pathway coupled to the biosynthesis of membrane lipids, glycoproteins, 
and secreted proteins, is the exocytotic vesicle flow from the ER via the Golgi apparatus to the plasma 
membrane. It has been shown that several drugs such as Brefeldin A, monensin, and vinblastine, which 
interfere with this intracellular membrane flow (Nakamura et al., 2003), can also reduce GSL biosynthesis 
(Townsend et al., 1984; van Echten and Sandhoff, 1989; van Echten et al., 1990). Using fluorescence 
microscopy, we showed that fibroblasts treated with 25 µM 5b in the culture medium underwent extensive 
Golgi vesiculation and reproduced the morphological phenotype of cells incubated with Brefeldin A (chapter 
4.5, figure 4.16). It can be suggested that the observed reduction of the biosynthesis of higher gangliosides 
in neuronal cells by 5b might be a consequence of the interruption of intracellular membrane flow, but we 
did not investigate the morphological studies in nerve cells. We cannot distinguish, whether Golgi 
vesiculation is responsible for the block in the biosynthesis of complex GSLs, or if the accumulation of GSLs 
leads to the change of the Golgi structure. Further experiments are required to identify the molecular target 
and to clarify the mechanism of action that leads to the metabolic and morphological effects in cell culture, 
and how they are related. 
 
As mentioned above, we observed that in the presence of 5b in culture medium, the incorporation of L-[3-
14C]serine into ceramide is increased. Therefore, we cannot distinguish whether the observed effect on 
Golgi morphology is caused by 5b directly, or results from the elevated ceramide content in the cell in a 
certain cellular compartment. Many examples are found in the literature, that decribe the change of the 
Golgi morphology in the presence of drugs that interfere with sphingolipid metabolism (Table 5.1). In 
addition, in a variety of human diseases, including amyotrophic lateral sclerosis, corticobasal degeneration, 
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Alzheimer’s and Creutzfeld-Jacob disease, spinocerebellar ataxia type 2, and in Niemann-Pick type C 
disease, the Golgi apparatus is fragmented (Gonatas et al., 2006). However, there is no plausible 
mechanism described, that explains the connection between sphingolipids and the constitution of the Golgi 
apparatus. Therefore, several aspects are briefly discussed. 
 
Hu and coworkers have reported, that the exogenous addition of 2.5 µM cell permeable C6-ceramide to the 
culture medium leads to a vesiculation of the Golgi in HeLa cells (Hu et al., 2005). They also showed that 
this treatment leads to a 50-fold increase in the levels of sphingosine, and that also the presence of 2,5 µM 
sphingosine causes Golgi fragmentation. However, also these authors provide no evidence about how 
ceramide or sphingosine induces the morphological change of the Golgi. To exclude the possibility that the 
disruption of these organelle results from unspecific factors, e. g. by altering the physicochemical properties 
of the membrane, they also tested L-erythro-ceramide, which failed to alter the morphology of the Golgi 
apparatus. Stereoisomers of naturally configured ceramide are often used as a control to rule out physico-
chemical factors. However, since the discovery of the ceramide-transporter CERT by Hanada and 
coworkers (Hanada et al., 2003) and the studies about its substrate-specifity (Kumagai et al., 2005), we 
know that the intermembrane transfer of unnatural stereoisomers of ceramide is very low compared to that 
of natural ceramide. Therefore, there is no information available about the local concentration of the 
different ceramide-derivatives in the Golgi or ER, when applied to the culture medium.  
 
 
 
Figure 5.2: Schematic representation of C16-ceramide recognition by the CERT START 
domain (Kudo et al., 2008). Residues lining the amphiphilic cavity are shown. Red dashed 
lines, hydrogen bonds; red circles, water molecules; black, blue, and red dots, C, N, and O 
atoms, respectively, of the residues involved in the hydrogen bond network. Green boxes 
indicate residues contributing to the hydrophobicity of the cavity in general, whereas green 
boxes with thick borders indicate those with direct hydrophobic interactions, which are 
represented as green dashed lines.  
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In this context, inactivation of CERT by a point mutation (Hanada et al., 2003) or by use of the 
stereospecific CERT inhibitor (1R,3R)N-(3-hydroxy-1-hydroxymethyl-3-phenylpropyl)dodecamide (HPA-12; 
Fig. 5.3; Yasuda et al., 2001) causes an increased ceramide content in the ER without vesiculation of the 
Golgi apparatus. Inhibition of this protein in drug-resistant cancer cell lines has also been shown to sensitize 
these cells to several cytotoxic agents (Swanton et al., 2007; Kolesnick et al., 2007). In addition, inactivation 
of CERT together with an inhibition of SMSr (sphingomyelin synthase related protein), which transforms 
ceramide to ceramidephosphoethanolamine, are proposed to cause an increase of ceramide content in the 
ER of HeLa cells, and leads to the fragmentation of the Golgi apparatus (J. Holthuis, personal 
communication).  
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Figure 5.3: HPA-12 
 
It can be expected that the synthetic ceramide-derivatives accumulate in the ER and induce the same effect 
as endogenous ceramide, or they can act as an agonist of CERT and elevate the endogenous ceramide 
content in the ER, or they do this by inhibiting SMSr, which can be expected for a ceramide analog. 
However, the mechanism of how ceramide, or sphingosine, induce Golgi vesiculation, is still unknown. 
Analysis of the crystal structure of the START (steroidogenic acute regulatory protein-related) domain of 
CERT demonstrated that the binding pocket forms a hydrogen bond network with the hydroxyl-groups and 
the amide-group of ceramide, and that there is no space for additional bulky groups (Kudo et al., 2008).  
In addition to CERT, the lipid-binding protein FAPP2 (four-phosphate adaptor protein) is reported to be 
required for the non-vesicular transport of glucosylceramide to the distal Golgi compartments (D’Angelo et 
al., 2007). Knockdown of FAPP2 leads to a reduction of the biosynthesis of glycosphingolipids (Halter et al., 
2007). In addition, FAPPs are decribed to be required for the formation of transport vesicles from the trans-
Golgi to the plasma membrane (Godi et al., 2004). It is therefore not unlikely that the ceramide derivatives 
5a and 5b can affect glycosphingolipid biosynthesis through the inhibition of CERT or FAPP2. 
 
The group of Brindley investigated the effect of ceramide on membrane trafficking (Abousalham et al., 
2002). They showed that C2-ceramide, but not dihydro-C2-ceramide, can block the association of ARF1 
(ADP-ribosylation factor) with Golgi-enriched membranes. The ARF family represents a group of several 
small G-proteins that play a central role in the organization of the secretory and endocytic pathways 
(Gillingham and Munro, 2007, Figure 5.2). In COP-coated (COP = coat protein) vesicle formation, the GDP-
bound form of ARF associates with the donor Golgi membrane, where guanine nucleotide exchange factors 
(GEFs) promote the exchange of the bound GDP for GTP. In its GTP-bound state, ARF promote the 
binding of the coatomer (COPI coat protein), leading to vesicle budding. The Golgi-disturbing drug Brefeldin  
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A specifically binds to the usually transient ARF*GDP-GEF complex, which cannot proceed to nucleotide 
dissociation, resulting in a block of vesicular traffic (Renault et al., 2003). It can be expected that the 
ceramide derivatives 5a and 5b interfere with this vesicle budding in the same way as it is proposed for C2-
ceramide. 
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Figure 5.6: Mechanism of COP-coated vesicle formation from the trans Golgi network modified from  
(Kirchhausen, 2000). Inhibition step for Brefeldin A and the hypothetical influence of ceramide are 
indicated. 
 
Many other factors contribute to the formation and maintenance of the structure of the Golgi apparatus 
including the cytoskeleton (Lázaro-Diéguez et al., 2006), regulatory kinases (PKC and PKA), calcium ion 
concentration within the Golgi lumen, or in the adjacent cytosol (Dolman and Tepikin, 2006). Several drugs 
that are unrelated to each other in their structure and reported mode of action have been described to 
disturb the integrity of the Golgi apparatus (Table 5.1). Further experiments are required to analyze the 
exact mechanism of how ceramide and ceramide-derivatives influence the morphology of this organell.  
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Compound (concentration applied to cultured cells) Reference 
Arachidonyltrifluoromethyl ketone (40 µM) Kuroiwa et al., 2001 
Brefeldin A (1 µg/ml) van Echten and Sandhoff, 1989 
Cetaben (100 µM) Kovacs et al., 2004 
Cyclofenil diphenol (40-100 µg/ml) Mason and Lancaster 1992 
Clofibrate (500 µM) Figueiredo and Brown 1999 
C6-ceramide (2,5 µM) Hu et al., 2005 
Cholesterol (5 µM as mβCD/Chol-Complex) Ying et al., 2003 
Colcemid (1 µM) Sandoval et al., 1984 
CI-976 (25 µM) Chambers et al., 2005 
2,4-Dichlorophenoxyacetic acid (1 mM) Rosso et al., 2000 
Dicumarol (200 µM) Mironov et al., 2004 
Methyl 2-(4-fluorophenylcarbamoyl)benzoate (100 µM) Feng et al., 2003 
Ilimaquinone (30 µM) Veit et al., 1993 
Isotetrandrine (25 µM) Chan et al., 2004 
Monensin (1 µM) Tartakoff, 1983 
Nocodazole (5 µM) Minin, 1997 
Norrisolide (40 µM) Guizzunti et al., 2006 
Nordihydroguaiaretic acid (NDGA, 25 µM) Nakamura et al., 2001 
Okadaic acid (1 µM) Lococq et al., 1991 
PDMP (100 µM) Nakamura et al., 2002 
Retinoic acid (10 µM) Wu et al., 1994 
Vinblastine (50 µM) Wehland et al., 1983 
  
Table 5.1: Golgi-disturbing agents 
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5.3. A Benzazepinone as conformationally restricted ceramide derivative 
 
Previous cell culture studies indicated that benzazepinone 24 (chapter 4.8; Figure 4.23) acts as an inhibitor 
of sialyltransferase II at a concentration of 10 µM in the culture medium, and as an inhibitor of GalNAc-
transferase at higher concentrations of 25 µM. The molecular bases for this inhibition are not known; even, 
if the effect is a direct or indirect one. In this work, the labeling experiments have been repeated in cultured 
neurons with D-[14C]galactose in the presence of benzazepinone 24 at a concentration of 25 µM (chapter 
4.8.2, Figure 4.24). The results were similar to the effects described in presence of 10 µM by Sawatzki 
(2003a). To investigate, if the conformational restriction or the presence of the bulky aromatic group within 
the benzazepinone 24 is responsible for the observed effects in cell culture, we synthesized the open chain 
analog 25 (chapter 4.8.1, figure 4.23) and tested 24 and 25 in cultured neuronal cells on its influence of 
glycosphingolipid biosynthesis. We have shown that the N-phenylacetylceramide derivative 25 has the 
same effect on sphingolipid biosynthesis, but additionally showed cytotoxic effects. It can be expected that 
the compound 25 behaves like a short-chain ceramide (C2- and C6-ceramide). It has been described that 
exogenous addition of short-chain ceramides to cultured cells leads to apoptotic responses, while the 
saturated form dihydroceramide has no effect (Bielawska et al., 1993). Hydrogenation of the double bond in 
25 should lead to a less toxic compound that should be even more comparable to compound 24.   
Ceramide and ceramide derivatives have been described as modulators of PKC activity, although their 
mechanism of action is controversially discussed. The Benzolactames 35 and 36 have been described as 
activators of Protein Kinase C (PKC) (Nakagawa et al., 2006; Mach et al., 2006; Endo et al., 1999). 
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Figure 5.3: Structures of ceramide derivative 24 and PKC activators 35 and 36 
 
To verify, if the enhancement of the relative amount of a-series gangliosides (e. g. GM3, GM2, GD1a and 
GT1b) can result from the stimulation of an intracellular phosphorylation of sialyltransferase II (Bieberich et 
al., 1998), we first wanted to analyze the influence of ceramide derivative 24 on PKC activity in a micellar 
assay. We observed that in the presence of 50 µM ceramide derivative 24 in the assay buffer, no activation 
of PKC occurs. From this result, we exclude the possibility that the ceramide derivative directly binds to 
PKC. Moreover, the activity of PKCs is regulated by many other factors, such as phosphatidylserine, 
calcium ions, and lipid mediators such as diacylglycerol, fatty acids, cholesterol sulfate, and 
lysophospholipids (Shirai and Saito, 2002). As discussed above for the oxazinones 5a and 5b, several other 
mechanisms exist that might account for the influence of the synthetic ceramide derivative on GSL 
metabolism.  
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6. Material and Methods 
6.1. Material 
6.1.1. Analytical Techniques and Instruments 
Autoclave FVS3, Fedegari/Integra, Fernwald, Germany 
Blotter Mini-TransBlot, BioRad, München, Germany 
Centrifuges Eppendorf, Hamburg, Germany 
L 8-80, mit SW-28-Ti-Rotor, Beckmann, Palo Alto, USA 
C, H, N Analysis: CHNO-Rapid Heraeus 
Centrifuge tubes 12 ml: Costar, Cambridge, USA 
15 ml: Greiner, Nürtingen, Germany 
50 ml: Falcon/BectonDickinson, Bedford, USA 
FAB-mass spectrometer H1, Kratos, Manchester 
Fluoroscanner Fluoroscan II, Labsystems 
Gel chamber Mini-TransBlot, BioRad, München, Germany 
Glass tools Schott-Duran, Jenaglas, Mainz, Germany 
Hot air gun Regulator 2000, Rapid, Hestra, Sweden 
Incubator Heraeus-Christ, Hanau, Germany 
IR: 1600 FT-IR spectrometer Perkin-Elmer, Boston, Massachusetts, USA 
Microscope Flourescence microscope Zeiss Axiovert 35 with filters (Bp 
485, Ft 510, 515-565), Oberkochen, Germany 
NMR: DPX300 and DPX400  Bruker, Karlsruhe, Germany 
Polarimeter: P341  Perkin-Elmer, Boston, Massachusetts, USA 
Overhead mixer Gesellschaft für Labortechnik, Burgwedel, germany 
PH-meter pH 537, WTW, Weinheim, Germany 
Phosphoimager Fuji BAS 1000 Bio Imaging Analyzer, Raytest, 
Straubenhardt, Germany 
Phosphoimaging plates 14C-screen BAS MS 2040, 3H-Screen BAS Tr 2040, Raytest, 
Straubenhardt, Germany 
Scintillation counter Tri-Carb 1900CA, Packard Instruments Co., Inc, Downers 
Grove, USA 
Shaker water bath Gesellschaft für Labortechnik, Burgwedel, Germany 
SigmaPlot software SPSS science, Erkrath, Germany 
Sterilbenches LaminAirHA 2472 GS, Heraeus, Düsseldorf, Germany 
Thermomixers Komfort, Eppendorf, Hamburg, Germany 
TLC-tank Desaga, Heidelberg, Germany 
TLC-heater TLC-Plate Heater III, Camag, Berlin, Germany 
Ultra centrifuge L8-70M, Beckman Instruments, München, Germany 
Ultrasound bath Sonorex RK 100, Bandelin, Berlin, Germany 
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Ultrasound  Cap horn, Sonifer B-12, Branson Ultrasonic Corp., Danbury, 
USA 
Vortex MS Minishaker, IKA-Werk, Staufen, Germany 
Water purification Millipore-Pelicon filtration device with polysulfone filter 
cassette, Millipore, Molsheim, France 
 
6.1.2. Consumables and Chemicals 
Agarose Invitrogen Life Technologies, Bethesda, USA 
AraC (cytosine arabinose) Sigma, Taufenkirchen, Germany 
Barrycidal-36 Biohit, Köln, Germany 
BCA Sigma, Taufkirchen, Germany 
BSA Sigma, Taufenkirchen, Germany 
CDP-Cholin Sigma, Taufkirchen, Germany 
Cell flask Costar, Bodenheim, Germany 
Chemiluminescence reagent Perkin Elmer Life Sciences, Rodgau-Jügesheim, Germany 
Coomassie brilliant blue Serva Feinbiochemika, Heidelberg, Germany 
DEAE Sephadex A-25 GE Healthcare, Uppsala, Sweden 
Deuterated solvents d1-Chloroform Uvasol®, Merck, Darmstadt, Germany 
d4-Methanol, Euriso-Top, Saint-Aubin Cedex, France  
Dry solvents (Crown-Cap) Fluka, Buchs, Switzerland 
Ganglioside GM3  Fidia Research Laboratories, Abano, Italy 
DNase Roche, Mannheim, Germany 
E-64 Serva, Heidelberg, Germany 
Glycerol Merck, Darmstadt, Germany 
HEPES Merck, Darmstadt, Germany 
Imaging plates 14C-Screen (BAS MS 2040), 3H-Screen (BAS Tr 2040), 
Raytest, Straubenhardt, Germany 
LiChroprep® RP18 (40-63 µM) Merck, Darmstadt, Germany 
Leupeptin Sigma, Deisenhofen, Germany 
Lipid standards Sigma, Taufenkirchen, Germany 
Nonidet P-40 Fluka, Buchs, CH 
Octyl-β-D-glucopyranoside Glycon, Luckenwalde, Germany 
Pepstatin A Boehringer, Mannheim, Germany 
Phytosphingosine (isolated from 
Sacharomyces cerevisiae) 
Cosmoferm B.V., Delft, Netherlands 
PMSF Sigma, Deisenhofen, Germany 
Reaction vessel Eppendorf, Hamburg, Germany 
Silica gel 60 F254 (40-63 µM) Merck, Darmstadt, Germany 
Screw cap glass Pyrex, Bibby Sterlin Ltd, Stone, Great Britain 
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Sterile filters Sarorius, Göttingen, Germany 
Szintillation vials Packard Biosciences, Gronigen, Netherlands 
TLC plates (aluminium coated with silica 
gel 60 F254 (40-63 µM) 
Merck, Darmstadt, Germany 
Triton X-100 Sigma, Taufkirchen, Germany 
Tween 20 Sigma, Taufkirchen, Germany 
Ultima Gold Packard, Frankfurt a.M., Germany 
 
6.1.3. Radiolabeled Chemicals 
D-[1-14C]Galactose Amersham Pharmacia, Freiburg, Germany 
L-[3-14C]Serine  Amersham Pharmacia, Freiburg, Germany 
UDP[3H]GalNAc American Radiolabeled Chemicals (obtained through 
Biotrend, Cologne, Germany) 
 
 
6.2. Biological materials 
6.2.1. Cells and additives 
Human fibroblasts Kinderklinik St. Augustin, Germany 
NMRI mice Animal house of the University of Bonn 
SF9 insect cells Invitrogen, Karlsruhe, Germany 
Baculovirus stock Michaela Wendeler 
DMEM, MEM Gibco, Eggenstein, Germany 
Glutamine  
Foetal calf serum (FCS) Cytogen, Berlin, Germany 
Leupeptin hemisulfate Sigma, Taufkirchen, Germany 
Horse serum  Cytogen, Berlin, Germany 
streptomycin Sigma, Deisenhofen, Germany 
Trypsin Cytogen, Berlin, Germany 
N-Acetyl-L-Alanine-L-Glutamine Seromed, Biochrom, Berlin, Germany 
TNM-FH medium Sigma, Deisenhofen, Germany 
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6.3. Methods 
6.3.1. General Conditions for synthesis 
All reactions were carried out with magnetic stirring and, if involving moisture– or air-sensitive reagents 
involved, were performed under nitrogen using syringe-septum cap techniques. All glassware was flame-
dried under vacuum and purged with argon prior to use.  
 
6.3.2. Chromatographic methods 
TLC (Thin layer chromatography) was carried out with aluminium plates coated with SiO2 to control the 
completion of a reaction or to analyze the profile of column chromatography. The chromatograms were 
examined under UV light (λ = 254 nm bzw. 366 nm) and by treatment of the TLC plate with one of the 
solutions given below, followed by heating with a heat gun.  
 
Column chromatography was performed using silica gel 60 (0.040-0.063 mm). 
 
Visualizing reagents: 
4-anisaldehyde/acetic acid/sulfuric 
acid 
2:500:10 (v/v/v) (Miescher, 1946) 
Ninhydrin/ethanol 1:10 (w/v) (Patton and Chism, 1951) 
Phosphomolybdic acid/ 
Ce(SO4)2/H2SO4/H2O 
5:2:12:230 (w/w/v/v)  
2,4-Dinitrophenylhydrazine/ethanol/ 
H2SO4/H2O 
2:50:10:15 (w/v/v/v) (Behforant et al., 1985) 
CuSO4 x 5 H2O/H3PO4 (85 %)/H2O 15.6:9.4:75 (w/v/v) (Yao and Rastetter, 1985) 
 
 
6.4. Instrumental Analytic 
 
1H- and 13C-NMR-spectra were recorded on a Bruker spectrometer in deuterated solvent at room 
temperature. Chemical shifts δ are relative to solvent and given in ppm. The coupling constants (J) are 
given in Hz. The following abbreviations are used for multiplicities: s = singlet, d = doublet, t = triplet, q = 
quartet, m = multiplet, br = broad.  
 
FAB (All Fast Atom Bombardment spectra) were recorded in meta-nitrobenzoic acid in the analytical 
laboratories of the department of Chemistry, University of Bonn.  
EI (electron impact ionization) spectra were recorded on a Kratos MS50, ThermoQuest Finnigin MAT 95 XL. 
HR (High-resolution) masses were determined by EI. 
ESI (electrospray ionization) mass spectra were measured on Q-TOF-2-mass spectrometer equipped with a 
nanospray source. Lipid samples to be analyzed were dissolved in methanol (100 pmol/µl).   
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IR (Infrared spectra) were recorded on a FT-IR 1600 spectrometer. Samples were measured either as a film 
on KBr plates or (for solids) as KBr tablets. The absorption bands are given in wave numbers (cm-1). For the 
band characterization the following abbreviations were used: br (broad), s (strong), m (medium), vs (very 
strong), w (weak).  
 
MPs (melting points) were determined with a capillary instrument SMP 20 and are uncorrected.  
 
Elemental analyses were performed in the microanalytical laboratories of the department ofChemistry, 
University of Bonn.  
 
Optical rotations were measured at rt on a P341 polarimeter with monochromatic light (λ = 589.3 nm). The 
samples with a concentration of 0.1-1.0g/100ml were measured in quarz glass cuvets (vol. 1 ml).  
 
 
6.5. Biological and biochemical experiments 
6.5.1. Cell culture 
 
All procedures with cells were carried out under sterile conditions. 
Granule cells were cultured from cerebella of 6-day-old mice as described before (van Echten et al., 1998). 
Briefly, cells were isolated by mild trypsinization (0.05%, w/v) and dissociated by repeated passage through 
a constricted Pasteur pipette in a DNAse solution (0.1%, w/v). The cells were then suspended in DMEM 
containing 10% heat-inactivated horse serum and plated onto poly-L-lysine-coated 8 cm2 Petri dishes. 
Twenty-four hours after plating, 40 µM cytosine arabinoside (AraC) was added to the medium to arrest the 
division of nonneuronal cells. After 5 or 6 days in culture, cells were used for metabolic studies. Cells were 
incubated at 35.5 °C in a 5% CO2 atmosphere.  
Fibroblasts and B104 cells were routinely cultured in 75 cm2 flasks in DMEM, supplemented with 2 mM 
glutamine, 10% heat-inactivated fetal calf serum, and streptomycin 100 mg/L. Cells were incubated at 37°C 
in a 5% CO2 atmosphere. After reaching a confluent state, the cells were subcultered 1:2 in culture flasks or 
seeded in plates for experiments. For passaging of cells, the medium was removed and the cells were 
washed with PBS. After addition of 2 mL trypsin/EDTA, the cells were incubated for 1-2 min at 37°C. Cells 
were carefully detached by gently tapping and the digestion was stopped by addition of 3 mL DMEM 
containing 10% FCS. The cells were centrifuged with 300 g for 10 min at 4°C, the supernatant was 
discarded and the cells were resuspended in growth medium. For experiments, cells were grown until 
confluence in 21 cm2 petri dishes or flasks.  
Sf9 Insect cells were cultured in TNM-FH medium containing 10% FCS in a shaking incubator at 28°C. 
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6.5.2. Metabolic studies with cultured fibroblasts and cerebellar granule cells 
 
Metabolic studies were performed with confluent cells in 8 cm2 (cerebellar neurons) or 21 cm2 (fibroblasts) 
plastic culture dishes. Growth medium was removed and the cells were rinsed two times with MEM. The 
cells were preincubated with synthetic lipid analogues in concentrations of 5-50 µM in the culture medium, 
together with 0.3% heat-inactivated calf serum (fibroblasts) or 0.3% heat-inactivated horse serum 
(cerebellar neurons) for 24 h. The stock solution (5 mM) of synthetic ceramide analogs in methanol was 
stored at –20°C. The sphingolipids of cultivated cells were metabolically labeled by addition of either L-[3-
14C]-Serine (1 µCi/mL) or D-[14C]-Galactose (2.5 µCi/mL). After 24 h, medium was removed, cells were 
washed twice with 1 mL of PBS, and harvested after addition of trypsin in screw cap glasses. After washing 
with PBS, cells were stored at  –20°C. 
 
6.5.3. Protein determination 
 
Cell protein was quantified as described by Bradford (Bradford, 1976) using BSA as standard. The Bradford 
reagent (5 mg Coomasie Blue G250, 5 mL methanol, 10 mL H3PO4 (85%), 85 mL H2O) was stored at 4°C. 
Prior to lipid extraction, cell pellets were homogenized in 400 µl of water and aliquots were used for protein 
determination. 5 µL of cell homogenate were filled to 20 µL with water in a multiwell plate. 200 µL of 
Bradford reagent working solution were added. After 20 min incubation at rt, the absorbtion of samples was 
measured at 595 nm. Protein content was calculated on the basis of a standard curve, obtained by diluting 
the BSA standard (0.25-5 µg BSA/20 µL).  
 
6.5.4. Lipid extraction 
 
Cell pellets were suspended in 1 mL water and homogenized 3 times (30 s) by ultrasonic treatment (120 
W). Aliquots for protein determination and radioactivity determination were issued and 4 mL methanol was 
added to the cell homogenate. The solution was vortexed, sonificated for 15 min and 2 mL of chloroform-
methanol-water (10:3:1, v/v/v) were added and incubated for 24 h at 50°C. Insoluble cellular components  
were separated by filtritation through wadding. The screw cap glass was rinsed with 2 mL of chloroform-
methanol-water (70:30:3, v/v/v), and the extract was dried under a stream of nitrogen. 
 
6.5.5. Anion-exchange chromatography 
 
The separation of acidic and neutral lipids was carried out by ion exchange chromatography with a weak 
anion exchanger, DEAE Sephadex A-25. To obtain maximum affinity of acidic lipids, the medium was 
converted first from the chloride to the acetate form. 500 g of ion exchanger was first slurred with 1 L 
methanol for 12 hours to allow the resin to swell. Then it was suspended in 0.5 L water and allowed to stand 
for 24 hours. Then the resin was transferred into a glass column and suspended in 0.5 L 1 M Sodium 
acetate solution. To eliminate almost all chloride, the resin had to be washed several times with 1 M Sodium 
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acetate solution, until no chloride was detectable by silver nitrate test. Then the acetate form was washed 
first with 1 L water and then with 1 L methanol and was stored as 1:1 suspension in methanol at 4°C before 
use. 
Small pieces of silanized glass fiber wadding were introduced into glass Pasteur pipettes and 1 mL of 
DEAE-Sephadex A-25/methanol suspension (1:1) in acetate form was added and equilibrated with 3 mL of 
chloroform-methanol-water (3:7:1, v/v/v). Samples were dissolved in 2 mL of the same solvent, sonicated 
for 1 min, and applied to the column. The column was washed with 6 mL of the same solvent. This pass-
through fraction contained the neutral sphingolipids. Acidic lipids were eluted with 8 mL of chloroform-
methanol-0.8 M potassium acetate (30:60:5, v/v/v). The lipid fractions were evaporated to dryness under a 
nitrogen stream.  
 
6.5.6. Alkaline hydrolysis 
 
Phospholipids were removed by mild alkaline hydrolysis. Samples were dissolved in 1 mL of chloroform-
methanol (1:1, v/v), vortexed, and the glass of the reaction vessel was rinsed with 1.5 mL of the same 
solvent. After 5 min ultrasonic treatment, addition of 62 µL 4 N NaOH, and additional 5 min ultrasound, the 
solution was incubated for 120 min at 37°C in a water bath. After the reaction mixture was cooled and 
neutralized with 10 µL glacial acetic acid, the lipids were evaporated under nitrogen to dryness.  
 
 
6.5.7. Reversed-Phase Chromatography (RP18) 
 
Desaltment of lipid samples was performed according to literature (Williams and McCluer, 1980). 
Small pieces of silanized glass fiber wadding were introduced into glass Pasteur pipettes and 1.5 mL of 
LiCroprep (1:1) was added and washed with 1 mL methanol, 2 mL water, 1 mL methanol, 2 mL of 
chloroform/methanol (1:1 (v/v)), 1 mL methanol and 2 mL of chloroform/methanol/0.1M KCl in water 
(3:48:47 (v/v/v)). Lipid samples were dissolved in 1 mL methanol, sonicated for 5 min, and 1 mL ammonium 
acetate (300mM in water) was added. The mixture was directly applied to the column. The probe glass was 
rinsed two times with 1 mL ammonium acetate (200 mM in methanol/water 1:1 (v/v)), and the solution was 
added to the column. The column was washed with 6 mL of water. Lipids were eluted with 1 mL methanol 
and 8 mL of chloroform/methanol (1:1 (v/v)). The lipid fractions were evaporated to dryness under a stream 
of nitrogen.  
 
6.5.8. Thin-layer chromatography 
 
Lipid samples corresponding to the same amounts of all protein were dissolved in 1 ml chloroform-methanol 
(1:1, v/v), transferred to eppendorf tubes, and evaporated to dryness under nitrogen stream. The residues 
were dissolved in 40 µL chloroform-methanol (1:1, v/v) and applied with glass capillaries to Silica gel 60-
precoated glass plates. The Eppendorf vessels were rinsed with 25 µL and 10 µL of the same solvent. The 
TLC-plates were dried under vacuum over sodiumhydroxid. The chromatography tank was lined with filter 
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paper and filled with 200 mL of mobile phase. For the separation of different lipids, the following mixtures 
were used: 
 
Neutral lipids chloroform/methanol/water 60:35:8 (v/v/v) 
Neutral lipids first: chloroform/methanol/glacial acetic acid 
second: chloroform 
70:30.8 (v/v/v); 2 times 2/3 
Acidic lipids chloroform/methanol/0.22% CaCl2 60:35:8 (v/v/v) 
Ceramides chloroform/methanol/water 190:9:1 (v/v/v) 
 
After drying, lipid bands were visualized by Phosphoimaging and treatment with cupric sulfate pentahydrate 
phosphoric acid reagent at 180 °C for 10 min. Data are analyzed using the TINA software. 
 
6.5.9. Preparation of lipid extracts for quantification by mass spectrometry 
 
Lipids were extracted according to the procedure of Bligh and Dyer (1959). Lipids were extracted for 12h at 
rt in 2.8 mL of a nonpolar solvent mixture with the composition: methanol/chloroform/water (2:1:0.8 (v/v/v)). 
Then a double-phase system was obtained by adding 1 mL chloroform and 1 mL water (final ratio: 
methanol/chloroform/water = 2:2:1.8 (v/v/v)). After the mixture was centrifuged at 2500 rpm for 10 min, 90% 
of the lower phase containing less polar lipids (ceramide, PC, PS, GlcCer, LacCer, Gb3, Gb4, SM) was 
separated from the upper phase and dried under a stream of nitrogen. The upper phase together with the 
interphase (containing gangliosides) was dried under a stream of nitrogen, redissolved in 100 mL methanol, 
and desalted as described under 6.5.7. For mass spectrometric analysis, the lipid probes were dissolved in 
methanol (lower phase in 50 µL MeOH, upper phase in 200 µL MeOH) and analyzed by ESI-MS in both 
positive and negative ion modes.  
 
6.5.10. Expression and membrane preparation of GM2 synthase (GalNAc-transferase) 
 
GM2 synthase was expressed using the baculovirus/Sf9 expression system as described previously 
(Wendeler, 2004). Cells were infected with a viral stock containing the expression vector pVL1393-GM2SM 
(Wendeler, 2004) at a multiplicity of infection of 1. After 72 h, insect cells were harvested by centrifugation 
with 1800 rpm for 5 min at 4°C. Cells were washed twice with ice-cold PBS and then resuspended in 50 mM 
HEPES (pH 7.3) containing 1mM MnCl2 to a cell density of 15 x 106 cells/mL, frozen in liquid nitrogen, and 
stored at –80°C. The cells were thawed on ice, and the same volume of lysis buffer (50 mM HEPES, pH 
7.3, 1 mM MnCl2, 0.3 M NaCl, 2mM PMSF, 10 µg/ml leupeptin, 10 µg/mL E-64) was added. Cells were 
disrupted by ultrasound (4 x 30s, 50% intensity, 60W), centrifugated at 800g, and the resulting supernatant 
was centrifugated at 100000 g for 1 h at 4°C. Then, the pellet was resuspended in extraction buffer (20 mM 
HEPES, pH 7.3, 1 mM MnCl2, 150 mM NaCl, 0.04 % PG) and homogenized by ultrasound (2 x 30s). 
Aliquots of the membrane fractions are frozen in liquid nitrogen and then stored at –80°C. 
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6.5.11. Glycosyltransferase Assay 
 
Enzyme activity was determined according to the in vitro-assay described by Pohlentz (Pohlentz et al., 
1988). This assay is based on the transfer of [3H]-GalNAc from UDP-[3H]GalNAc and quantification of the 
resulting ganglioside GM2 by scintillation counting. The assay volume was 50 µL, consisting of 40 µL assay 
buffer and 10 µL cell homogenate. The required amounts of UDP-[3H]GalNAc (100 000 cpm/nmol) and 
GM3 (0-7 nmol) were applied to the test tubes, and organic solvent was removed under a stream of 
nitrogen. 40 µL of assay buffer (125 mM HEPES, pH 7.3, 12.5 mM MnCl2, 0.5% w/v N-Octyl-beta-D-
glucopyranoside, 12.5 mM CDP-choline (immediately added before use)) was added and each tube was 
sonicated for 30 sec. in a cup horn sonicator at 100 W. The transferase preparation was added, and the 
tubes were incubated at 37°C for 30 min. The reaction was stopped by adding 134 µL methanol and 150 µL 
water on ice. The samples were applied to RP18 chromatography. The assay samples were applied to the 
column and the reaction vial was rinsed with 0.5 mL methanol-water (4:6, v/v). After washing the column 
with water the [3H]-GM2 was eluted with 3 x 1 mL methanol and 3 x 1 mL chloroform-methanol (1:1, v/v). 
The eluate was evaporated to dryness under a stream of nitrogen. The residue was dissolved in 1 mL 
chloroform-methanol (1:1, v/v), and 0.5 mL were used for scintillation counting. Data were analyzed with the 
Enzyme Kinetics module of the SigmaPlot software.  
 
6.5.12. Fluorescence microscopy  
 
Human fibroblasts (104-105) were plated into each well of an 8-well Lab-Tek TM II chambered cover slide 
coated with 10% FCS and cultured in 200 µl DMEM, supplemented with 2 mM glutamine, 10% heat-
inactivated fetal calf serum, and streptomycin 100 mg/L, at 37°C, 5% CO2. Drugs were added to the 
medium to a final concentration of 1µg/ml BFA, or 25 µM ceramide derivative 5b, repectively. The Golgi was 
labeled in the absence (control) or presence of drugs with C6-NBD-ceramide/BSA complex (1 µM) for 1h at 
4°C according to literature (Puetz and Schwarzmann, 1995). Then, the cells were washed twice with 
HMEM, warmed to 37°C for 1h, and observed by live imaging using a fluorescence microscope (Zeiss 
Axiovert 35, filter: BP 485, FT 510, 515-565). Images were collected with the AxioCam MRc, and the 
images were visualized with the AxioVision 3.1. The C6-NBD-ceramide/BSA-complex was kindly provided 
by Dr. Günter Schwarzmann. 
 
6.5.13. PKC activity assay 
 
The PKC activity assay was obtained from Promega and the experiment was made according to the 
manufacturer’s instructions. The assay is based on a rhodamine-labeled fluorescent peptide that is 
phosphorylated by PKC according to a literature protocol (Isbell et al., 1995). In agarose gel 
electrophoresis, the phosphorylated peptide migrates toward the anode, while the non-phosphorylated 
peptide migrates toward the cathode.  
The assay volume was 25 µL and the reactions were carried out in 500 µL test tubes. The required 
amounts of Phorbolic ester (5.10-3 nmol), ceramide derivative 5b (1,25 nmol), and ceramide derivative 24 
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(1,25 nmol) were applied to the test tubes, and organic solvent was removed under a stream of nitrogen. 
The tubes were kept on ice and for each sample, 5 µL of fivefold concentrated assay buffer, 5 µL (20 µg) 
PepTag®C1Peptide, 5 µL of fivefold concentrated PKC activator solution, 1 µL peptide protection solution 
were added. At time zero, the tubes were removed from ice and incubated in a water bath at 30°C for 2 
minutes. Then, 4 µL (10 ng) of Protein Kinase C was added to each tube (with the exception of the negative 
control) and incubated at 30°C for 30 minutes. The reaction was stopped by submerging the reaction tube 
in a boiling water bath. The samples were stored at –20°C in the dark until ready to load on the agarose gel.  
 
6.5.14. Agarose Gel 
 
Separation of non-phosphorylated substrate (PepTagC1petide) and phosphorylated product was carried out 
by Agarose gel electrophoresis. The samples were loaded to an agarose gel (0.8% agarose in 50 mM Tris-
HCl, pH 8.0). Electrophoresis was performed at 70 V for 3 h. The gel was examined under UV light (λ = 365 
nm) and photographed. 
 
6.5.15. Quantification by Spectrophotometry 
 
The negatively charged phosphorylated bands were excised from the gel and placed into a 1.5 mL tube. 
After melting the gel by heating to 95°C, 125 µL of the hot agarose was added to a tube containing 75 µL 
Solubilization Solution and 50 µL glacial acetic acid. The probes were quickly vortexed and transferred to a 
well in a 96-well plate and and the absorbance was measured at 544 nm.  
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7. Synthetic section 
 
7.1. Synthesis of Garner aldehydes 2a and 2b 
 
(S)-tert-Butyl 4-(N-methoxy-N-methylcarbamoyl)-2,2-dimethyloxazolidine-3-carboxylate (1a) 
 
1O
2
3
4
N
5
Boc
O
N
O
 
 
The synthesis was carried out according to literature (Campbell et al. 1998). The analytical data are in 
agreement with those reported in the literature. Yield: 63-81% over 3 steps, white solid, C13H24N2O5, M = 
288.34 g/mol, Rf (petroleum ether/ethyl acetate, 1:1 (v/v)) = 0.41.  
1H-NMR (400 MHz, CDCl3, mixture of rotamers) δ [ppm]: 1.43 (s, 9H, C(CH3)3), 1.50 (s, 3H, C(CH3)2), 1.64 
(s, 3H, C(CH3)2), 3.14 (s, 3H, NCH3), 3.68 (s, 3H, OCH3), 3.90 (dd, 1H, 2JHH = 9.1 Hz, 3JHH = 3.4 Hz, H-5A), 
4.13 (dd, 1H, 2JHH = 9.1 Hz, 3JHH = 7.2 Hz, H-5B), 4.74 (dd, 1H, 3JHH = 3.4 Hz, 3JHH = 7.2 Hz, H-4). 13C-NMR 
(100 MHz, CDCl3, mixture of rotamers) δ [ppm]: 24.7, 25.7 and 28.5 (C(CH3)2 and C(CH3)3), 32.6 (NCH3), 
57.9 (OCH3), 61.2 (C-4), 66.2 (C-5), 80.6 (C(CH3)3), 95.1 (C(CH3)2, 152.2 (CO), 171.4 (CO). FAB-MS: m/z 
(%): 289.2 ([M+H]+, 40%). Elemental analysis: [C13H24N2O5] calc.: C 54.15, H 8.39, N 9.72; found.: C 54.23, 
H 8.36, N 9.76. 
 
 
(S)-tert-Butyl 4-formyl-2,2-dimethyloxazolidine-3-carboxylate (2a) 
 
1O
2
3
4
N
5
Boc
O
H
 
 
The synthesis was carried out according to literature (Garner, 1984). 1a (2 eq.) was dissolved in anhydrous 
THF, cooled to 0°C, Lithiumaluminiumhydride (1M in THF, 1.5 eq.) was added dropwise, and then the 
mixture was stirred for 30 min. The mixture was cooled to –15°C, and potassium hydrogensulfate (saturated 
aqueous solution, 100 mL) was added slowly. The product was extracted with diethylether, dried over 
sodium sulfate, filtered, and the solvent was removed under reduced pressure. To avoid racemization of the 
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aldehyde, it was directly used as a raw product without further purification. Raw yield: 83 – 95 %, yellow oil, 
C11H19NO4, M = 229.27 g/mol, Rf (cyclohexane/ethyl acetate, 1:1 (v/v)) = 0.81. 
1H-NMR (300 MHz, CDCl3) δ [ppm]: 1.41 (s, 9H, C(CH3)3), 1.48 (s, 6H, C(CH3)2), 4.05 (t, 1H, 3JHH = 5.2 Hz,    
H-4), 3.90 (m, 2H, H-5), 9.55 (s, 1H, CHO). 13C-NMR (75 MHz, CDCl3) δ [ppm]: 23.8 (C(CH3)2), 28.3 
(C(CH3)3), 63.9 and 64.7 (C-5 and  C-4), 81.1 (C(CH3)3), 95.1 (C(CH3)2), 152.0 (C=O), 199.3 (C=O). FAB-
MS: m/z (%) : 230.1 ([M+H]+, 30%). 
 
 
(4S,5R)-tert-Butyl 4-(N-methoxy-N-methylcarbamoyl)-2,2,5-trimethyloxazolidine-3-
carboxylate (1b) 
1O
2
3
4
N
5
Boc
O
N
O
 
 
The synthesis was conducted according to the preparation of compound 1a (Campbell et al., 1998). Yield: 
4.17 g (13.8 mmol) = 55 % over 3 steps, white solid, C14H26N2O5, M = 302.37 g/mol, Rf (cyclohexane/ethyl 
acetate, 1:1 (v/v)) = 0.64, αD = -11.3° (c = 0.577, CHCl3). 
1H-NMR (400 MHz, CDCl3, mixture of rotamers) δ [ppm]: 1.33 (d, 3H, 3JHH = 7.3 Hz, CH3), 1.36 (s, 9H, 
C(CH3)3), 1.43 (s, 6H, C(CH3)2), 3.18 (s, 3H, NCH3), 3.69 (s, 3H, OCH3), 4.06 (dq, 1H, 3JHH = 4.8 Hz, 3JHH = 
7.3 Hz, H-5), 4.46 (d, 1H, CHN, 3JHH = 4.8 Hz, H-4). 13C-NMR (100 MHz, CDCl3, mixture of rotamers) δ 
[ppm]: 19.5 (CH3), 24.2 (C(CH3)2), 28.6 (C(CH3)3), 32.6 (NCH3), 61.3 and 63.5 (OCH3 and C-4), 74.6 (C-5), 
80.6 (C(CH3)3), 95.2 (C(CH3)2), 151.4 (CO), 152.2 (CO). ESI-MS (positive mode): m/z (%) = 303.18 ([M+H]+, 
45%), 325.16 ([M+Na]+, 8%). Elemental analysis:[C14H26N2O5] calc.: C 55.61, H 8.67, N 9.26; found.:C 
55.22, H 8.59, N 9.10. 
 
 
(4S,5R)-tert-Butyl 4-formyl-2,2,5-trimethyloxazolidine-3-carboxylate (2b) 
 
1O
2
3
4
N
5
Boc
O
H
 
 
The synthesis was conducted according to the synthesis of compound 2a (Garner, 1984). To a solution of 
Weinreb amide 1b (3.69 g, 12.8 mmol) in dry THF (70 mL), Lithiumaluminiumhydride (1M solution in THF, 
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12.8 mL, 12.8 mmol) was slowly added at 0°C. The aldehyde was used directly without further purification 
to avoid racemization. Colorless oil, C12H21NO4, M = 243.30 g/mol, Rf (cyclohexane/ethyl acetate, 1:1 (v/v) = 
0.64. 
 
 
7.2. Synthesis of iodine-containing heterocycles 5a, 5b, and 8a 
 
(R)-tert-Butyl 2,2-dimethyl-4-(pentadec-1’-enyl)oxazolidine-3-carboxylate (3a) 
 
1
2
3
45
O N
(CH2)12CH3
Boc
 
 
The alkene was synthesized according to literature (Campbell et al., 1998). To a suspension of 
tetradecyltriphenylphosphonium bromide (9.81 g, 18.19 mmol) in dry tetrahydrofuran under an argon 
atmosphere cooled to –78°C, n-Butyllithium (1.6 M solution in hexane, 11.38 mL, 18.21 mmol) was added 
dropwise. The mixture was stirred for 15 min, allowing the temperature to reach 0°C, and the resulting dark 
red solution was stirred for an additional hour. After cooling to –78°C, tert-Butyl 4(S)-formyl-2,2-
dimethyloxazolidin-3-carboxylate 2a (2.88 g, 12.56 mmol) dissolved in dry THF (30 mL), was added 
dropwise over a 10 min period. The reaction mixture was stirred until the temperature reached rt, and then 
for additional 3 h. The mixture was quenched with saturated aqueous ammonium chloride (100 mL) and 
extracted with ethyl acetate (3x 120 mL). The combined organic phases were washed with water and dried 
with Na2SO4. After evaporation of the solvent under reduced pressure, the residue was purified by 
chromatography on silica gel (cyclohexane/ethyl acetate, 10:1 (v/v)) to give alkene as colorless oil. 
Combined yield: mixture of Z/E-isomers = 8:1; 3.76 g (9 mmol) = 73%. The (Z)-alkene was isolated in 43% 
of total product. Colorless oil, C26H49NO3, M = 409.36 g/mol, Rf (petroleum ether/ethyl acetate = 10:1 (v/v)) 
= 0.36 (E-alkene) and 0.41 (Z-alkene).  
1H-NMR (400 MHz, CDCl3) δ [ppm]: 0.81 (t, 3H, 3JHH = 6.9 Hz, CH3), 1.19 (m, 22H, CH2), 1.37 (m, 17H, 
CH2, C(CH3)3 and C(CH3)2), 1.95 (dt, 2H, 3JHH = 7.0 Hz, 3JHH = 7.0 Hz, CH2), 3.56 (dd, 1H, 3JHH = 3.3 Hz, 
2JHH = 8.6 Hz, H-5A), 3.98 (dd, 1H, 3JHH = 6.2 Hz, 2JHH = 8.6 Hz, H-5B), 4.56 (m, 1H, H-4), 5.34 (m, 2H, CH). 
13C-NMR (100 MHz, CDCl3) δ [ppm]: 14.1 (CH3), 22.9 (CH2), 28.7 (C(CH3)3), 29.3-29.9 (CH2, C(CH3)2), 32.1 
(CH2), 32.3 (CH2), 54.7 (C-4), 69.2 (C-5), 79.7 (C(CH3)3), 94.1 (C(CH3)2, 128.7 and 134.0 (CH), 152.0 
(C=O). FAB-MS: m/z (%) = 410.4 (11%, [M+H]+) 
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(1R,7aS)-Dihydro-1-(1’(R)-iodotetradecyl)-5,5-dimethyl-1H-oxazolo[3,4-c]oxazol-3(5H)-one 
(4b) 
O N
O
O
C13H27I
7
1
2
3
4
5
6
7a
1'
 
 
The oxazolidinone 4b was prepared according to the literature method (Jordá-Gregori et al., 2000). To a 
solution of Z-alkene 3a (1.3 g, 3.07 mmol) in dichloromethane (15 mL), N-iodosyccinimide (NIS, 1.54 g, 
6.87 mmol) was added at room temperature and was stirred for 48 h. The reaction was quenched with 
aqueous sodium thiosulfate (10% solution) and was extracted three times with CH2Cl2 (50 mL). The extracts 
were washed with NaHCO3 (10% aqueous solution, 100 mL) dried over Na2SO4, and evaporated to dryness 
under reduced pressure. The residue was purified by column chromatography on silica gel 
(cyclohexane/ethyl acetate, 9:1 (v/v)). Yield: 382 mg (770 µmol) = 26 %, white solid, C21H38INO3, M = 
479.43 g/mol, Rf (cyclohexane/ethyl acetate, 9:1 (v/v)) = 0.46.  
1H-NMR (400 MHz, CDCl3) δ [ppm]: 0.85 (t, 3H, 3JHH = 6.8 Hz, CH3), 1.23 (m, 20H, CH2), 1.33 (m, 2H, CH2), 
1.44 (s, 3H, C(CH3)2), 1.69 (s, 3H, C(CH3)2), 1.77 (td, 2H, 3JHH =  6.3 Hz, 3JHH = 2.1 Hz, CH2), 3.67 (ddd, 1H, 
3JHH = 11.6 Hz, 3JHH = 6.8 Hz, 3JHH = 4.3 Hz, H-7a), 4.18 (m, 3H, H-1’ and H-7A,B), 4.42 (dd, 1H, 3JHH = 5.4 
Hz, 3JHH = 3.8 Hz, H-1). 13C-NMR (100 MHz, CDCl3) δ [ppm]: 14.2 (CH3), 22.7 – 32.3 (CH2 and C(CH3)2), 
35.2 (CH2 and CHI), 61.9 (C-8), 70.0 (C-1), 76.8 (C-7), 95.1 (C(CH3)2), 156.3 (C-5). FAB-MS: m/z (%) = 
480.2 (41%, [M+H]+) 
 
 
(7S,8S,8aS)-Dihydro-8-iodo-3,3-dimethyl-7-tridecyl-oxazolo[3,4-c][1,3]oxazin-5(1H,3H,7H)-
one(4a) 
O N
1
2
3
O
O
I
C13H27
4 5
6
78
8a
 
 
Compound 4a was obtained as by-product in the synthesis of 4b. Yield: 128 mg (267 µmol) = 10%, yellow 
solid, C21H38INO3, M = 479.43 g/mol, Rf (cyclohexane/ethylacetate, 9:1 (v/v)) = 0.49.  
1H-NMR (400 MHz, CDCl3) δ [ppm]: 0.86 (t, 3H, 3JHH = 7.0 Hz, CH3), 1.24 (m, 20H, CH2), 1.35 (m, 1H, CH2), 
1.56 (s, 3H, C(CH3)2), 1.59 (s, 3H, C(CH3)2), 1.63 (m, 1H, CH2), 2.08 (m, 2H, CH2), 3.53 (dd, 1H, 2JHH = 3JHH 
= 9.3 Hz, 3JHH = 9.3 Hz, H-1A), 3.95 (dd, 1H, 3JHH = 11.3 Hz, 3JHH = 4.5 Hz, H-8), 4.02 (ddd, 1H, 3JHH = 11.3 
Hz, 3JHH = 9.3 Hz, 3JHH = 5.2 Hz, H-8a), 4.26 (dd, 1H, 3JHH = 8.6 Hz, 3JHH = 5.2 Hz, H-1B), 4.36 (ddd, 1H, 
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3JHH = 10.6 Hz, 3JHH = 4.5 Hz, 3JHH = 2.1 Hz, H-7). 13C-NMR (100 MHz, CDCl3) δ [ppm]: 13.1 (CH3), 20.6 
(CH2), 21.7 - 32.5 (CH2 and C(CH3)2), 60.5 (C-8a), 69.3 (C-4), 76.3 (C-7), 81.4 (C-3), 96.1 (C(CH3)2), 147.8 
(C-5). ESI-MS (positive mode): m/z (%) = 480.2 (100%, [M+H]+). 
 
 
(4S,5R)-4-Hydroxymethyl-5-[1’(R)-iodotetradecyl]-1,3-oxazolidin-2-one (5b) 
 
HN
O
HO O
I
C13H27
1
2
3
4 5
1'
1''
 
 
Carbamate 4b (144 mg, 300 µmol) was dissolved in THF (3 ml). Hydrochloric acid (1M solution, 3 mL) was 
added and the reaction mixture was stirred for 16 h. The reaction mixture was diluted with water (10 mL), 
extracted three times with dichloromethane (20 mL), and the combined organic phases were dried with 
Na2SO4. After removal of the solvent under pressure, the residue was purified by silica gel chromatography 
(chloroform/methanol, 10:1 (v/v)). Yield : 128 mg (291.5 µmol) = 97%, white solid, C18H34INO3, M = 439.37 
g/mol, Rf (chloroform/methanol, 10:1 (v/v)). = 0.49. 
1H-NMR (400 MHz, CD3OD/CDCl3 = 6:1) δ [ppm]: 0.74 (t, 3H, 3JHH = 7.0 Hz, CH3), 1.07 (d, 2H, 3JHH = 6.5 
Hz, CH2), 1.15 (m, 20H, CH2), 1.22 (m, 1H, CH2), 1.45 (m, 1H, CH2), 3.51 (dd, 1H, 3JHH = 5.1 Hz, 2JHH = 
11.5 Hz, H-1’’A), 3.63 (dd, 1H, 3JHH = 3.5 Hz, 2JHH = 11.5 Hz, H-1’’B), 3.69 (ddd, 1H, 3JHH = 5.2 Hz, 3JHH = 3.5 
Hz, 3JHH = 3.5 Hz, H-4), 4.06 (ddd, 1H, 3JHH = 10.5 Hz, 3JHH = 4.3 Hz, 3JHH = 3.0 Hz, H-1’), 4.21 (dd, 1H, 3JHH 
= 4.1 Hz, 3JHH = 3.0 Hz, H-5). 13C-NMR (100 MHz, CD3OD/CDCl3 = 6:1) δ [ppm]: 14.1 (CH3), 18.8 – 35.4 
(CH2), 39.0 (CHI), 63.2 (C-4), 68.2 (C-1), 80.5 (C-5), 159.9 (C-2). IR: v  [cm-1] = 1698.4 (C=O). ESI-MS 
(positive mode): m/z (%) = 440.2 (87%, [M+H]+), 268 (100%, [C6H7INO3]+), 238 (82%, [C5H5INO2]+). 
 
 
(4S,5S,6S)-4-Hydroxymethyl-5-iodo-6-tridecyl-1,3-oxazinan-2-one (5a) 
 
1
2
3
4
5
HN O
HO
O
I
C13H27
6
1'
 
 
Carbamate 4b (128 mg, 267 µmol) was dissolved in THF (3 mL) and hydrochloric acid (1M solution, 3 mL), 
and the mixture was stirred for 12 h at 60°C. The reaction was diluted with water (10 mL), extracted three 
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times with dichloromethane (20 mL) and the combined organic phases were dried with Na2SO4. After 
removal of the solvent under pressure, the residue was purified by silica gel chromatography 
(chloroform/methanol, 10:1 (v/v)). Yield: 30 mg (68 µmol) = 26%, white solid, C18H34INO3, M = 439.37 g/mol, 
Rf (chloroform/methanol, 10:1 (v/v)) = 0.49. 
1H-NMR (400 MHz, CDCl3) δ [ppm]: 0.86 (t, 3H, 3JHH = 7.1 Hz, CH3), 1.24 (m, 20H, CH2), 1.33 (m, 1H, CH2), 
1.57 (m, 1H, CH2), 1.72 (m, 1H, CH2), 1.81 (m, 1H, CH2), 3.64 (m, 1H, H-1’A), 3.80 (m, 2H, H-6, H-1’B), 4.10 
(m, 1H, H-4), 4.34 (m, 1H, H-5), 6.60 (br, 1H, OH), 9.10 (m, 1H, NH). 13C-NMR (100 MHz, CDCl3) δ [ppm]: 
14.2 (CH3), 22.7 (CH2), 28.7 (CH2), 29.4 (CH2), 29.6 (CH2), 29.7 (CH2), 32.0 (CH2), 34.0 (CH2), 58.1 (C-4), 
64.3 (C-1’), 80.3 (C-6), 154.7 (C-2). IR: v  [cm-1] = 1634.0 (C=O). ESI-MS (positive mode): m/z (%) = 
462.10 (100%, [M+Na]+), 901.24 (10%, [2M+Na]+). 
 
 
(4S,5S,6S)-5-Iodo-2-oxo-6-tridecyl-1,3-oxazinane-4-carbaldehyde (8a) 
 
HN O
O
I
C13H27
O
1
2
3
4
5
6
H  
 
A solution of pyridinium chlorochromate (17 mg, 78.9 µmol) and oxazinanone 5a (15 mg, 34.1 µmol) in 
dichloromethane (2 mL) was stirred for 12h at rt. The product was extracted with ether and purified by 
column chromatography with silica gel (hexane/ethyl acetate, 2:1 (v/v)). Yield: 13 mg (29.7 µmol) = 87 %, 
colorless solid, C18H32INO3, M = 437.36 g/mol, Rf (hexane/ethyl acetate, 2:1(v/v)) = 0.42.  
1H-NMR (400 MHz, CDCl3) δ [ppm]: 0.86 (t, 3H, 3JHH = 7.0 Hz), 1.24 (m, 22H, CH2), 1.82 (m, 2H, CH2), 5.18 
(ddd, 1H, 3JHH = 6.6 Hz, 3JHH = 6.1 Hz, 3JHH = 3.3 Hz, H-6), 5.88 (dd, 1H, 3JHH = 3.3 Hz, 3JHH = 1.4 Hz, H-5), 
6.96 (dd, 1H, 3JHH = 3.3 Hz, 3JHH = 1.3 Hz, H-4), 9.27 (s, 1H, CHO). 13C-NMR (100 MHz, CDCl3) selected 
peaks δ [ppm]: 14.15 (CH3), 22.7, 29.7, 76.7 (C-6). ESI-MS (positive mode): m/z (%) = 438.18 (8%, [M+H]+). 
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7.3. Synthesis of bromine-containing heterocycles 7.2a and 7.2b 
 
(1R,7aS)-Dihydro-1-((1’R)-bromotetradecyl)-5,5-dimethyl-1H-oxazolo[3,4-c]oxazol-3(5H)-one 
(7.1b) 
O N
O
O
C13H27Br
7
1
2
3
4
5
6
7a
1'
 
 
To a solution of Z-alkene 3a (512.2 µmol, 217 mg) in CH2Cl2 (1 mL) was added N-bromosuccinimide (NBS, 
1.21 mmol, 215 mg) at room temperature. The mixture was stirred at the same temperature for 3d. The 
reaction was quenched with aqueous sodium thiosulfate (10% solution) and was extracted three times with 
CH2Cl2 (50 mL). The extracts were washed with NaHCO3 (10% aqueous solution, 100 mL), dried over 
Na2SO4, and evaporated to dryness under reduced pressure. The residue was purified by column 
chromatography on silica gel (cyclohexane/ethyl acetate, 4:1 (v/v)). Yield: 46 mg (106.7 µmol) = 21%, 
yellow solid, C21H38BrNO3, M = 431.20 g/mol, Rf (cyclohexane/ethyl acetate, 5:1 (v/v)) = 0.46.  
1H-NMR (400 MHz, CDCl3) δ [ppm]: 0.86 (t, 3H, 3JHH = 6.8 Hz, CH3), 1.24 (s, 22H, CH2), 1.43 (s, 3H, 
C(CH3)2), 1.70 (s, 3H, C(CH3)2), 1.72 (m, 1H, CH2), 1.90 (m, 1H, CH2), 3.67 (dd, 3JHH = 2JHH = 8.1 Hz, H-7A), 
4.10 (dt, 1H, 3JHH = 10.8 Hz, 3JHH = 3.7 Hz, H-1’), 4.14 (dd, 1H, 2JHH = 8.4 Hz, 3JHH = 6.8 Hz, H-7B), 4.25 
(ddd, 1H, 3JHH = 6.5 Hz, 3JHH = 7.8 Hz, 3JHH = 5.4 Hz, H-7a), 4.47 (dd, 1H, 3JHH = 5.3 Hz, 3JHH = 3.9 Hz, H-1).  
13C-NMR (100 MHz, CDCl3) δ [ppm]: 14.1 (CH3), 22.7 – 32.0 (CH2 and C(CH3)2), 43.1(C-1’), 61.0 (C-7a), 
68.8 (C-7), 79.1 (C-1), 95.1 (C-5), 156.1 (C-3). ESI-MS (positive scan): m/z (%) = 432.27 and 434.23 (20%, 
[M+H]+). 
 
 
(4S,5R)-4-Hydroxymethyl-5-[1’(R)-bromotetradecyl]-1,3-oxazolidin-2-one (7.2b) 
 
HN
O
HO O
Br
C13H27
1
2
3
4 5
1'
1''
 
 
Compound 7.1b (40 mg, 92.8 µmol) was dissolved in THF (2 mL). Hydrochloric acid (1M solution, 2 mL) 
was added and the reaction mixture was stirred for 16 h at rt. The reaction was diluted with water (10 mL), 
extracted three times with dichloromethane (20 mL), and the combined organic phases were dried with 
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Na2SO4. After removal of the solvent under pressure, the residue was purified by silica gel chromatography 
(chloroform/methanol, 10:1 (v/v)). Yield: 23 mg (58.6 µmol) = 63%, white solid, C18H34BrNO3, M = 392.37 
g/mol, Rf (chloroform/methanol, 10:1 (v/v)) = 0.49  
1H-NMR (400 MHz, CD3OD/CDCl3 = 10:1) δ [ppm]: 0.70 (t, 3H, 3JHH = 7.1 Hz, CH3), 1.09 (m, 20H, CH2), 
1.15 (m, 1H, CH2), 1.43 (m, 1H, CH2) 1.52 (m, 2H, CH2), 3.79 (dd, 1H, 3JHH = 4.5 Hz, 2JHH = 11.5 Hz, H-1’’A), 
3.83 (dd, 1H, 3JHH = 4.7 Hz, 2JHH = 11.5 Hz, H-1’’B), 4.02 (ddd, 1H, 3JHH = 4.7 Hz, 3JHH = 4.7 Hz, 3JHH = 4.5 
Hz, H-4), 4.34 (ddd, 1H, 3JHH = 7.8 Hz, 3JHH = 6.5 Hz, 3JHH = 2.7 Hz, H-1’), 4.74 (dd, 1H, 3JHH = 4.6 Hz, 3JHH 
= 2.7 Hz, H-5). 13C-NMR (100 MHz, CD3OD/CDCl3 = 10:1) δ [ppm]: 14.3 (CH3), 23.8 – 33.2 (CH2), 43.3 (C-
4), 64.3 (C-1’), 69.6 (C-1’’), 79.6 (C-5), 159.1 (C-2). ESI-MS (positive mode): m/z (%) = 392.2 and 394.2 
(20%, [M+H]+),  
 
 
(4S,5S,6S)-4-Hydroxymethyl-5-bromo-6-tridecyl-1,3-oxazinan-2-one (7a) 
 
1
2
3
4
5
HN O
HO
O
Br
C13H27
6
1'
 
 
The oxazinanone 7a was obtained from Z-alkene 3a over 2 steps. Yield: 10 mg (25.5 µmol) = 5% over two 
steps, white solid, C18H34BrNO3, M = 392.37 g/mol, Rf (chloroform/methanol, 10:1 (v/v)) = 0.49.  
1H-NMR (400 MHz, CDCl3/CD3OD = 10:1) δ [ppm]: 0.72 (t, 3H, 3JHH = 7.0 Hz, CH3), 1.11 (s, 22H, CH2), 1.60 
(m, 1H, CH2), 1.72 (m, 1H, CH2), 3.20 (dt, 3JHH = 3.1 Hz, 3JHH = 1.6 Hz, H-6), 3.43 (dd, 1H, 2JHH = 11.5 Hz, 
3JHH = 5.1 Hz, H-1’A), 3.51 (dd, 1H, 2JHH = 11.5 Hz, 3JHH = 4.2 Hz, H-1’B), 3.58 (m, 1H, H-4), 4.08 (dd, 1H, 
3JHH = 4.6 Hz, 3JHH = 3.1 Hz, H-5).  
 
 
 
7.4. Synthesis of alkyne oxazinanones 10.2a-c and 11 
 
3-Decyne-1-methanesulfonate 
 
OSH3C
O
O
1
2
3 4 C5H11
5
 
 
3-Decyne-1-ol (2.9 mL, 16.49 mmol) was dissolved in pyridine (70 mL) and cooled to -10°C. 
Methanesulfonyl chloride (1.5 mL, 19.4 mmol) was added dropwise over a period of 10 min, and solution 
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was stirred for 1h at –10°C, and for 3h at rt. The solvent was removed under reduced pressure and the 
residue was purified with silica gel by column chromatography (toluene/ethyl acetate, 17:3 (v/v)). Yield: 3.29 
g (14.17 mmol) = 86%, colorless oil, C11H20O3S, M = 232.34 g/mol, Rf (toluene/ethyl acetate, 17:3 (v/v)) = 
0.54.  
1H-NMR (400 MHz, CD3OD) δ [ppm]: 0.82 (t, 3H, 3JHH = 7.0 Hz), 1.17-1.33 (m, 6H, CH2), 1.40 (dd, 2H, 3JHH 
= 7.7 Hz, 3JHH = 7.4 Hz, 6-CH2), 2.06 (dt, 1H, 2JHH = 7.1 Hz, 3JHH = 2.4 Hz, 5-HA), 2.08 (dt, 1H, 2JHH = 7.0 Hz, 
3JHH = 2.4 Hz, 5-HB), 2.54 (dt, 1H, 2JHH = 7.0 Hz, 3JHH = 2.4 Hz, 2-HA), 2.56 (dt, 1H, 2JHH = 6.9 Hz, 3JHH = 2.4 
Hz, 2-HB), 2.97 (s, 3H, CH3), 4.19 (t, 2H, 1-HA,B). 13C-NMR (100 MHz, CD3OD) δ [ppm]: 14.1 (10-CH3), 18.7 
(5-CH2), 20.1 (2-CH2), 22.6 (9-CH2), 28.6 and 28.8 (C-6 and C-7), 37.6 (CH3), 68.2 (1-CH2), 74.2 (4-C), 83.2 
(3-C). FAB-MS: m/z (%) = 233.1 ([M+H]+, 100%), 464.2 ([2M+H)]+, 4%), Elemental analysis:  [C11H20O3S] 
calc.: C 56.86, H 8.68; found: C 55.93, H 8.23. 
 
 
1-Iodo-3-decyne 
I
1
2
3 4 C5H11
5
 
 
Method A: To a solution of sodiumiodide (12.41 g, 82 mmol) in acetone (230 mL), 3-Decin-1-
methansulfonate (3.84 g, 16.54 mmol) was added and stirred for 2h at 60°C, and for 12h at rt. The reaction 
was diluted with water (200 mL), extracted with ethyl acetate (3x 100 mL) and the combined organic phases 
were dried with Na2SO4. After removal of the solvent under reduced pressure, the residue was purified by 
silica gel chromatography (toluene/ethyl acetate, 85:15 (v/v)). Method B: 3-Decin-1-ol (2.28 ml, 12.96 mmol) 
was suspended in THF (60 ml), cooled to –70°C, and methyltriphenoxyphosphonium iodide (5.9 g, 13.05 
mmol) was added. After 30 min of stirring, the reaction mixture was allowed to warm to rt and stirred for 
another 4 h. Then, methanol (12 ml) was added and the solvent was removed under reduced pressure. The 
residue was purified by silica gel chromatography (toluene/ethyl acetate, 85:15 (v/v)). Yield: Method A: 4.04 
g (15.3 mmol) = 93%, Method B: 3.14 g (11.89 mmol) = 92 %, colorless oil, C10H17I, M = 264.04 g/mol, Rf 
(cyclohexane) = 0.51. 
1H-NMR (400 MHz, CD3OD) δ [ppm]: 0.82 (t, 3H, 3JHH = 6.9 Hz, CH3), 1.23 (m, 6H, CH2), 1.32 (m, 2H, CH2), 
1.40 (m, 2H, CH2), 2.05 (dt, 1H, 2JHH = 6.9 Hz, 3JHH = 2.3 Hz, 5-HA), 2.07 (dt, 1H, 2JHH = 6.8 Hz, 3JHH = 2.4 
Hz, 5-HB), 2.64 (dt, 1H, 2JHH = 7.5 Hz, 3JHH = 2.3 Hz, 2-HA), 2.67 (dt, 1H, 2JHH = 7.4 Hz, 3JHH = 2.3 Hz, 2-HB), 
3.13 (t, 2H, 3JHH = 7.4 Hz, 1-HA,B). 13C-NMR (100 MHz, CD3OD) δ [ppm]: 2.7 (C-2), 14.2 (C-10), 18.8 (C-5), 
22.7 (C-9), 24.3 (C-1), 28.6 and 28.9 (C-6 und C-7), 31.4 (C-8), 78.9 (C-4), 82.5 (C-3). ESI-MS (positive 
mode): m/z (%) = 265.06 ([M+H]+). IR: v  [cm-1] = 2926.2 ν(-CH2-), 2250 ν(-C≡C), 1465.2 δ(-CH2-), 1377.7 
δ(-CH3). Elemental analysis:  [C10H17I] calc.: C 45.47, H 6.49; found.: C 45.06, H 6.62. 
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3-Decynyl-1-triphenylphosphonium iodide 
 
(CH2)5CH3
Ph3PI  
 
In toluene (160 mL), 1-Iodo-3-Decyne (16.17 g, 61.23 mmol) and triphenylphosphine (16.04 g, 61.23 mmol) 
were dissolved and stirred for 12h at 110°C. The solvent was decanted, and the product was washed with 
ether. Yield: 9.92 g (18.28 mmol) = 30%, colorless solid, C28H32IP, M = 526.43 g/mol.  
1H-NMR (400 MHz, CD3OD) δ [ppm]: 0.85 (t, 3H, CH3), 1.22 (m, 8H, CH2), 1.85 (m, 2H, CH2), 2.72 (tt, 1H, 
3JHH = 6.9 Hz, 4JHH = 2.4 Hz, 2-HA), 2.76 (tt, 1H, 3JHH = 6.9 Hz, 4JHH = 2.4 Hz, 2-HB), 4.12 (dt, 2H, 2JPH = 12.3 
Hz, 3JHH = 6.9 Hz, H-1), 7.79 (dd, 6H, 3JHH = 7.7 Hz, 4JPH = 3.4 Hz, Harom), 7.93 (dm, 3H, 3JHH = 7.5 Hz,  
Harom), 8.03 (ddd, 6H, 3JPH = 12.8 Hz, 3JHH = 7.3 Hz, 4JHH = 0.9 Hz, Harom). 13C-NMR (100 MHz, CD3OD) δ 
[ppm]: 13.7 (C-1), 14.4 (CH3), 19.0, 21.5, 23.0, 23.2 and 32.1(CH2), 77.5 and 85.3 (C-3 and C-4), 119.1 and 
126.1 (qCarom), 131.0 – 135.9 (Carom). IR:  v  [cm-1] = 3100 ν(CHarom), 2922.5 ν(-CH2-), 2120 ν(-C≡C-), 
1435.8 δ(-CH2-). ESI-MS (positive mode): m/z (%) = 399.2 (100%, [C28H32P]+), 527.1 (2%, [M+H]+). 
 
 
(R)-tert-Butyl 2,2-dimethyl-4-(undec-1-en-4-ynyl)oxazolidine-3-carboxylate (9) 
 
1
2
3
45
O N
CH2C C(CH2)5CH3
Boc
 
 
The alkene (9) was synthesized according to the synthesis of alkene 3a (Campbell et al., 1998): Weinreb 
amide 1a (3.52 g, 12.8 mmol), Lithiumaluminium hydride (1M solution in THF, 12.8 ml, 12.8 mmol), Dec-3-
ynyltriphenyl-phosphonium iodide (6.07 g, 11.18 mmol), and n-Butyllithium (1.6 M solution in hexane, 6.4 
mL, 10.2 mmol). The product was purified by chromatography on silica gel (cyclohexane/ethyl acetate, 10:1 
(v/v)).  Yield: 1.99 g (5.69 mmol) = 44 % over 2 steps, yellow oil, C21H35NO3, M = 349.51 g/mol,  
Rf (chloroform/methanol, 20:1 (v/v)) = 0.33 (E-alkene), 0.29 (Z-alkene).  
1H-NMR (400 MHz, CDCl3) δ [ppm]: 0.82 (t, 3H, 3JHH = 7.0 Hz), 1.21 (m, 4H, CH2), 1.29 (m, 5H, CH2 and 
C(CH3)2), 1.44 (s, 9H, C(CH3)3), 1.49 (s, 3H, C(CH3)2), 1.52 (m, 2H, CH2), 2.05 (dt, 2H, 3JHH = 7.0 Hz, 3JHH = 
2.1 Hz, CH2), 2.90 (m, 2H, CH2), 3.61 (dd, 1H, 2JHH = 8.6 Hz, 3JHH = 2.8 Hz, H-5A), 4.00 (dd, 1H, 2JHH = 8.6 
Hz, 3JHH = 6.4 Hz,   H-5B), 4.54 (m, 1H, H-4), 5.77 (dt, 1H, 3JHH = 15.6 Hz, 3JHH = 8.4 Hz, CH), 6.21 (dd, 1H, 
3JHH = 15.6 Hz, 3JHH = 2.1 Hz). 13C-NMR (100 MHz, CDCl3) δ [ppm]: 14.0 (CH3), 17.3 (CH2), 18.7 (CH2), 
22.5 (CH2), 26.9 (C(CH3)2), 28.4 (CH2), 28.5 (C(CH3)3), 28.9 (CH2), 31.3 (CH2), 54.3 (C-4), 68.6 (C-5), 85.3 
and 85.9 (C-2 and C(CH3)3), 127.4 (CH), 131.3 (CH), 151.9 (CO). IR: v  [cm-1] = 3445.4 ν(C(CH3)2), 2930.1 
ν(-CH2-), 2450 ν(-C≡C-), 1760.3 ν(C=O), 1465.2, 1371.9 δ(-CH3). FAB-MS: m/z (%) = 350.2 (18 %, [M+H]+), 
250.2 (50 %, [M+H-C5H9O2]+). 
        89
(7S,8S,8aS)-Dihydro-8-iodo-3,3-dimethyl-7-(non-2-inyl)oxazolo[3,4-c][1,3]oxazin-
5(1H,3H,7H)-one (10.1a) 
 
1
2
3
4 5
6
78
8a
O N
O
O
I
(CH2)5CH3
1'
 
 
The compound (10.1a) was obtained as by-product within the synthesis of 10.1b. Yield: 4 mg (9.5 µmol) = 
3%, white solid, C17H26INO3, M = 419.30 g/mol, Rf (cyclohexane/ethyl acetate = 5:1 (v/v)) = 0.31.  
1H-NMR (400 MHz, CD3Cl3) δ [ppm]: 0.82 (t, 3H, 3JHH = 7.0 Hz, CH3), 1.21-1.40 (m, 8H, CH2), 1.52 (s, 3H, 
C(CH3)2), 1.55 (s, 3H, C(CH3)2), 2.10 (m, 2H, CH2), 2.81 (dd, 1H, 2JHH = 17.5 Hz, 3JHH = 3.7 Hz, CH2),  2.87 
(dd, 1H, 2JHH = 17.5 Hz, 3JHH = 3.5 Hz, CH2), 3.56 (“t”, 1H, 3JHH = 2JHH  = 9.1 Hz, H-1A), 3.85 (“t”, 1H, 3JHH = 
10.7 Hz, H-8), 3.99 (ddd, 1H, 3JHH = 10.9 Hz, 3JHH = 9.4 Hz, 3JHH = 5.9 Hz, H-8a), 4.19 (dd, 1H, 2JHH = 9.0 
Hz, 3JHH = 5.7 Hz, H-1B), 4.39 (ddd, 1H, 3JHH = 10.5 Hz, 3JHH = 3.6 Hz, 3JHH = 3.5 Hz, H-7). 
13C-NMR (100 MHz, CD3OD) δ [ppm]: 14.1 (CH3), 18.8 (CH2), 19.7 (C-5), 22.6 (CH2), 23.8 (C(CH3)2), 24.3 
(CH2) 26.2 (C(CH3)2), 28.8 (CH2), 28.6 (CH2), 31.4 (CH2), 60.7 (C-8a), 70.3 (C-1), 72.4 (qC), 80.5 (C-4), 
84.6 (qC), 97.2 (C-3), 148.5 (C-5). FAB-MS: m/z (%) = 420.1 ([M+H]+, 64%). 
 
 
(1R,7aS)-Dihydro-1-(1’(R)-iododec-3-inyl)-dihydro-5,5-dimethyl-1H-oxazolo[3,4-c]oxazol-
3(5H)-one (10.1b) 
7
1
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6
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O
O
I
(CH2)5CH3
2'  
 
 
The compound was prepared according to synthesis of 4b. Alkene 9 (E/Z-isomeres, 980.2 mg, 2.80 mmol) 
was dissolved in dichloromethane (10 ml) and N-iodosuccinimide (1.26 g, 5.6 mmol) was added. The 
reaction was stirred for 48 h at rt. The residue was purified by column chromatography with silica gel 
(hexane/ethyl acetate, 10:1 (v/v)). Yield: 370.1 mg (882 µmol) = 32 %, white solid, C17H26INO3, M = 419.30 
g/mol, Rf (hexane/ethyl acetate = 5:1 (v/v)) = 0.31.  
1H-NMR (400 MHz, CD3Cl3) δ [ppm]: 0.82 (t, 3H, 3JHH = 7.2 Hz, CH3), 1.26 (m, 4H, CH2), 1.35 (m, 2H, CH2), 
1.42 (s, 3H, C(CH3)2), 1.47 (m, 2H, CH2), 1.69 (s, 3H, C(CH3)2), 2.07 (tt, 2H, 3JHH = 7.0 Hz, 5JHH = 2.4 Hz, 
CH2), 2.79 (ddt, 1H, 2JHH = 17.2 Hz, 3JHH = 7.1 Hz, 5JHH = 2.3 Hz, H-2’A), 2.88 (ddt, 1H, 2JHH = 17.2 Hz, 3JHH 
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= 7.2 Hz, 5JHH = 2.4 Hz, H.2’B), 3.64 (dd, 1H, 2JHH = 3JHH = 7.2 Hz, H-7A), 4.13 (m, 3H, H-1’ and H-7B and H-
7a), 4.29 (dd, 1H, 3JHH = 5.2 Hz, 3JHH = 3.7 Hz, H-1). 13C-NMR (100 MHz, CD3OD) δ [ppm]: 14.2 (CH3), 18.9 
(CH2), 22.7 (CH2), 23.5 (C-1’), 26.2 (CH2), 27.6 (C(CH3)2), 28.7 (CH2), 28.8 (CH2), 31.0 (C(CH3)2), 31.5 
(CH2), 63.3 (C-7a), 68.7  (C-7), 76.8 and 79.0 (C-3’ and C-4’), 84.3 (C-1), 95.2 (C-5), 156.1 (C-3). IR: v  
[cm-1] = 3378.0 ν(C(CH3)2), 2930.0 ν(-CH2-), 2250 ν(-C≡C-), 1694.0 ν(C=O), 1455.3 δ(-CH2-), 1384.0 δ(-
CH3). FAB-MS: m/z (%) = 420.1 (64 %, [M+H]+).  
 
 
(4S,5R)-4-Hydroxymethyl-5-(1’(R)-iododec-3-inyl)oxazolidin-2-one (10.2b) 
 
1'
1
23
4
5
HO HN
O
O
I
(CH2)5CH3
1''
 
 
The compound 10.2b was obtained according to the synthesis of oxazolidinone 5b. Carbamate 10.1b             
(144 mg, 300 µmol) was dissolved in THF (3 mL), and hydrochloric acid (1M solution, 3 mL) was added and 
stirred for 16 h at rt. The reaction was diluted with water (10 mL), extracted three times with 
dichloromethane (20 mL) and the combined organic phases were dried with Na2SO4. After removal of the 
solvent under pressure, the residue was purified by silica gel chromatography (chloroform/methanol, 10:1 
(v/v)). Yield: 81 mg (213.6 µmol) = 71%, white solid, C14H22INO3, M = 379.23 g/mol, Rf 
(chloroform/methanol = 10:1 (v/v)) = 0.19.  
1H-NMR (400 MHz, CD3OD/CDCl3 = 1:1 (v/v)) δ [ppm]: 0.82 (t, 3H, 3JHH = 7.0 Hz, CH3), 1.23 (m, 6H, CH2), 
1.42 (m, 2H, CH2), 2.15 (t, 2H, 3JHH = 7.0 Hz, CH2), 2.79 (ddt, 1H, 2JHH = 17.2 Hz, 3JHH = 7.3 Hz, 5JHH = 2.3 
Hz, H-2’A), 2.87 (ddt, 1H, 2JHH = 17.2 Hz, 3JHH = 7.5 Hz, 5JHH = 2.3 Hz, H-2’B), 3.57 (dd, 1H, 2JHH = 12.1 Hz, 
3JHH = 5.7 Hz, H-1’A), 3.72 (m, 2H, H-1’B and H-4), 4.08 (td, 1H, 3JHH = 7.3 Hz, 3JHH = 3.0 Hz, H-1’), 4.30 (dd, 
1H, 3JHH = 4.4 Hz, 3JHH = 3.0 Hz). 13C-NMR (100 MHz, CD3OD/CDCl3 = 1:1 (v/v)) δ [ppm]: 13.1 (CH3), 18.0 
(CH2), 22.2 (CH2), 28.4 (CH2), 31.4 (CH2), 34.2 (CH2), 36.2 (CH2), 48.3 (CH2), 59.8 (CH2), 50.9 (CH2), 62.6 
(CH2), 77.0 (CH2), 79.0 (qC), 79.4 (qC), 83.0 (C-5), 159.5 (C-2). FAB-MS: m/z (%) = 380.1 (100%, [M+H]+). 
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(7R,8S,8aS)-Dihydro-8-iodo-3,3-dimethyl-7-(non-2-inyl)oxazolo[3,4-c][1,3]oxazin-
5(1H,3H,7H)-one (10.1c) 
1
2
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4 5
6
78
8a
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(CH2)5CH3
1'
 
 
The compound (10.1c) was obtained as major product within the synthesis of 10.1b. Yield: 697.6 mg             
(1.84 mmol) = 66%, white solid, C17H26INO3, M = 419.30 g/mol, Rf (chloroform/methanol = 10:1 (v/v)) = 
0.81. 
1H-NMR (400 MHz, CD3Cl3) δ [ppm]: = 0.70 (t, 3H, 3JHH = 7.3 Hz, CH3), 1.07 (m, 6H, CH2), 1.24 (m, 2H, 
CH2), 1.42 (s, 3H, C(CH3)2), 1.46 (s, 3H, C(CH3)2), 1.85 (tt, 2H, 3JHH = 7.0 Hz, 5JHH = 2.4 Hz, CH2), 2.34 (ddt, 
1H, 2JHH = 17.2 Hz, 3JHH = 6.4 Hz, 5JHH = 2.3 Hz, CH2), 2.62 (ddt, 1H, 2JHH = 17.2 Hz, 3JHH = 4.7 Hz, 5JHH = 
2.3 Hz, CH2), 2.92 (dd, 1H, 3JHH = 9.6 Hz, 2JHH = 8.5 Hz, H-1A), 3.04 (dd, 1H, 3JHH = 11.1 Hz, 3JHH = 5.1 Hz, 
H-8), 3.81 (ddd, 1H, 2JHH = 8.4 Hz, 3JHH = 5.4 Hz, H-1B), 3.94 (ddd, 1H, 3JHH = 11.1 Hz, 3JHH = 9.7 Hz, 3JHH = 
5.4 Hz, H-8a), 4.00 (ddd, 1H, 3JHH = 6.4 Hz, 3JHH = 4.7 Hz, 3JHH = 4.7 Hz, H-7). 13C-NMR (100 MHz, CD3OD) 
δ [ppm]: 14.6 (CH3), 19.5 (CH2), 19.9 (C-8), 23.3 (CH2), 24.4 (C(CH3)2), 24.5 (CH2), 27.0 (C(CH3)2), 29.3 
(CH2), 29.4 (CH2), 32.0 (CH2), 57.5 (C-8a), 71.0 (C-2’), 75.4 (C-3’), 78.0 (C-1), 84.5 (C-7), 97.4 (C-3), 147.9 
(C-5). ESI-MS (positive mode): m/z (%) = 420.07 (100 %, [M+H]+), 839.20 (31 %, [2M+H]+), 861.20 (6 %, 
[2M+Na]+) 
 
 
(4S,5S,6R)-4-Hydroxymethyl-5-iodo-6-(non-2-inyl)-1,3-oxazinan-2-one (10.2c) 
 
HO HN
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4
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1'
1''
 
 
The oxazinanone 10.2c was synthesized according to the synthesis of oxazinanone 5a. Oxazinanone 10.1c 
(226.4 mg, 597 µmol) and THF/1M HCl (1:1 (v/v), 5 mL). Yield: 60 mg (158 µmol) = 27%, white solid, 
C14H22INO3, M = 379.23 g/mol, Rf (chloroform/methanol = 10:1 (v/v)) = 0.23.  
1H-NMR (400 MHz, CD3OD/CDCl3 = 1:1 (v/v)) δ [ppm]: 0.82 (t, 3H, 3JHH = 7.0 Hz, CH3), 2.08 (tt, 2H, 3JHH = 
7.0 Hz, 3JHH = 2.3 Hz), 2.79 (ddt, 1H, 2JHH = 17.2 Hz, 3JHH = 7.3 Hz, 3JHH = 2.3 Hz, CH2), 2.87 (ddt, 1H, 2JHH 
= 17.1 Hz, 3JHH = 7.5 Hz, 3JHH = 2.3 Hz, CH2), 3.58 (dd, 1H, 3JHH = 12.6 Hz, 3JHH = 5.7 Hz, H-1’’A), 3.77 (m, 
2H, H-1’’B and H-4), 4.08 (td, 1H, 3JHH = 7.3 Hz, 3JHH = 3.0 Hz, H-6), 4.30 (dd, 1H, 3JHH = 4.4 Hz, 3JHH = 3.0 
Hz, H-5). 13C-NMR (100 MHz, CD3OD/CDCl3 = 1:1 (v/v)) δ [ppm]: 14.1 (CH3), 18.8 (CH2), 22.6 (CH2), 27.1 
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(CH2), 28.6 (CH2), 28.7 (CH2), 31.4 (CH2), 33.0 (C-5), 59.2 (C-4), 63.6 (CH2), 78.9 (C-6), 84.1 (qC), 159.3 
(C-2). ESI-MS (positive mode): m/z (%) = 380.05 (49 %, [M+H]+), 402.04 (20 %, [M+Na]+). 
 
 
(4S,5S,6R)-4-Hydroxymethyl-5-iodo-6-(non-2-enyl)-1,3-oxazinan-2-one (11) 
 
HO HN
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Oxazinanone 10.2c (53 mg, 139.7 µmol) was dissolved in dichloromethane (1 mL), and trifluoroacetic acid 
(25 µL, 194 µmol) and triethylsilane (89 µL, 558.8 µmol) were added. The mixture was stirred for 16 h at 
room temperature. The reaction was diluted with ethyl acetate (100 mL), washed with water (2x 50 mL), 
sodium hydrogencarbonate (50 mL), and brine (50 mL), and the organic layer was dried with Na2SO4. Then 
the solvent was removed under reduced pressure and the residue was purified by column chromatography 
on silica gel (chloroform/methanol, 10:1 (v/v)). The product (11) could only be isolated in a mixture with 
alkyne 10.2c. White solid, C14H24INO3, M = 381.25 g/mol Rf (chloroform/methanol = 10:1 (v/v)) = 0.12. Yield: 
17 mg (mixture of 10.2c and 11 ((1:10)). 
1H-NMR (400 MHz, CD3OD) δ [ppm]: = 0.81 (t, 3H, 3JHH = 7.1 Hz, CH3), 1.10 (m, 8H, CH2), 1.96 (m, 2H, 
CH2), 2.66 (dd, 2H, 3JHH = 7.0 Hz, JHH = 6.7 Hz, H-1’A,B), 3.62 (dd, 1H, 2JHH = 12.5 Hz, 3JHH = 5.5 Hz, H-
1’’A), 3.78 (m, 2H, H-1’’B and H-4), 4.02 (ddd, 1H, 3JHH = 8.2 Hz, 3JHH = 6.7 Hz, 3JHH = 2.8 Hz, H-6), 4.22 (dd, 
1H, 3JHH = 4.6 Hz, 3JHH = 2.8 Hz, H-5), 5.26 (ddt, 1H, 3JHH = 18.0 Hz, 3JHH = 7.2 Hz, 4JHH = 1.6 Hz, CHalkene), 
5.52 (ddt, 1H, 3JHH = 18.0 Hz, 3JHH = 7.4 Hz, 4JHH = 1.5 Hz, CHalkene). ESI-MS (positive mode): m/z (%) = 
404.7 (93%, [M+Na]+). 
3
 
 
 
7.5. Synthesis of ω-azido-oxazinanone (12) 
 
(R)-tert-Butyl 2,2-dimethyl-4-ethenyloxazolidine-3-carboxylate (14) 
 
1O
2
3
4
N
5
Boc
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The alkene was synthesized according to literature (Campbell et al., 1998). To a suspension of 
Methyltriphenylphosphonium bromide (7.47 g, 20.9 mmol) in dry tetrahydrofuran (150 mL), KHMDS 
(potassium bis(trimethylsilyl)amide, 0.5 M solution in toluene, 41.84 mL, 20.9 mmol) was added dropwise in 
argon atmosphere, and the mixture was stirred for 1 hour at rt. After cooling to –78°C, tert-Butyl 4(S)-formyl-
2,2-dimethyloxazolidin-3-carboxylate (1a, 2 g, 8.7 mmol) dissolved in dry THF (30 mL) was added dropwise 
over a 10 min period. The reaction mixture was stirred until the temperature reached rt and then for further 
12h. After addition of methanol (20 ml), the mixture was quenched with saturated aqueous ammonium 
chloride (100 mL) and extracted with ethyl acetate (3x 120 mL). The combined organic phases were 
washed with water and dried with Na2SO4. After evaporation of the solvent under reduced pressure, the 
residue was purified by chromatography on silica gel (cyclohexane/ethyl acetate, 20:1 (v/v)) to give alkene 
as colorless oil. Yield: 1.82 g (8.01 mmol) = 92%, colorless oil, C12H21NO3, M  = 227.3 g/mol, Rf 
(hexane/ethyl acetate, 7:1 (v/v)) = 0.38.  
1H-NMR (400 MHz, CDCl3) δ [ppm]: 1.43 (s, 9H, C(CH3)3), 1.50 (s, 3H, C(CH3)2), 1.59 (s, 3H, C(CH3)2), 3.68 
(dd, 1H, 2JHH = 8.8 Hz, 3JHH = 2.4 Hz, H-5A), 3.97 (dd, 1H, 2JHH = 8.8 Hz, 3JHH = 6.2 Hz, H-5B), 4.25 (m, 1H,  
H-4), 5.14 (m, 2H, H-2’), 5.80 (m, 1H, H-1´). 13C-NMR (100 MHz, CDCl3) δ [ppm]: 23.9 (C(CH3)2), 25.1 
(C(CH3)2), 28.6 (C(CH3)3), 59.9 (C-4), 68.4 (C-5), 80.4 (C(CH3)3), 93.9 (C-2), 116.0 (C-2’), 137.7 (C-1’), 
152.3 (CO). ESI-MS (positive mode): m/z (%) = 250.1 ([M+Na]+, 100%). 
 
(R)-tert-Butyl 4-((E)-11-hydroxy-undec-1-enyl)-2,2-dimethyloxazolidine-3-carboxylate (15) 
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Alkene 14 (282.3 mg, 1.26 mmol) was dissolved in dichloromethane (30 mL), and undec-10-enol (363.6 µL, 
2.52 mmol) and Grubbs second-generation catalyst (10 mg, 11.7 µmol) were added. The reaction mixture 
was refluxed for 4 hours, during which the color of the solution turned from red into brown. After evaporation 
of the solvent under reduced pressure, the residue was purified by chromatography on silica gel 
(cyclohexane/ethyl acetate, 8:1 (v/v)) to give alkene 15 as colorless oil. Yield: 279 mg (756 µmol) = 60%, 
colorless oil, C21H39NO4, M = 369.54 g/mol, Rf (hexane/ethyl acetate, 8:1 (v/v)) = 0.14. 
1H-NMR (400 MHz, CDCl3) δ [ppm]: 1.25 (m, 14H, CH2), 1.42 (s, 9H, C(CH3)3), 1.48 (s, 3H, C(CH3)2), 1.57 
(s, 3H, C(CH3)2), 2.00 (dt, 2H, 3JHH = 7.0 Hz, 3JHH = 7.1 Hz, CH2), 3.60 (t, 2H, 3JHH = 6.7 Hz, CH2), 3.69 (dd, 
1H, 2JHH = 8.8 Hz, 3JHH = 2.0 Hz, H-5A), 3.99 (dd, 1H, 2JHH = 8.8 Hz, 3JHH = 6.0 Hz, H-5B), 4.15 (m, 1H, OH), 
4.28 (m, 1H, H-4), 5.29 (dt, 1H, 3JHH = 15.3 Hz, 3JHH = 5.6 Hz, H-2’), 5.34 (dd, 1H, 3JHH = 15.1 Hz, 3JHH = 7.6 
Hz, H-1’). 
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13C-NMR (100 MHz, CDCl3) δ [ppm]: 22.3 (CH2), 25.9 (C(CH3)2), 27.6 (CH2), 28.7 (C(CH3)3), 29.3-33.0 
(CH2), 44.1 (CH2), 59.4 (CH2), 63.2 (C-4), 68.7 (C-5), 79.6 (C(CH3)3), 93.9 (C-2), 130.5 and 132.9 (C-1’ and 
C-2’), 152.2 (CO). ESI-MS (positive mode): m/z (%) = 370.29 ([M+H]+, 13%), 392.26 ([M+Na]+, 100%). 
 
 
(R)-tert-Butyl 4-((E)-11-azido-undec-1-enyl)-2,2-dimethyloxazolidine-3-carboxylate (16) 
 
1
2
3
45
O N
Boc
(CH2)9N3
1'
2'
 
 
Method A: Alcohol 15 (217 mg, 587 µmol) and pyridine (1 mL) were dissolved in dichloromethane (10 mL) 
and cooled to –20°C. Methanesulfonyl chloride (54 µL, 704.6 µmol) was added slowly and the reaction was 
stirred for 1h at 0°C and additional 4h at rt. After addition of NaHCO3-solution (10 ml), the methane 
sulfonate was extracted with dichloromethane (3x 50 mL) and dried with Na2SO4. After evaporation of the 
solvent under reduced pressure, the residue was dissolved in dimethylformamide (10 mL), and sodium 
azide (4.76 g, 73 mmol) was added. The reaction mixture was stirred for 12 hours, quenched with water 
(100 mL), and the product was extracted with ethylacetate (4x 50 mL). After evaporation of the solvent 
under reduced pressure, alkene 16 was purified by chromatography on silica gel (cyclohexane/ethyl 
acetate, 20:1 (v/v)).  
Method B: Alkene 14 (400 mg, 1.76 mmol) was dissolved in dichloromethane (50 mL), and 11-azido-undec-
1-ene (1.72 g, 8.81 mmol) and Grubbs second-generation catalyst (10 mg, 11.7 µmol) were added. The 
reaction mixture was refluxed for 12 hours. After evaporation of the solvent under reduced pressure, the 
residue was purified by chromatography on silica gel (cyclohexane/ethyl acetate, 20:1 (v/v)). Yield: Method 
A: 53 mg (134 µmol) = 23 % over 2 steps, Method B: 373 mg (945 µmol) = 54 %, colorless oil, C21H38N4O3, 
M = 394.55 g/mol, Rf (hexane/ethyl acetate, 5:1 (v/v)) = 0.75.  
1H-NMR (400 MHz, CDCl3) δ [ppm]: 1.26 (m, 14H, CH2), 1.42 (s, 9H, C(CH3)3), 1.48 (s, 3H, C(CH3)2), 1.57 
(s, 3H, C(CH3)2), 2.0 (dt, 2H, 3JHH = 6.9 Hz, 3JHH = 6.9 Hz, CH2), 3.23 (t, 2H, 3JHH = 6.9 Hz, CH2), 3.68 (dd, 
1H, 2JHH = 8.7 Hz, 3JHH = 2.1 Hz, H-5A), 3.99 (dd, 1H, 2JHH = 8.7 Hz, 3JHH = 6.0 Hz, H-5B), 4.28 (m, 1H, H-4), 
5.29 (dt, 1H, 3JHH = 15.4 Hz, 3JHH = 7.7 Hz, H-2’), 5.30 (dd, 1H, 3JHH = 15.4 Hz, 3JHH = 5.4 Hz, H-1’). 
13C-NMR (100 MHz, CDCl3) δ [ppm]: 22.3 (CH2), 26.9 (C(CH3)2), 27.6 (CH2), 28.6 (C(CH3)3), 29.0-32.3 
(CH2), 44.1 (CH2), 51.7 (CH2), 59.4 (C-4), 68.7 (C-5), 79.5 (C(CH3)3), 93.9 (C-2), 129.3 and 132.8 (C-1’ and 
C-2’), 152.2 (CO). ESI-MS (positive mode): m/z (%) = 417.3 ([M+Na]+, 100%).  
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11-Azido-undec-1-ene  
 
N3
 
 
10-Undecenol (2.95 mL, 14.65 mmol) and pyridine (15 mL) were dissolved in dichloromethane (50 mL) and 
cooled to –20°C. Methanesulfonyl chloride (2.74 mL, 17.6 mmol) was added slowly and the reaction was 
stirred for 1h at 0°C and for additional 8h at rt. After addition of NaHCO3-solution (30 ml), the methane 
sulfonate was extracted with dichloromethane (4x 100 mL) and dried with Na2SO4. After evaporation of the 
solvent under reduced pressure, the residue was dissolved in dimethylformamide (30 mL) and sodium azide 
(14.3 g, 220 mmol) was added. The reaction mixture was stirred for 12 hours, quenched with water (100 
mL) and the product was extracted with ethylacetate (4x 100 mL). After evaporation of the solvent under 
reduced pressure, the azide was purified by chromatography on silica gel (cyclohexane/ethyl acetate, 20:1 
(v/v)). Yield: 2.317 g (11.86 mmol) = 81 % over 2 steps, colorless oil, C11H21N3, M = 195.31 g/mol,  
Rf (hexane/ethyl acetate 20:1 (v/v)) = 0.58.  
1H-NMR (400 MHz, CDCl3) δ [ppm]: 1.20 (m, 12H, CH2), 1.59 (m, 2H, CH2), 2.04 (m, 2H, CH2), 3.24 (t, 2H, 
3JHH = 7.0 Hz, H-10), 4.92 (ddt, 1H, 3JHH = 10.2 Hz, 4JHH = 2.2 Hz, 2JHH = 1.8 Hz, H-1a), 4.99 (ddt, 1H, 3JHH = 
17.1 Hz, 2JHH = 3.7 Hz, 2JHH = 1.6 Hz, H-1b), 5.80 (ddt, 1H, 3JHH = 17.0 Hz, 3JHH = 10.3 Hz, 3JHH = 6.7 Hz, H-
2). 13C-NMR (100 MHz, CDCl3) δ [ppm]: 26.9-29.6 (CH2), 34.0 (C-3), 51.6 (C-11), 114.3 (C-1), 139.3 (C-2). 
EI-MS: m/z (%) = 194.1 ([M-H]+, 37%).  
 
 
(7S,8S,8aS)-7-(9-Azidononyl)-dihydro-8-iodo-3,3-dimethyloxazolo[3,4-c][1,3]oxazin 
(1H,3H,7H)-one (17) 
1
2
3 4
5
6
7
8
8a
N O
O
I
(CH2)9N3
O
 
Oxazolidinone 17 was prepared according to the synthesis of compound 4b. To a solution of alkene 16    
(300 mg, 760 µmol) in dichloromethane (30 mL), N-iodosuccinimide (342 mg, 1.52 mmol) was added at 
room temperature. After stirring for 24 h, the reaction was diluted with dichloromethane (20 mL), the organic 
phase washed with 10% aqueous sodiumthiosulfate (20 mL), and then extracted with dichloromethane (4x 
50 mL). The combined organic layers were washed with 10% aqueous NaHCO3 and dried with Na2SO4. 
After removal of the solvent under pressure, the residue was purified by silica gel chromatography 
(cyclohexane/ethyl acetate, 5:1 (v/v)). Yield: 124 mg (267 µmol) = 35 %, white solid, C17H29IN4O3, M = 
464.34 g/mol, Rf (cyclohexane/ethyl acetate, 5:1 (v/v)) = 0.50. 1H-NMR (400 MHz, CD3OD) δ [ppm]: 1.30 
(m, 14H, CH2), 1.58 (s, 3H, C(CH3)2), 1.60 (s, 3H, C(CH3)2), 1.72 (m, 1H, CH2), 2.11 (m, 1H, CH2), 3.23 (t, 
2H, 3JHH = 7.0 Hz, CH2), 3.58 (dd, 1H, 3JHH = 8.8 Hz, 3JHH = 9.6 Hz, H-1A), 3.65 (t, 1H, 3JHH = 10.7 Hz, H-7), 
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4.01 (ddd, 1H, 3JHH = 10.6 Hz, 3JHH = 9.6 Hz, 3JHH = 5.5 Hz H-8a), 4.31 (dd, 1H, 2JHH = 8.8 Hz, 3JHH = 5.5 Hz, 
H-1B), 4.34 (dd, 1H, 3JHH = 10.7 Hz, 3JHH = 8.1 Hz, H-8). 13C-NMR (100 MHz, CD3OD) δ [ppm]: 21.7 - 29.6 
(CH2 and C(CH3)2), 33.7 (C-8), 51.7 (CH2), 61.8 (C-8a), 70.5 (C-1), 82.6 (C-7), 97.4 (C-3), 149.1 (C-5). 
FAB-MS: m/z (%) = 465.1 (1%, [M+H]+), 487.1 (100%, [M+Na]+).  
 
 
(4S,5S,6R)-6-(9-Azidononyl)-4-hydroxymethyl-5-iodo-1,3-oxazinan-2-one (12) 
HN O
HO
I
(CH2)9N3
O
1
2
3
4
5
6
1'
 
The compound 12 was obtained according to the synthesis of oxazolidinone 5b. Carbamate 17 (124 mg,      
300 µmol) was dissolved in THF (5 mL), hydrochloric acid (1M solution, 5 mL) was added, and the reaction 
mixture was stirred for 12 h under reflux. The reaction was neutralized with sodium hydrogencarbonate      
(5 mL), extracted three times with dichloromethane (20 mL), and the combined organic phases were dried 
with Na2SO4. After removal of the solvent under reduced pressure, the residue was purified by silica gel 
chromatography (chloroform/methanol, 10:1 (v/v)). Yield: 90 mg (212.1 µmol) = 71%, colorless wax, 
C14H25IN4O3, M = 424.28 g/mol, Rf (chloroform/methanol = 10:1 (v/v)) = 0.29.  
1H-NMR (400 MHz, CDCl3) δ [ppm]: 1.18 (m, 14H, CH2), 1.23 (m, 1H, CH2), 1.50 (m, 1H, CH2), 3.19 (t, 2H, 
3JHH = 6.9 Hz, CH2), 3.67 (dd, 1H, 2JHH = 12.4 Hz, 3JHH = 6.4 Hz, H-1’A), 3.69 (dd, 1H, 2JHH = 12.4 Hz, 3JHH = 
4.8 Hz, H-1’B), 3.97 (dd, 1H, 3JHH = 9.2 Hz, 3JHH = 9.9 Hz, H-5), 4.25 (ddd, 3JHH = 9.4 Hz, 3JHH = 6.4 Hz, 3JHH 
= 4.8 Hz, H-4), 4.25 (dt, 3JHH = 10.1 Hz, 3JHH = 3.4 Hz, H-6). 13C-NMR (100 MHz, CDCl3) δ [ppm]: 21.7-37.5 
(CH2), 51.7 (C-1’), 58.2 and 64.6 (CH2 and C-4), 77.5 (CH2) 80.6 (C-5), 161.8 (C-2). FAB-MS: m/z (%) = 
425.1 (25%, [M+H]+), 447.1 (6%, [M+Na]+). 
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7.7. Synthesis of 1’C Methyl-oxazinanones 23.2a and 23.2b 
 
(4R,5R)-tert-Butyl 2,2,5-trimethyl-4-(pentadec-1’-enyl)oxazolidine-3-carboxylate (3b) 
 
O N
(CH2)12CH3
Boc2
1
2'
3
45
1'  
 
To a solution of Weinreb amide 1b (1.67 mmol, 480.7 mg) in dry THF (12 mL), lithiumaluminiumhydride (1M 
solution in THF, 1.7 mL, 1.7 mmol) was added slowly at 0°C. The reaction was stirred for 1 h, cooled to        
–15°C, and a saturated aqueous solution of potassium hydrogensulfate (10 mL) was added slowly. After 
dilution with ether (10 mL), the solution was stirred for 30 min. The aqueous layer was extracted three times 
with diethyl ether (20 mL) and the combined organic layers were dried with sodiumsulfate. The solvent was 
removed and the residue was dried under reduced pressure. Dry tetradecyltriphenylphosphoniumbromide 
(2.92 mmol, 1.57 g) was suspended in dry THF (20 ml), cooled to –78°C, and n-butyllithium (1.6 M in 
Hexan, 3.03 mmol, 1.82 mL) was added dropwise while stirring. The dark red solution was stirred for 30 min 
at 0°C and cooled down again to -78°C. A solution of the aldehyde 2b in dry THF (10 mL) was added 
dropwise. The reaction was stirred for 3h at room temperature. Then, the reaction was quenched with an 
saturated aqueous ammonium chloride solution (20 mL) and the aqueous layer was extracted three times 
with ethyl acetate (3x 20 mL). The combined organic layers were washed with water (50 mL), dried with 
sodiumsulfate, and the solvent was removed under reduced pressure. The residue was purified by column 
chromatography with silica gel (cyclohexane/ethyl acetate, 10:1). Both isomers were obtained in a ratio of 
E/Z = 1: 5. Yield: 565.00 mg (1.33 mmol) = 97 % over 2 steps, colorless oil, C26H49NO3, M = 423.37 g/mol, 
Rf (cyclohexane/ethyl acetate, 5:1 (v/v)) = 0.58 (Z-alkene), 0.52 (E-alkene).  
1H-NMR (400 MHz, CD3OD) δ [ppm]: 0.81 (t, 3H, CH3, 3JHH = 7.0 Hz), 1.20 (m, 22H, CH2), 1.21 (m, 3H, 
CH3), 1.36 (s, 9H, C(CH3)3), 1.44 (s, 3H, C(CH3)2), 1.53 (s, 3H, C(CH3)2), 2.03 (m, 2H, CH2), 3,68 (dd, 1H, 
3JHH = 7.9 Hz, 3JHH = 6.9 Hz, H-4), 4.06 (m, 1H, H-5), 5.10 (Z-alkene: dd, 1H, 2JHH = 10.8 Hz, 3JHH = 9.2 Hz), 
5.18  (E-alkene: dd, 1H, , 2JHH = 15.3 Hz, 3JHH = 8.1 Hz). 13C-NMR (100 MHz, CD3OD) δ [ppm]: 14.3 (CH3), 
17.8 (CH3), 22.9 (CH2), 28.0 (C(CH3)2), 28.6 (C(CH3)3, 28.4 - 31.9 (CH2), 61.6 (C-4), 75.8 (C-5), 79.8 
(C(CH3)3), 94.1 (C(CH3)2), 125.7 and 130.1 (C-1’ and C-2’), 152.4 (CO). FAB-MS: m/z = 424.3 ([M+H]+, 
7%), 322.3 [(M-C5H10O2+H)]+, 45%). IR: v  [cm-1] = 721.6 and 980.5 δ(C-H), 1061.3, 1090.2, 1176.5 and 
1254.2 (C-O), 1384.5 (C(CH3)3 and C(CH3)2), 1456.0 (s), 643.9 (C=C), 1698.4 (C=O), 2052.9 and 2920.6 ν 
(CH2 and CH3). EI-HR-MS:[C26H49NO3] m/z = calc.: 423.3711, found: 423.3705. 
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(1R,7R,7aS)-Dihydro-1-[1’(R)iodotetradecyl]-5,5,7-trimethyl-1H-oxazolo[3,4-c]oxazol-3(5H)-
one (23.1b) 
7
1
34
5
6
7a
O N
O
O
(CH2)12CH3I
1'
2
 
 
To a solution of E/Z-alkene 3b (409 mg, 0.97 mmol) in dichloromethane (12 mL), N-iodosyccinimide (NIS, 
437 mg, 1.94 mmol) was added at room temperature. After stirring for 48 h, the reaction was diluted with 
dichloromethane (10 mL), the organic phase washed with 10% aqueous sodiumthiosulfate (10 mL), and 
then extracted with dichloromethane (4x 20 mL). The combined organic layers were washed with 10% 
aqueous NaHCO3 and dried with Na2SO4. After removal of the solvent under pressure, the residue was 
purified by silica gel chromatography (cyclohexane/ethyl acetate, 10:1 (v/v)). Yield: 274.2 mg (556 µmol) = 
57 %, white solid, C22H40INO3, M = 493.46 g/mol, Rf (cyclohexane/ethyl acetate, 5:1 (v/v)) = 0.25. 
1H-NMR (400 MHz, CD3OD) δ [ppm]: 0.84 (t, 3H, 3JHH = 7.1 Hz, CH3), 1.23 (m, 24H, CH2), 1.46 (s, 3H, 
C(CH3)2), 1.68 (s, 3H, C(CH3)2), 1.33 (d, 1H, 3JHH = 5.9 Hz, CH3), 3.65 (dd, 1H, 3JHH = 8.7 Hz, 3JHH = 3.9 Hz, 
H-7a), 3.81 (dq, 1H, 3JHH = 8.6 Hz, 3JHH = 5.9 Hz, H-7), 4.10 (ddd, 1H, 3JHH = 9.0 Hz, 3JHH = 5.3 Hz, 3JHH = 
3.7 Hz, H-1’), 4.38 (dd, 1H, 3JHH = 3.8 Hz, 3JHH = 3.8 Hz, H-1). 13C-NMR (100 MHz, CD3OD) δ [ppm]: 14.4 
(CH3), 22.9 (CH2), 24.0 (CH2), 26.6 (CH2), 28.9 (CH2), 29.5 - 29.9 (CH2, C(CH3)2 und C-1’), 32.1 (CH2), 32.4 
(CH2), 36.1 (CH2), 67.8 (C-7a), 76.5 and 78.0 (C-1 and C-7), 95.0 (C-5), 156.4 (C-3). FAB-MS: m/z (%) = 
494.2 (100%, [M+H]+), 987.5 (3%, [2M+H]+).  
 
 
(1R,7S,8S,8aS)-Dihydro-8-iodo-1,3,3-trimethyl-7-tridecyloxazolo[3,4-c][1,3]oxazin-
5(1H,3H,7H)-one (23.1a)  
1
2
3
4 5
6
78
8a
O N
O
O
I
(CH2)12CH3
 
 
The compound was obtained as by-product within the reaction of Z-alkene 3b with NIS. Yield: 173 mg       
(351 µmol) = 36 %, white solid, C22H40INO3, M = 493.46 g/mol, Rf (cyclohexane/ethyl acetate = 10:1) = 0.19.  
1H-NMR (400 MHz, CD3OD) δ [ppm]: 0.86 (t, 3H, 3JHH = 7.0 Hz), 1.23 (m, 24H, CH2), 1.48 (d, 3H, 3JHH =         
5.9 Hz, CH3), 1.58 (s, 6H, C(CH3)2), 1.64 (m, 1H, CH2), 2.12 (m, 1H, CH2), 3.44 (dd, 1H, 3JHH = 10.7 Hz, 
3JHH = 8.7 Hz, H-8a), 3.74 (dq, 1H, 3JHH = 8.6 Hz, 3JHH = 5.9 Hz, H-1), 3.97 (dd, 1H, 3JHH = 10.7 Hz, 3JHH = 
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4.5 Hz, H-8), 4.23 (ddd, 1H, 3JHH = 10.5 Hz, 3JHH = 4.4 Hz, 3JHH = 1.8 Hz, H-7). 13C-NMR (100 MHz, CD3OD) 
δ [ppm]: 14.2 (CH3), 20.1 and 24.1 (C(CH3)2), 18.9 (CH3), 26.2 (C-8), 22.7-32.0 (CH2), 62.6 (C-8a), 76.7 (C-
1), 80.6 (C-7), 94.6 (C-3), 148.8 (C-5). FAB-MS: m/z (%) = 494.2 ([M+H]+, 100 %), 987.4 ([2M+H]+, 6%), 
Elemental analysis: [C22H40INO3] calc.: C 53.55, H 8.17, N 2.84; found.:C 53.13, H 8.12, N 2.79. 
 
 
(1R,7R,8S,8aS)-Dihydro-8-iodo-1,3,3-trimethyl-7-tridecyloxazolo[3,4-c][1,3]oxazin-
5(1H,3H,7H)-one (23.1c) 
1
2
3
4 5
6
7
8
8a
O N
O
O
I
(CH2)12CH3
 
 
The oxazolidinone was obtained in a mixture with the oxazolidinone and oxazinanone as by-product within 
the reaction of E-alkene 3b with NIS. C22H40INO3, M = 493.46 g/mol, Rf (cyclohexane/ethyl acetate, 10:1 
(v/v)) = 0.19.  
1H-NMR (400 MHz, CD3OD) δ [ppm]: 0.84 (t, 3H, 3JHH = 7.1 Hz, CH3), 1.23 (m, 24H, CH2), 1.33 (d, 1H, 3JHH 
= 5.9 Hz, CH3), 1.54 (s, 3H, (CH3)2), 1.58 (s, 3H, (CH3)2), 3.49 (dd, 1H, 3JHH = 10.5 Hz, 3JHH = 8.4 Hz, H-8a), 
3.58 (dd, 1H, 3JHH = 10.6 Hz, 3JHH = 10.6 Hz, H-8), 3.73 (dq, 1H, 3JHH = 8.4 Hz, 3JHH = 5.9 Hz, H-1), 4.31 
(ddd, 1H, 3JHH = 10.6 Hz, 3JHH = 7.7 Hz, 3JHH = 2.6 Hz, H-7). 13C-NMR (100 MHz, CD3OD) δ [ppm]: 14.3 
(CH3), 19.9 (CH3), 22.6 - 33.7 (CH2, C(CH3)2 and C-8), 66.3 (C-8a), 77.0 (C-1), 82.4 (C-7), 94.1 (C-3), 149.0 
(C-5). FAB-MS: m/z (%) = 494.2 ([M+H]+, 100 %), 987.4 ([2M+H]+, 6%). 
 
 
(4S,5R)-4-(1’’(R)-Hydroxyethyl)-5-(1’(R)-iodotetradecyl)oxazolidin-2-one (23.2b) 
 
1
23
4
5
HO HN
O
O
(CH2)12CH3I
1'
1''
 
 
Compound 23.2b was made according to the synthesis of compound 5b. Oxazolidinone 23.1b (371 µmol, 
183 mg) was dissolved in a solution of 1N HCl in THF (1:1, 5 mL), stirred for 5 h at rt. After the volume was 
reduced under reduced pressure, the product was extracted with ethyl acetate and dried with 
sodiumsulfate. The solvent was removed under reduced pressure and the residue was purified by 
chromatography on silica gel (cyclohexane/ethyl acetate = 10:1 (v/v)). Yield: 62.1 mg (13.7 mmol) = 37 %, 
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white solid, C19H36INO3, M = 453.40 g/mol, Rf (chloroform/methanol, 20:1 (v/v)) = 0.16, αD = -33.1° (c = 
0.39, CHCl3/MeOH, 1:1 (v/v)).  
1H-NMR (400 MHz, CDCl3) δ [ppm]: 0.89 (t, 3H, 3JHH = 6.5 Hz, CH3), 1.24 (d, 3H, 3JHH = 6.4 Hz, CH3), 1.28 
(m, 24H, CH2), 3.44 (dd, 1H, 3JHH = 4.5 Hz, 3JHH = 4.5 Hz, H-4), 3.66 (qd, 1H, 3JHH = 6.3 Hz, 3JHH = 4.8 Hz, 
H-1’’), 3.9 (ddd, 1H, 3JHH = 10.1 Hz, 3JHH = 4.1 Hz, 3JHH = 2.8 Hz, H-1’), 4.50 (dd, 3JHH = 3.5 Hz, 3JHH = 2.4 
Hz, H-5), 7.59 (m, 1H, NH). 13C-NMR (100 MHz, CDCl3) δ [ppm]: 13.9 (CH3), 18.6 (CH3), 22.6 (CH2), 28.6 – 
29.6 (CH2), 31.9 (CH2), 35.2 (CH2), 38.8 (C-1’), 63.0 (C-4), 68.0 (C-1’’), 80.3 (C-5), 159.7 (C-2). IR: v  [cm-1] 
= 2536.3 ν(-CH2), 1651.9 ν(C=O), 1457.9 δ(-CH3). FAB-MS: m/z (%) = 454.18 (100%, [M+H]+). 
 
 
(4S,5S,6S)-4-(1’(R)-Hydroxyethyl)-5-iodo-6-tridecyl-1,3-oxazinan-2-one (23.2a) 
 
1'
1
23
4
5 6
HO HN
O
O
I
(CH2)12CH3
 
 
Synthesis and purification of 23.2a was done according to the preparation of lipid 5a. Oxazinanone 23.1a 
(351 µmol, 137 mg) was dissolved in 1N HCl in THF (1:1, 5 mL) and the reaction mixture was stirred for 24 
h at 60 °C. Yield: 21 mg (46 µmol) = 13%, white solid, C19H36INO3, M = 453.40 g/mol, Rf(chloroform/ 
methanol, 20:1 (v/v)) = 0.19.  
1H-NMR (400 MHz, CDCl3/CD3OD = 5:1) δ [ppm]: 0.72 (t, 3H, 3JHH = 7.0 Hz, CH3), 1.26 (d, 3H, 3JHH = 6.6 
Hz, CH3), 1.31 (m, 21H, CH2), 1.65 (m, 1H, CH2), 1.81 (m, 1H, CH2), 1.95 (m, 1H, CH2), 3.36 (t, 1H, 3JHH = 
4.5 Hz, H-4), 3.66 (qd, 1H, 3JHH = 6.4 Hz, 3JHH = 4.6 Hz, H-1’), 3.93 (ddd, 1H, 3JHH = 10.2 Hz, 3JHH = 4.1 Hz, 
3JHH = 2.7 Hz, H-6), 4.04 (dd, 1H, 3JHH = 4.3 Hz, 3JHH = 2.7 Hz, H-5). 13C-NMR (100 MHz, CDCl3/CD3OD = 
5:1) δ [ppm]: 14.6 (CH3), 20.5 (CH3), 23.5 (CH2), 28.6 (CH2), 30.2 (CH), 30.4 (CH2), 32.7 (CH2), 67.1 (CH), 
70.7 (CH), 77.2 (CH2), 155.5 (C-2). IR: v  [cm-1] = 2932.4 ν(-CH2-), 1722.3 ν(C=O), 1456.1 δ(-CH3). FAB-
MS: m/z (%) = 454.2 (68%, [M+H]+), 476.1, (74%, [M+Na]+).  
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7.8. Synthesis of oxazinanones 18a and 18b 
 
(2S,3S,4R)tert-Butyl 1,3,4-trihydroxyoctadecane-2-ylcarbamate (19) 
 
1
2 3 4 (CH2)13CH3
HN OH
OHOH
Boc
 
 
Triethylamine (7.21 mmol, 1.0 mL was added to a solution of phytosphingosine (4.72 mmol, 1.50 g) in 
tetrahydrofurane (15 ml) at 0°C. Then di-tert-butyl-dicarbonate (7.08 mmol, 1.55 g) was added to, and the 
mixture was stirred for 24 h at room temperature. The solvent was removed under reduced pressure and 
the crude product was purified by chromatography on silica gel (chloroform/methanol, 10:1 (v/v)). Yield: 
1.47 g (mmol) = 75 %, white solid, C23H47NO5, M = 417.62 g/mol, Rf (chloroform/ methanol, 10:1 (v/v)) = 
0.54.  
1H-NMR (400 MHz, CD3OD/CDCl3 = 1:1) δ [ppm]: 0.84 (t, 3H, 3JHH = 7.2 Hz, CH3), 1.19 (m, 24H, CH2), 1.23 
(m, 2H, CH2), 1.37 (s, 9H, C(CH3)3), 3.58 (m, 2H, H-2 and H-4), 3.65 (dd, 1H, 2JHH = 11.0 Hz, 3JHH = 5.2 Hz, 
H-1A), 3.74 (m, 1H, H-4), 3.80 (dd, 1H, 2JHH = 10.8 Hz, 3JHH = 3.2 Hz, H-1B), 3.93 (m, 1H, H-3), 5.43 (d, 1H, 
3JHH = 8.6 Hz, NH). 13C-NMR (100 MHz, CD3OD/CDCl3 = 1:1) δ [ppm]: 14.3 (CH3), 22.9 (CH2), 26.2 (CH2), 
28.6 (C(CH3)3), 28.5 – 32.1 (CH2), 53.1 (C-2), 62.1 (C-1), 73.2 (C-4), 76.2 (C-3), 80.3 (C(CH3)3), 156.7 
(CO). FAB-MS: m/z (%) = 418.4 (20%, [M+H]+). Elemental analysis: [C23H47INO5] calc.: C 66.15, H 11.34, N 
3.35; found: C 66.10, H 11.43, N 3.30. 
 
 
(4S,5S)tert-Butyl 2,2-di-tert-butyl-4-(1’(R)-hydroxypentadecyl)-1,3,2-dioxasilinan-5-
ylcarbamate (20) 
1
2
3
4 (CH2)13CH3
HN OH
O
1'
O
6
Si
5
t-But-Bu
Boc
 
 
The synthesis of 20 followed (Hoberg, 1997). Di-tert-butylsilylbis(trifluoromethane)sulfonate (2.83 mmol, 
1.03 mL) was added dropwise over 30 min to a solution of compound 19 (2.85 mmol, 1.19 g) in N,N-
Dimethylformamide (20 mL) at –40°C. The solution was stirred for 1 h at rt, pyridine (7.37 mmol, 600 µL) 
was added and stirred for 5 min. The solution was diluted with ether (20 mL) and washed once with 
saturated NaHCO3 (70 mL), twice with water (70 mL), and dried over Na2SO4. Solvents were removed 
under reduced pressure and the residue was purified by chromatography with silica gel (cyclohexane/ethyl 
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acetate, 5:1 (v/v)). Yield: 986.8 mg (1.77 mmol) = 62 %, white solid, C31H63NO5Si, M = 557.92 g/mol,            
Rf (cyclohexane/ethyl acetate, 5 :1 (v/v)) = 0.51. 1H-NMR (400 MHz,CDCl3) δ [ppm]: 0.85 (t, 3H, 3JHH = 6.4 
Hz), 0.99 (s, 9H, C(CH3)3), 1.01 (s, 9H, C(CH3)3), 1.23 (m, 24H, CH2), 1.40 (m, 10H, C(CH3)3 und CH2), 1.46 
(m, 1H, CH2), 2.16 (dt, 1H, 3JHH = 9.1 Hz, 3JHH = 2.1, H-1’), 3.63 (m, 1H, H-4), 3.64 (dd, 1H, 2JHH = 10.2 Hz, 
3JHH = 10.2 Hz, H-6A), 3.81 (m, 1H, OH), 3.86 (dd, 1H, 3JHH = 9.6 Hz, 3JHH = 3.7 Hz, H-5), 4.03 (dd, 1H, 2JHH 
= 10.4 Hz, 3JHH = 4.3 Hz, H-6B), 4.39 (d, 1H, 3JHH = 9.2 Hz, NH). 13C-NMR (100 MHz,CDCl3) δ [ppm]: 14.3 
(CH3), 20.5 (C(CH3)3, 22.9 (CH2), 23.0 (CH2), 26.0 (CH2), 27.3 (CH2), 27.8 (C(CH3)3), 28.5 (CH2), 29.6, 29.8 
– 29.9 (CH2), 49.9 (C-5), 67.8 (C-6), 73.2 (C-1’), 80.7 (C-4), 155.2 (CO). ESI-MS (positive mode): m/z (%) = 
558.46 (100%, [M+H]+), 580.45 (70%, [M+Na]+). 
 
 
(4S,5S)tert-Butyl 2,2-di-tert-butyl-4-(1’(R)-methanesulfonyloxypentadecyl)-1,3,2-dioxa-
silinan-5-ylcarbamate (21) 
1
2
3
4 (CH2)13CH3
HN OMs
O
1'
O
6
Si
5
t-But-Bu
Boc
 
 
A solution of compound 20 (0.78 mmol, 454.2 mg) in pyridine (4.5 mL) was cooled to –10°C. Then, 
methanesulfonylchloride (1.29 mmol, 100 µL) was added slowly, and the mixture stirred for 30 min at the 
same temperature. The mixture was warmed to rt and stirred for 12 h. After evaporation of the solvent, the 
residue was purified by column chromatography (cyclohexane/ethyl acetate, 2:1(v/v)). Yield: 391.85 mg 
(0.63 mmol) = 81 %, colorless solid, C32H65NO7SSi, M = 636.01 g/mol, Rf (cyclohexane/ethyl acetate, 5:1 
(v/v)) = 0.58.  
1H-NMR (400 MHz, CDCl3) δ [ppm]: 0.85 (t, 3H, 3JHH = 7.1 Hz), 0.99 (s, 9H, C(CH3)3), 1.02 (9H, C(CH3)3), 
1.23 (m, 24H, CH2), 1.41 (s, 9H, (C(CH3)3), 1.46 (m, 2H, CH2), 3.00 (s, 3H, CH3), 3.70 (m, 1H, H-5), 3.75 
(dd, 1H, 2JHH = 10.0 Hz, 3JHH = 4.1 Hz, H-6A), 4.06 (dd, 1H, 2JHH = 9.7 Hz, 3JHH = 4.0 Hz, H-6B), 4.33 (dd, 1H, 
2JHH = 10.0 Hz, 3JHH = 2.0 Hz, H-4), 4.41 (d, 1H, 3JHH = 9.5 Hz, NH), 4.79 (dt, 1H, 3JHH = 10.4 Hz,  3JHH = 2.0 
Hz,  H-1’). 13C-NMR (100 MHz, CDCl3) δ [ppm]: 14.3 (CH3), 20.5 (CH3), 22.9 (CH2), 23.0 (CH2), 25.7 (CH2), 
27.3 (CH2), 27.7 (CH2), 27.8 (C(CH3)3), 27.9 (C(CH3)3), 28.0 (CH2), 28.5 (C(CH3)3), 29.4 (CH2), 29.6 (CH2), 
29.8 (CH2), 29.9 (CH2), 32.1 (CH2), 38.9 (CH2), 49.4 (C-5), 67.8 (C-6), 79.2 (C-4), 80.6 (C(CH3)3), 83.8 (C-
1’), 155.1 (CO). IR: ν [cm-1] = 2919.6 and 2850.5 ν(-CH2-), 1670.9 ν(C=O), 1468.6 δ(-CH3). ESI-MS 
(positive mode): m/z (%) = 658.41 (76 %, [M+Na]+), 1293.84 (4 %, [2M+Na]+).  
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(4aS,8R,8aS)-2,2-Di-tert-Butyl-8-tetradecyl-tetrahydro-1,3,7-trioxa-5-aza-2-sila-naphtalen-6-
one (22b) 
(CH2)13CH3
HN O
OO
Si
t-But-Bu
O
4
84a
3 1
2
8a
6
5 7
 
 
Compound 20 (0.17 mmol, 104.7 mg) was dissolved in tetrahydrofurane (1 mL) and cooled to 0°C. 
Lithiumdiisopropylamine (189 µmol, 97.5 µL) was added to the mixture and stirred for 1h at room 
temperature. After evaporation of the solvent under vacuum, the residue was purified by column 
chromatography (cyclohexane/ethyl acetate, 4:1 (v/v)). Yield: 71.36 mg (147.5 µmol) = 82 %, colorless 
solid, C27H53NO4Si, M = 483.80 g/mol, Rf (cyclohexane/ethyl acetate/trietylamine = 3:1:0,001 (v/v/v)) = 0,17, 
[α]D = +39.5° (c = 0.4, CHCl3).  
1H-NMR (400 MHz, CDCl3): δ [ppm] = 0.81 (t, 3H, 3JHH = 6.7 Hz, CH3), 0.90 (s, 9H, C(CH3)3), 0.97 (s, 9H, 
C(CH3)3), 1.19 (m, 24H, CH2), 1.39 (m, 1H, CH2), 1.54 (m, 2H, CH2), 1.83 (m, 1H, CH2), 3.38 (ddd, 1H, 3JHH 
= 10.6 Hz, 3JHH = 9.3 Hz, 3JHH = 4.5 Hz, H-4a), 3.68 (dd, 1H, 2JHH = 10.1 Hz, 3JHH = 9.3 Hz, H-4A), 3.74 (dd, 
1H, 2JHH = 10.1 Hz, 3JHH = 10.5 Hz, H-4B), 4.01 (ddd, 1H, 3JHH = 9.4 Hz, 3JHH = 7.2 Hz, 3JHH = 5.6 Hz, H-8), 
4.06 (dd, 1H, 2JHH = 10.1 Hz, 3JHH = 5.6 Hz, H-8a), 6.50 (m, 1H, NH). 13C-NMR (100 MHz, CDCl3) δ [ppm] = 
13.1 (CH3), 18.9 (C(CH3)3), 21.7 (CH2), 21.8 (CH2), 23.1 (CH2), 25.9 (CH2), 26.4 (C(CH3)3), 28.4 (CH2), 28.5 
(CH2), 28.6 (CH2), 28.7 (CH2), 29.2 (CH2), 29.8 (CH2), 30.9 (CH2), 52.5 (C-4a), 66.3 (C-4), 71.0, 79.7 (C-8 
and C-8a), 154.2 (C-6). ESI-MS: m/z (%) = 484.4 ([M+H]+, 100%), 506.3 ([M+Na]+, 12%), 968.7 ([2M+H]+, 
11%). ESI-HR-MS: [C27H53NO4Si+Na]+ m/z = calcd.: 506.36359, found: 506.36520 
 
 
(4S,5S,6R)-5-Hydroxy-4-hydroxymethyl-6-tetradecyl-1,3-oxazinan-2-one (18b) 
 
(CH2)13CH3
HN O
OHHO
O
4
3
2
1
6
57
 
 
tert-Butylammoniumfluoride (1 M solution in THF, 500 µmol, 500 µL) was added dropwise to a solution of 
tetrahydronaphtalene 22b (124 µmol, 60.0 mg) in THF (5 mL) at 0°C. The reaction was stirred for 1 h at 0°C 
and then for additional 30 min at room temperature. After removal of the solvent under reduced pressure, 
the residue was purified by chromatography on silica gel (toluene/ethanol, 5:1 (v/v)). Yield: 12 mg (34.9 
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µmol) = 26 %, white solid, FP = 123°C, C19H37NO4, M = 343.50 g/mol, Rf (toluene/ethanol, 5:1 (v/v)) = 0.26, 
[α]D = +17.0° (c = 0.19, CHCl3/MeOH, 5:1 (v/v)).  
1H-NMR (400 MHz, CDCl3/CD3OD = 5:1 (v/v)): δ [ppm] = 0.80 (t, 3H, 3JHH = 6.7 Hz, CH3), 1.18 (m, 22H, 
CH2), 1.30 (m, 1H, CH2), 1.50 (m, 2H, CH2), 1.83 (m, 1H, CH2), 3.18 (ddd, 1H, 3JHH = 9.2 Hz, 3JHH = 6.3 Hz, 
3JHH = 3.2 Hz, H-4), 3.33 (pt, 1H, 3JHH = 9.2 Hz, H-5), 3.47 (dd, 1H, 2JHH = 11.5 Hz, 3JHH = 6.3 Hz, H-7A), 
3.72 (dd, 1H, 2JHH = 11.5 Hz, 3JHH = 3.2 Hz, H-7B), 3.95 (m, 1H, H-6). 13C-NMR (100 MHz, CDCl3/CD3OD = 
5:1 (v/v)): δ [ppm] = 14.9 (CH3), 23.8 (CH2), 25.7 (CH2), 30.6 (CH2), 30.7 (CH2), 30.8 (CH2), 30.9 (CH2), 32.4 
(CH2), 33.1 (CH2), 59.6 (C-4), 63.2 (C-7), 66.1 (C-5), 81.3 (C-6), 156.9 (C-2). 
IR: ν [cm-1] = 3282 (OH), 2918 (CH2), 2851 (CH2), 1682 (CO), 1472 (CH3). FAB-MS: m/z (%) = 344.3 
([M+H]+, 4%). ESI-HR-MS: [C19H37NO4+Na]+ m/z = calcd.: 366.26147, found: 366.26208 
 
 
(4aS,8S,8aS)-2,2-Di-tert-Butyl-8-tetradecyltetrahydro-1,3,7-trioxa-5-aza-2-sila-naphtalen-6-
one (22a)  
(CH2)13CH3
HN O
OO
Si
t-But-Bu
O
4
84a
3 1
2
8a
6
5 7
 
 
Compound 21 (170 µmol, 104.7 mg) was dissolved in THF and refluxed for 8 h. The solvent was removed 
under reduced pressure and the residue was purified by column chromatography with silica gel 
(cyclohexane/ethyl acetate, 3:1 (v/v)). Yield: 65.7 mg (135.8 µmol) = 75 %, colorless solid, C27H53NO4Si, M 
= 483.80 g/mol, Rf (cyclohexane/ethyl acetate, 3:1(v/v)) = 0.25.  
1H-NMR (500 MHz, CDCl3): δ [ppm] = 0.90 (t, 3H, 3JHH = 6.9 Hz, CH3), 1.02 (s, 9H, C(CH3)3), 1.09 (s, 9H, 
C(CH3)3), 1.28 (m, 22H, CH2), 1.59 (m, 2H, CH2), 1.73 (m, 1H, CH2), 1.89 (m, 1H, CH2), 3.59 (ddd, 1H, 2JHH 
= 3JHH = 10.3 Hz, 3JHH = 4.68 Hz, H-4a), 3.88 (dd, 1H, 2JHH = 3JHH = 10.3 Hz, H-4A), 4.12 (dd, 1H, 3JHH = 10.0 
Hz, 3JHH = 4.6 Hz, H-4B), 4.26 (dd, 1H, 3JHH = 9.6 Hz, 3JHH = 5.2 Hz, H-8a), 4.39 (ddd, 1H, 3JHH = 7.6 Hz, 
3JHH = 5.3 Hz, 3JHH = 2.4 Hz, H-8), 5.19 (m, 1H, NH). 13C-NMR (125 MHz, CDCl3): δ [ppm] = 13.1 (CH3), 
19.0 (C(CH3)3), 21.7 (CH2), 21.9 (CH2), 24.6 (CH2), 25.9 (C(CH3)3), 26.0 (C(CH3)3), 27.5 (CH2), 28.4 (CH2), 
28.5 (CH2), 28.6 (CH2), 28.7 (CH2), 30.9 (CH2), 48.5 (C-4a), 66.8 (C-4), 69.7 and 78.2 (C-8 and C-8a), 
151.3 (C-6). FAB-MS: m/z (%) = 484.4 ([M+H]+, 7%). 
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(4S,5S,6S)-5-Hydroxy-4-hydroxymethyl-6-tetradecyl-1,3-oxazinan-2-one (18a) 
 
(CH2)13CH3
HN O
OHHO
O
4
3
2
1
6
57
 
 
Compound 18a was prepared according to synthesis of compound 18b. A solution of tetrahydronaphtalen 
22a      (134.4 µmol, 65 mg) in THF (5 mL) was cooled to 0°C and tert-butylammoniumfluoride (1 M solution 
in THF, 500 µmol, 500 µL) was added. The reaction was stirred for 1 h at 0°C, warmed to rt and stirred for 
additional 30 min. After evaporation of the solvent under reduced pressure, the residue was purified by 
column chromatography with silica gel (toluene/ethanol, 5:1 (v/v)). Yield: 3.1 mg (9.0 µmol) = 93%, white 
solid, C19H37NO4, M =  343.50 g/mol, Rf (toluene/ ethanol, 5:1 (v/v)) = 0.16.  
1H-NMR (400 MHz, CDCl3/CD3OD = 5:1 (v/v)): δ [ppm] = 0.80 (t, 3H, 3JHH = 6.7 Hz, CH3), 1.18 (m, 24H, 
CH2), 1.44 (m, 2H, CH2), 3.33 (ddd, 1H, 3JHH = 2.4 Hz, 3JHH = 5.7 Hz, 3JHH = 8.3 Hz, H-6), 3.46 (d, 2H, 3JHH = 
6.1 Hz, H-7A and H-7B), 3.75 (pt, 1H, 3JHH = 2.4 Hz, H-5), 4.13 (ddd, 1H, 3JHH = 2.0, 3JHH = 5.2, 3JHH = 7.2 
Hz, H-4). 13C-NMR (125 MHz, CDCl3/CD3OD = 5:1 (v/v)): δ [ppm] = 13.7 (CH3), 19.5 (CH2), 22.5 (CH2), 
23.6 (CH2), 25.1 (CH2), 26.9 (CH2), 27.5 (CH2), 29.2 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 29.8 (CH2), 
31.8 (CH2), 58.1 and 63.0 (C-4 and C-5), 63.3 (CH2), 77.6 (C-6), 155.3 (C-2). IR: v  [cm-1] = 3423 (OH), 
2920 (CH2), 1654 (CO). ESI-MS (positive mode): m/z (%) = 344.3 ([M+H]+, 60 %), 366.25 ([M+Na]+, 100 %) 
 
 
7.9. Synthesis of N-Phenylacetylsphingosine (25) 
 
(4S)-tert-Butyl 4-(1’(R)-hydroxyhexadec-2-ynyl)-2,2-dimethyloxazolidine-3-carboxylate (3c) 
 
1O
2
3
4
N
5
Boc
C13H27
HO  
 
Compound 3c was prepared according to a described method (Garner et al., 1988). Pentadecyne (3.97 mL, 
15.13 mmol), nButyllithium (2.7 M solution in heptane, 5.09 ml, 13.76 mmol) and Garner aldehyde (3.16 g, 
13.76 mmol). The reaction mixture was stirred for 3 h at –20°C. The product was purified by column 
chromatography with silica gel (petroleum ether/ethyl acetate, 7:1, (v/v)). Yield: 1.45 g (3.32 mmol) = 24 %, 
white solid, C26H47NO4, M = 437.66 g/mol, Rf (petroleum ether/ethyl acetate, 7:1, (v/v)) = 0.25.  
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1H-NMR (400 MHz, CDCl3): δ [ppm] = 0.86 (t, 3H, 3JHH = 6.9 Hz, CH3), 1.24 (m, 14H, CH2), 1.48 (s, 9H, 
C(CH3)3), 1.49 (s, 3H, C(CH3)2), 1.54 (s, 3H, C(CH3)2), 2.17 (td, 2H, 3JHH = 7.0 Hz, 4JHH = 1.8 Hz, CH2), 3.89 
(m, 1H, H-5A), 4.05 (m, 1H, H-5B), 4.11 (m, 1H, H-4), 4.71 (m, 1H, H-1’). FAB-MS: m/z (%) = 438.3 ([M+H]+, 
13 %). 
 
 
(4S)-tert-Butyl (1’(R)-Hydroxyhexadec-2(E)-enyl)-2,2-dimethyloxazolidine-3-carboxylate (27) 
 
1'
1
2
3
45
O N
Boc
HO
C13H27
 
 
Compound 27 was prepared and purified according to a described method (Nyangulu et al., 2006). Alkyne 
26 (896.7 mg, 2.04 mmol), RedAl (2.91 mL, 10.2 mmol) and diethylether (30 mL). The reaction mixture was 
stirred for 12h at rt. The product was purified by column chromatography with silica gel (cyclohexane/ethyl 
acetate, 5:1, (v/v)). Yield: 70 mg (159 µmol) = 8 %, white solid, C26H49NO4, M = 439.67 g/mol,  
Rf (cyclohexane/ ethyl acetate, 5:1, (v/v)). = 0.23.  
1H-NMR (400 MHz, CDCl3): δ [ppm] = 0.85 (t, 3H, 3JHH = 7.1 Hz, CH3), 1.24 (m, 20H, CH2), 1.40 (m, 2H, 
CH2), 2.02 (s, 15H, C(CH3)2 and C(CH3)3), 2.19 (m, 2H, CH2), 3.61 (“t”, 1H, 3JHH = 6.6 Hz), 3.81 (m, 1H, 
CH2), 4.01 (m, 1H), 4.10 (m, 1H), 5.37 (dd, 1H, 3JHH = 15.4 Hz, 3JHH = 6.3 Hz, H-2’), 5.67 (dt, 1H, 3JHH = 15.4 
Hz, 3JHH = 6.8 Hz, H-3’). 13C-NMR (100 MHz, CDCl3): δ [ppm] = 14.1 (CH3), 22.9 (CH2), 24.9 (C(CH3)2), 26.5 
(CH2), 28.6 (CH2), 29.4 (CH2), 29.5 (CH2), 29.7 (CH2), 29.8 (CH2), 29.9 (CH2), 31.0 (C(CH3)3), 32.1 (CH2), 
32.6 (CH2), 62.3 (C-4), 74.1 (C-1’), 81.2 (C(CH3)3), 94.7 (C-2), 133.3 and 133.5 (C-2’ and C-3’), 166.7 
(C=O). FAB-MS: m/z (%) = 440.3 (7 %, [M+H]+). 
 
 
N-((2S,3R,E)-1,3-dihydroxyoctadec-4-en-2yl)phenylacetamide (25) 
 
HO
HN
OH
C13H27
O
 
 
Compound 27 (70 mg ,159 µmol) was dissolved in THF (5 ml) and hydrochloric acid (1M solution, 5 mL) 
was added, and the solution was stirred for 24 h at rt. The reaction was diluted with water (10 mL), 
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extracted three times with dichloromethane (20 mL) and the combined organic phases were dried with 
Na2SO4. After removal of the solvent under reduced pressure, the residue was dissolved in methanol (5 
mL), cooled to 0°C and triethylamine and benzoyl chloride (45 µL, 340 µmol) were added. The reaction 
mixture was stirred for 12 h and the solvent was evaporated under vacuum. The product was purified by 
column chromatography with silica gel (chloroform/methanol, 20:1, (v/v)). Yield: 7 mg (17 µmol) = 11 % over 
2 steps, white solid, C26H43NO3, M = 417.63 g/mol, Rf (chloroform/methanol, 20:1, (v/v)) = 0.3.  
1H-NMR (400 MHz, CDCl3): δ [ppm] = 0.81 (t, 3H, 3JHH = 7.0 Hz, CH3), 1.93 (m, 2H, CH2), 3.59 (dd, 1H, 2JHH 
= 10.8 Hz, 3JHH = 2.9 Hz), 3.82 (dd, 1H, 2JHH = 12.8 Hz, 3JHH = 4.0 Hz), 4.18 (dd, 1H, 3JHH = 5.2 Hz, 3JHH = 
4.6 Hz), 5.37 (ddt, 1H, 3JHH = 15.4 Hz, 3JHH = 6.5 Hz, 5JHH = 1.4 Hz, H-5), 5.63 (dtd, 1H, 3JHH = 15.4 Hz, 3JHH 
= 6.8 Hz, 5JHH = 1.2 Hz, H-4). 13C-NMR (125 MHz, CDCl3): δ [ppm] = 14.3 (CH3), 22.9 (CH2), 29.3 (CH2), 
29.5 (CH2), 29.6 (CH2), 29.7 (CH2), 29.9 (CH2), 32.2 (CH2), 32.5 (CH2), 44.1 (CH2), 55.2 (C-2), 62.6 (C-1), 
74.5 (C-3), 127.6, 128.8, 129.2, 129.6, 134.7 and 134.8 (Carom and Calkene), 172.0 (CO). FAB-MS: m/z (%) = 
418.2 (32%, [M+H]+). 
 
 
7.11. Synthesis of glycolipid standards 30 and 34 
 
O-(5-Acetamino-3,5-dideoxy-D-glycero-α-D-galacto-2-nonulopyranosylonic acid)-(2,3)-O-β-
D-galactopyranosyl-(1,4)-O-β-D-glucopyranosyl-(1,1)-(2S,3R,4E)-2-hexanoylamino-4-
oktadecen-1,3 diol (30) 
 
O
O
HO
OH
O
OH
O
OH
O
OH
OH
AcHN
O
HO
COOH
HO
OHHO
HN
O
C4H9
OH
C13H27
 
 
Acetylated GM3-C6 29 (67.9 mg, 44.21 µmol) was dissolved in methanol (5 mL) and cooled to 0°C. Sodium 
methylate (0.5 M solution in methanol, 500 µL, 250 µmol) was added and the reaction mixture was stirred 
for 12h at rt. Then, the reaction mixture was cooled to 0°C, water (500 µL) was added, and the reaction 
mixture was stirred for 5h. After Amberlyst 15 was added to the reaction mixture, the product was filtrated, 
the solvent was removed under reduced pressure. The product was purified by reverse phase 
chromatography with RP18 (Elution: chloroform/methanol = 1:1 (v/v)). Yield: 37.1 mg (36.64 µmol) = 84%, 
white solid, C47H84N2O21, M = 1013.17 g/mol, Rf (nbutanol/ethanol/water = 2:1:1 (v/v/v)) = 0.5. ESI-MS 
(positive mode): m/z (%) = 1057.53 ([M+2Na]+, 100%), 1035.56 ([M+Na]+, 18%). EI-HR-
MS:[C47H83N2Na2O21]+ m/z = calcd.: 1057.5278, found: 1057.5258 
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Lyso-sulfatide (32) 
O
O
OH
O
OH
NH2
OH
C13H27
HO
S
O
O
O
Na
 
Lysosulfatide 32 was prepared according to a described method (Koshy et al., 1982). Sulfatide (49 mg,    
60.4 µmol) was dissolved in a mixture of sodium hydroxide (0.5 M aqueous solution) in methanol/water (9:1 
(v/v), 2 mL) and stirred at 80°C for 6d. The solvent was removed under a stream of nitrogen and the residue 
was purified by column chromatography with silica gel (chloroform/methanol/triethylamine, 3:1:0.001 
(v/v/v)). Yield: 4.7 mg (8.34 µmol) = 14%, white solid, C24H46NNaO10S, M = 563.27 g/mol,                       
Rf (chloroform/methanol/triethylamine, 3:1:0.001 (v/v/v)) = 0.24. ESI-MS (negative mode): m/z (%) = 540.31 
([M]-, 53%), ESI-MS (positive mode): m/z (%) = 564.84 ([M+Na]+, 58). 
 
 
Heptadecanoicacid-2,5-Dioxopyrrolidine-1-ylester (33) 
 
N
O
O
O
O
H33C16
 
 
Ester 33 was prepared according to a described method (Kim et al., 2004). Heptadecanoic acid (500 mg, 
1.85 mmol), EDC (389.2 mg, 2.03 mmol) and N-hydroxy-succinimide (255.5 mg, 2.22 mmol) were dissolved 
in dichloromethane (20 mL) and stirred at 40°C. The reaction mixture was diluted with water (20 mL) and 
the product was extracted with ether (3x 60 mL). The combined organic layers were dried with sodium 
sulfate, filtered and solvent was removed under reduced pressure. Yield: 462.7 mg (1.26 mmol) = 68%,  
white solid, C21H37NO4, M = 367.27 g/mol.  
1H-NMR (300 MHz, CDCl3) δ [ppm]: 0.81 (t, 3H, 3JHH = 6.2 Hz, CH3), 1.19 (m, 26H, CH2), 1.66 (m, 2H, CH2), 
2.52 (t, 2H, 3JHH = 7.4 Hz, CH2), 2.74 (s, 4H, CH2). 13C-NMR (100 MHz, CDCl3) δ [ppm]: 14.1 (CH3), 22.7 
(CH2), 24.6 (CH2), 25.6 (CH2), 28.8 (CH2), 29.1 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2), 29.7 
(CH2), 30.9 (CH2), 31.9 (CH2), 34.0 (CH2), 168.7 (C=O), 169.3 (C=O). 
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C17-sulfatide (34) 
 
O
O
OH
O
OH
HN C16H33
O
OH
C13H27
HO
S
O
O
O
Na
 
 
Amide 34 was prepared according to a described method (Kim et al., 2004). Ester 33 (34.4 µmol, 12.66 mg) 
was dissolved in tetrahydrofurane (0.5 mL) and lysosulfatide (32, 4.7 mg, 8.34 µmol) and triethylamine (28.8 
µL, 103.4 µmol) were added. The reaction mixture was stirred for 14h at 50°C, water (5 mL) was added and 
the product was extracted with ethyl acetate (3x 10 mL). The combined organic layers were dried with 
Na2SO4, filtered and solvent was removed under reduced pressure. The residue was purified by column 
chromatography with silica gel (chloroform/methanol = 3:1 (v/v)). Yield: 1.17 mg (1.43 µmol) = 17%, white 
solid, C41H78NNaO11S, M = 815.52 g/mol, Rf  (chloroform/methanol, 3:1 (v/v)) = 0.28. ESI-MS (negative 
mode): m/z (%) = 792.49 ([M]-, 100 %), ESI-MS (positive mode): m/z (%) = 816.69 ([M+Na]+, 100%).  
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9. Abbreviations 
 
[α]D optical rotation 
δ chemical shifts (relative to the solvent) of 1H or 14C-NMR signal 
λ wave length 
Ac acetyl 
Bu butyl 
CHAPS 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate 
DEAE diethylaminoethyl 
DMF dimethylformamide 
DMEM Dulbecco’s modified Eagle’s medium 
ESI-MS electrospray ionization mass spectrometry 
ER Endoplasmic reticulum 
FP melting point 
FAB-MS fast atom bombardement mass spectrometry 
Gal galactose 
GalNAc N-Acetyl-D-galactosamine 
GalNAc-T N-Acetyl-D-galactosaminyl transferase 
Glc glucose 
GSL glycosphingolipids 
HEPES N-2-Hydroxyethylpiperazine-N-2-ethansulfoic acid 
Hz  Hertz 
xJy,z coupling constant 
MEM minimal essential medium 
mNBA meta-nitrobenzyl alcohol 
MS mass spectrometry 
NMR nuclear magnetic resonance 
NMRI Navy Marine Research Institute 
PBS phosphate buffered saline 
THF tetrahydrofuran 
tBu Tert-Butyl 
TLC thin layer chromatography 
        127
Triton TritonX-100 (polyethylene glycol p-(1,1,3,3-tetramethylbutyl)-
phenyl ether) 
UDP Uridine 5'-(trihydrogen diphosphate) 
GlcT Glucosyltransferase 
GalT I Galactosyltransferase I 
GalT II Galactosyltransferase II 
SAT I Sialyltransferase I, ST3Gal V  
SAT II Sialyltransferase II, ST8Sia I  
SAT III Sialyltransferase III, ST3Sia V 
SAT IV Sialyltransferase IV, ST3Gal I 
SAT V Sialyltransferase V, ST8Sia III 
SAT X Sialyltransferase X, ST8Sia II 
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10. Nomenclature of glycosphingolipids 
 
Glycosphingolipids are named according to commonly used nomenclature that is introduced by 
Svennerholm (Svennerholm, 1963; IUPAC-IUB, 1998).  
 
 
Cer ceramide, N-Acylsphingosine 
GlcCer Glcβ1Cer 
GalCer Galβ1Cer 
LacCer Galβ1,4Glcβ1Cer 
Gb3 Galα1,4Galβ1,4Glcβ1Cer 
Gb4 GalNAcβ1,3Galα1,4Galβ1,4Glcβ1Cer 
GA2 GalNAcβ1,4Galβ1,4Glcβ1Cer 
GA1 Galβ1,3GalNAcβ1,4Galβ1,4Glcβ1Cer 
GM1b NeuAcα2,3Galβ1,3GalNAcβ1,4Galβ1,4Glcβ1Cer 
GD1c NeuAcα2,8NeuAcα2,3Galβ1,3GalNAcβ1,4Galβ1,4Glcβ1Cer 
GD1α NeuAcα2,3Galβ1,3(NeuAcα2,6)GalNAcβ1,4Galβ1,4Glcβ1Cer 
GM3 NeuAcα2,3Galβ1,4Glcβ1Cer 
GM2 GalNAcβ1,4(NeuAcα2,3)Galβ1,4Glcβ1Cer 
GM1a Galβ1,3GalNAcβ1,4(NeuAcα2,3)Galβ1,4Glcβ1Cer 
GD1a NeuAcα2,3Galβ1,3GalNAcβ1,4(NeuAcα2,3)Galβ1,4Glcβ1Cer 
GT1a NeuAcα2,8NeuAcα2,3Galβ1,3GalNAcβ1,4(NeuAcα2,3)Galβ1,4Glcβ1Cer 
GT1α NeuAcα2,3Galβ1,3(NeuAcα2,6)GalNAcβ1,4(NeuAcα2,3)Galβ1,4Glcβ1Cer 
GD3 NeuAcα2,8NeuAcα2,3Galβ1,4Glcβ1Cer 
GD2 GalNAcβ1,4(NeuAcα2,8NeuAcα2,3)Galβ1,4Glcβ1Cer 
GD1b 
GT1b 
Galβ1,3GalNAcβ1,4(NeuAcα2,8NeuAcα2,3)Galβ1,4Glcβ1Cer 
NeuAcα2,3Galβ1,3GalNAcβ1,4(NeuAcα2,8NeuAcα2,3)Galβ1,4Glcβ1Cer 
GQ1b NeuAcα2,8NeuAcα2,3Galβ1,3GalNAcβ1,4(NeuAcα2,8NeuAcα2,3)Galβ1,4Glcβ1Cer 
GQ1bα NeuAcα2,3Galβ1,3(NeuAcα2,6)GalNAcβ1,4(NeuAcα2,8NeuAcα2,3)Galβ1,4Glcβ1Cer 
GT3 NeuAcα2,8NeuAcα2,8NeuAcα2,3Galβ1,4Glcβ1Cer 
GT2 GalNAcβ1,4(NeuAcα2,8NeuAcα2,8NeuAcα2,3)Galβ1,4Glcβ1Cer 
GT1c Galβ1,3GalNAcβ1,4(NeuAcα2,8NeuAcα2,8NeuAcα2,3)Galβ1,4Glcβ1Cer 
GQ1 NeuAcα2,3Galβ1,3GalNAcβ1,4(NeuAcα2,8NeuAcα2,8NeuAcα2,3)Galβ1,4Glcβ1Cer 
GP1c NeuAcα2,8NeuAcα2,3Galβ1,3GalNAcβ1,4(NeuAcα2,8NeuAcα2,8NeuAcα2,3)Galβ1,4Glcβ1Cer 
GP1cα NeuAcα2,3Galβ1,3(NeuAcα2,6)GalNAcβ1,4(NeuAcα2,8NeuAcα2,8NeuAcα2,3)Galβ1,4Glcβ1Cer 
GM4 NeuAcα2,3Galβ1Cer 
 
  
